Patent Grant
11911168
The exemplary systems and methods described herein may be configured to assist users (e.g., physicians, clinicians, doctors, etc.) to determine whether a patient may benefit from cardiac conduction system therapy prior to implantation and configuration of cardiac therapy apparatus to perform one or both of cardiac conduction system pacing therapy and conventional cardiac pacing therapy. Thus, the illustrative systems and methods may be performed during intrinsic activation of the patient's heart (e.g., without any cardiac therapy being delivered to the patient and allowing the patient's heart to beat naturally). Further, the systems and methods may be described as being noninvasive. For example, the systems and methods may not use implantable devices such as leads, probes, sensors, catheters, etc. to evaluate whether the patient may benefit from the cardiac conduction system therapy or to determine the location or position of a cardiac conduction system block. Instead, the systems and methods may use electrical measurements taken noninvasively using, e.g., a plurality of external electrodes attached to the skin of a patient about the patient's torso.
One illustrative system may include an electrode apparatus and a computing apparatus coupled to the electrode apparatus. The electrode apparatus may include a plurality of external electrodes to be disposed proximate a patient's skin, and the plurality of external electrodes may include a plurality of left external electrodes positioned to the left side of the patient's torso. The computing apparatus may include processing circuitry and be configured to measure surrogate cardiac electrical activation times using the plurality external electrodes of the electrode apparatus during intrinsic activation of the patient's heart. The surrogate cardiac electrical activation times may be representative of depolarization of cardiac tissue that propagates through the torso of the patient. The computing apparatus may be further configured to generate electrical heterogeneity information (EHI) based on the measured surrogate cardiac electrical activation times. The EHI may include one or more left metrics generated based on left-sided activation times of the surrogate cardiac electrical activation times measured using the plurality of left external electrodes. The computing apparatus may be further configured to determine whether the cardiac conduction system pacing therapy would benefit the patient based on at least the one or more left metrics.
One illustrative method may include measuring surrogate cardiac electrical activation times using a plurality external electrodes disposed proximate a patient's skin during intrinsic activation of the patient's heart. The plurality of external electrodes may include a plurality of left external electrodes positioned to the left side of the patient's torso, and the surrogate cardiac electrical activation times may be representative of depolarization of cardiac tissue that propagates through the torso of the patient. The illustrative method may further include generating electrical heterogeneity information (EHI) based on the measured surrogate cardiac electrical activation times. The EHI may include one or more left metrics generated based on left-sided activation times of the surrogate cardiac electrical activation times measured using the plurality of left external electrodes. The illustrative method may further include determining whether the cardiac conduction system pacing therapy would benefit the patient based on at least the one or more left metrics.
One illustrative system may include an electrode apparatus and a computing apparatus coupled to the electrode apparatus. The electrode apparatus may include a plurality of external electrodes to be disposed proximate a patient's skin, and the plurality of external electrodes may include a plurality of left external electrodes positioned to the left side of the patient's torso. The computing apparatus may include processing circuitry and be configured to measure surrogate cardiac electrical activation times using the plurality external electrodes of the electrode apparatus during intrinsic activation of the patient's heart. The surrogate cardiac electrical activation times may be representative of depolarization of cardiac tissue that propagates through the torso of the patient. The computing apparatus may be further configured to generate electrical heterogeneity information (EHI) based on the measured surrogate cardiac electrical activation times. The EHI may include one or more left metrics generated based on left-sided activation times of the surrogate cardiac electrical activation times measured using the plurality of left external electrodes. The computing apparatus may be further configured to determine whether a cardiac conduction system block is located closer to a proximal region than a distal region along the patient's cardiac conduction network based on at least the one or more left metrics. The patient's cardiac conduction system may extend from the proximal region located near the patient's sinoatrial node or atrioventricular node to the distal region located near the patient's Purkinje fibers.
One illustrative system may include an electrode apparatus, a display, and a computing apparatus coupled to the electrode apparatus and the display. The electrode apparatus may include a plurality of external electrodes to be disposed proximate a patient's skin, and the plurality of external electrodes may include a plurality of left external electrodes positioned to the left side of the patient's torso. The display may include a graphical user interface to present information for use in assisting a user in assessing whether the patient would benefit from cardiac conduction system pacing therapy. The computing apparatus may include processing circuitry and be configured to allow the user to initiate, on the graphical user interface, a cardiac conduction system pacing therapy benefit determination, and, in response to the user initiating the cardiac conduction system pacing therapy benefit determination, measure surrogate cardiac electrical activation times using the plurality external electrodes of the electrode apparatus during intrinsic activation of the patient's heart. The surrogate cardiac electrical activation times may be representative of depolarization of cardiac tissue that propagates through the torso of the patient. The computing apparatus may be further configured to generate electrical heterogeneity information (EHI) based on the measured surrogate cardiac electrical activation times. The EHI may include one or more left metrics generated based on left-sided activation times of the surrogate cardiac electrical activation times measured using the plurality of left external electrodes. The computing apparatus may be further configured to display, on the graphical user interface, an indication of whether the cardiac conduction system pacing therapy would benefit the patient based on at least the one or more left metrics.
In at least one embodiment, the illustrative systems and methods may determine a percentage of late activating electrodes on the left side of the body (e.g., external electrodes positioned on the patient's skin in an array wrapping around from the sternum on the patient's anterior to the left side to the spine on the patient's posterior) to estimate the extent of left ventricular activation delay during intrinsic rhythm (e.g., due to left bundle branch block (LBBB)). For example, how many external electrodes on the left side of the patient monitor surrogate cardiac activation later than a certain time threshold (e.g., 40 milliseconds (ms), 50 ms, etc.) relative to the earliest detected surrogate cardiac activation divided by total number of external electrodes on the left side may be expressed as a percentage. If the percentage is greater than or equal to a percentage threshold (e.g., 40%, 50%, 60%, etc.) and/or the average activation time of the left sided electrodes (LVAT) is greater than or equal to a certain threshold (e.g., 40 ms, 50 ms, 60 ms, etc.), then the block in the left bundle may be more proximal and such patients may be correctable by proximal conduction system pacing therapy, and thus, the patient would be a candidate for attempting conduction system pacing during an implant procedure (e.g., prior to conventional pacing to areas of the heart other than the cardiac conduction system such a muscular heart tissue). Conversely, if the percentage is less than the percentage threshold and/or the LVAT is less than the certain threshold, then the block in the left bundle may be more distal, which may not be correctable by proximal conduction system pacing.
Therefore, it may be described that the illustrative systems and methods may provide a screening system to determine which patients may likely benefit from cardiac conduction system pacing ahead of any invasive procedure to implantation a cardiac conduction system pacing apparatus based on intrinsic ECG maps and metrics derived therefrom.
The above summary is not intended to describe each embodiment or every implementation of the present disclosure. A more complete understanding will become apparent and appreciated by referring to the following detailed description and claims taken in conjunction with the accompanying drawings.
In the following detailed description of illustrative embodiments, reference is made to the accompanying figures of the drawing which form a part hereof, and in which are shown, by way of illustration, specific embodiments which may be practiced. It is to be understood that other embodiments may be utilized, and structural changes may be made without departing from (e.g., still falling within) the scope of the disclosure presented hereby.
Illustrative systems and methods shall be described with reference to
A plurality of electrocardiogram (ECG) signals (e.g., torso-surface potentials) may be measured, or monitored, using a plurality of external electrodes positioned about the surface, or skin, of a patient. The ECG signals may be used to evaluate a patient's cardiac health, to determine whether the patient may benefit from cardiac conduction pacing therapy and/or another cardiac therapy, and to determine the location or relative position of a cardiac conduction system block. As described herein, the ECG signals may be gathered or obtained noninvasively since, e.g., implantable electrodes may not be used to measure the ECG signals. Further, the ECG signals may be used to determine cardiac electrical activation times, which may be used to generate various metrics (e.g., electrical heterogeneity information) that may be used by a user (e.g., physician) to determine whether a patient may benefit from cardiac pacing therapy such as, e.g., cardiac conduction system pacing therapy and/or conventional pacing therapy
Various illustrative systems, methods, and graphical user interfaces may be configured to use electrode apparatus including external electrodes, display apparatus, and computing apparatus to noninvasively assist a user (e.g., a physician) in the evaluation of cardiac health, in the determination of a location of cardiac conduction system block, and in the determination of whether a patient may benefit from cardiac conduction system pacing therapy and/or another type of cardiac therapy. An illustrative system 100 including electrode apparatus 110, computing apparatus 140, and a remote computing device 160 is depicted in
The electrode apparatus 110 as shown includes a plurality of electrodes incorporated, or included, within a band wrapped around the chest, or torso, of a patient 14. The electrode apparatus 110 is operatively coupled to the computing apparatus 140 (e.g., through one or wired electrical connections, wirelessly, etc.) to provide electrical signals from each of the electrodes to the computing apparatus 140 for analysis, evaluation, etc. Illustrative electrode apparatus may be described in U.S. Pat. No. 9,320,446 entitled “Bioelectric Sensor Device and Methods” filed Mar. 27, 2014, and issued on Mar. 26, 2016, and U.S. Provisional Patent Application Ser. No. 62/957,449 filed on Jan. 6, 2020, entitled “Bioelectric Sensor Device and Methods,” each of which is incorporated herein by reference in its entirety. Further, illustrative electrode apparatus 110 will be described in more detail in reference to
Although not described herein, the illustrative system 100 may further include imaging apparatus. The imaging apparatus may be any type of imaging apparatus configured to image, or provide images of, at least a portion of the patient in a noninvasive manner. For example, the imaging apparatus may not use any components or parts that may be located within the patient to provide images of the patient except noninvasive tools such as contrast solution. It is to be understood that the illustrative systems, methods, and interfaces described herein may further use imaging apparatus to provide noninvasive assistance to a user (e.g., a physician) to locate, or place, one or more pacing electrodes proximate the patient's heart in conjunction with the configuration of cardiac therapy.
For example, the illustrative systems and methods may provide image guided navigation that may be used to navigate leads including electrodes, leadless electrodes, wireless electrodes, catheters, etc., within the patient's body while also providing noninvasive cardiac therapy configuration including determining an effective, or optimal, pre-excitation intervals such as A-V and V-V intervals, etc. Illustrative systems and methods that use imaging apparatus and/or electrode apparatus may be described in U.S. Pat. No. 9,877,789 B2 to Ghosh issued on Jan. 30, 2018, U.S. Pat. No. 10,251,555 B2 to Ghosh et al. issued on Apr. 9, 2019, U.S. Pat. No. 9,924,884 B2 to Ghosh et al. issued on Mar. 27, 2018, U.S. Pat. No. 10,064,567 B2 to Ghosh et al. issued on Sep. 4, 2018, each of which is incorporated herein by reference in its entirety.
Illustrative imaging apparatus may be configured to capture x-ray images and/or any other alternative imaging modality. For example, the imaging apparatus may be configured to capture images, or image data, using isocentric fluoroscopy, bi-plane fluoroscopy, ultrasound, computed tomography (CT), multi-slice computed tomography (MSCT), magnetic resonance imaging (MM), high frequency ultrasound (HIFU), optical coherence tomography (OCT), intra-vascular ultrasound (IVUS), two dimensional (2D) ultrasound, three dimensional (3D) ultrasound, four dimensional (4D) ultrasound, intraoperative CT, intraoperative MRI, etc. Further, it is to be understood that the imaging apparatus may be configured to capture a plurality of consecutive images (e.g., continuously) to provide video frame data. In other words, a plurality of images taken over time using the imaging apparatus may provide video frame, or motion picture, data. An exemplary system that employs ultrasound can be found in U.S. Pat. App. Pub. No. 2017/0303840 entitled NONINVASIVE ASSESSMENT OF CARDIAC RESYNCHRONIZATION THERAPY to Stadler et al., incorporated by reference in its entirety. Additionally, the images may also be obtained and displayed in two, three, or four dimensions. In more advanced forms, four-dimensional surface rendering of the heart or other regions of the body may also be achieved by incorporating heart data or other soft tissue data from a map or from pre-operative image data captured by MM, CT, or echocardiography modalities. Image datasets from hybrid modalities, such as positron emission tomography (PET) combined with CT, or single photon emission computer tomography (SPECT) combined with CT, could also provide functional image data superimposed onto anatomical data, e.g., to be used to navigate implantable apparatus to target locations within the heart or other areas of interest.
Systems and/or imaging apparatus that may be used in conjunction with the illustrative systems and method described herein are described in U.S. Pat. App. Pub. No. 2005/0008210 to Evron et al. published on Jan. 13, 2005, U.S. Pat. App. Pub. No. 2006/0074285 to Zarkh et al. published on Apr. 6, 2006, U.S. Pat. No. 8,731,642 to Zarkh et al. issued on May 20, 2014, U.S. Pat. No. 8,861,830 to Brada et al. issued on Oct. 14, 2014, U.S. Pat. No. 6,980,675 to Evron et al. issued on Dec. 27, 2005, U.S. Pat. No. 7,286,866 to Okerlund et al. issued on Oct. 23, 2007, U.S. Pat. No. 7,308,297 to Reddy et al. issued on Dec. 11, 2011, U.S. Pat. No. 7,308,299 to Burrell et al. issued on Dec. 11, 2011, U.S. Pat. No. 7,321,677 to Evron et al. issued on Jan. 22, 2008, U.S. Pat. No. 7,346,381 to Okerlund et al. issued on Mar. 18, 2008, U.S. Pat. No. 7,454,248 to Burrell et al. issued on Nov. 18, 2008, U.S. Pat. No. 7,499,743 to Vass et al. issued on Mar. 3, 2009, U.S. Pat. No. 7,565,190 to Okerlund et al. issued on Jul. 21, 2009, U.S. Pat. No. 7,587,074 to Zarkh et al. issued on Sep. 8, 2009, U.S. Pat. No. 7,599,730 to Hunter et al. issued on Oct. 6, 2009, U.S. Pat. No. 7,613,500 to Vass et al. issued on Nov. 3, 2009, U.S. Pat. No. 7,742,629 to Zarkh et al. issued on Jun. 22, 2010, U.S. Pat. No. 7,747,047 to Okerlund et al. issued on Jun. 29, 2010, U.S. Pat. No. 7,778,685 to Evron et al. issued on Aug. 17, 2010, U.S. Pat. No. 7,778,686 to Vass et al. issued on Aug. 17, 2010, U.S. Pat. No. 7,813,785 to Okerlund et al. issued on Oct. 12, 2010, U.S. Pat. No. 7,996,063 to Vass et al. issued on Aug. 9, 2011, U.S. Pat. No. 8,060,185 to Hunter et al. issued on Nov. 15, 2011, and U.S. Pat. No. 8,401,616 to Verard et al. issued on Mar. 19, 2013, each of which is incorporated herein by reference in its entirety.
The computing apparatus 140 and the remote computing device 160 may each include display apparatus 130, 170, respectively, that may be configured to display and analyze data such as, e.g., electrical signals (e.g., electrocardiogram data), electrical activation times, electrical heterogeneity information, etc. For example, one cardiac cycle, or one heartbeat, of a plurality of cardiac cycles, or heartbeats, represented by the electrical signals collected or monitored by the electrode apparatus 110 may be analyzed and evaluated for one or more metrics including surrogate cardiac electrical activation times and electrical heterogeneity information that may be pertinent to determining the location or relative position of cardiac conduction system block within a patient's cardiac conduction network and to determining whether a patient would benefit from one or more different types of cardiac therapy such as cardiac conduction system pacing therapy. Additionally, such surrogate cardiac electrical activation times and electrical heterogeneity information may also be pertinent to the therapeutic nature of one or more parameters related to cardiac therapy such as, e.g., pacing parameters, lead location, etc., and thus, may be useful for the adjustment thereof. More specifically, for example, the QRS complex of a single cardiac cycle may be evaluated for one or more metrics such as, e.g., QRS onset, QRS offset, QRS peak, electrical heterogeneity information (EHI), electrical activation times referenced to earliest activation time, left-sided late-activation percentage of left-sided activation times, left ventricular or thoracic standard deviation of electrical activation times (LVED), standard deviation of activation times (SDAT), average left ventricular or thoracic surrogate cardiac electrical activation times (LVAT), QRS duration (e.g., interval between QRS onset to QRS offset), difference between average left surrogate and average right surrogate activation times, relative or absolute QRS morphology, difference between a higher percentile and a lower percentile of activation times (higher percentile may be 90%, 80%, 75%, 70%, etc. and lower percentile may be 10%, 15%, 20%, 25% and 30%, etc.), other statistical measures of central tendency (e.g., median or mode), dispersion (e.g., mean deviation, standard deviation, variance, interquartile deviations, range), etc. Further, each of the one or more metrics may be location specific. For example, some metrics may be computed from signals recorded, or monitored, from electrodes positioned about a selected area of the patient such as, e.g., the left side of the patient, the right side of the patient, etc.
In at least one embodiment, one or both of the computing apparatus 140 and the remote computing device 160 may be a server, a personal computer, a tablet computer, a mobile device, and a cellular telephone. The computing apparatus 140 may be configured to receive input from input apparatus 142 (e.g., a keyboard) and transmit output to the display apparatus 130, and the remote computing device 160 may be configured to receive input from input apparatus 162 (e.g., a touchscreen) and transmit output to the display apparatus 170. One or both of the computing apparatus 140 and the remote computing device 160 may include data storage that may allow for access to processing programs or routines and/or one or more other types of data, e.g., for analyzing a plurality of electrical signals captured by the electrode apparatus 110, for determining QRS onsets, QRS offsets, medians, modes, averages, peaks or maximum values, valleys or minimum values, for determining electrical activation times, for driving a graphical user interface configured to noninvasively assist a user in determining whether a patient may benefit from cardiac conduction system pacing therapy and/or another cardiac therapy, for driving a graphical user interface configured to noninvasively assist a user in determining the location or relative position of a cardiac conduction system block, for driving a graphical user interface configured to noninvasively assist a user in configuring one or more pacing parameters, or settings, such as, e.g., pacing rate, ventricular pacing rate, A-V interval, V-V interval, pacing pulse width, pacing vector, multipoint pacing vector (e.g., left ventricular vector quad lead), pacing voltage, pacing configuration (e.g., biventricular pacing, right ventricle only pacing, left ventricle only pacing, etc.), and arrhythmia detection and treatment, rate adaptive settings and performance, etc.
The computing apparatus 140 may be operatively coupled to the input apparatus 142 and the display apparatus 130 to, e.g., transmit data to and from each of the input apparatus 142 and the display apparatus 130, and the remote computing device 160 may be operatively coupled to the input apparatus 162 and the display apparatus 170 to, e.g., transmit data to and from each of the input apparatus 162 and the display apparatus 170. For example, the computing apparatus 140 and the remote computing device 160 may be electrically coupled to the input apparatus 142, 162 and the display apparatus 130, 170 using, e.g., analog electrical connections, digital electrical connections, wireless connections, bus-based connections, network-based connections, internet-based connections, etc. As described further herein, a user may provide input to the input apparatus 142, 162 to view and/or select one or more pieces of configuration information related to the cardiac therapy delivered by cardiac therapy apparatus such as, e.g., an implantable medical device.
Although as depicted the input apparatus 142 is a keyboard and the input apparatus 162 is a touchscreen, it is to be understood that the input apparatus 142, 162 may include any apparatus capable of providing input to the computing apparatus 140 and the computing device 160 to perform the functionality, methods, and/or logic described herein. For example, the input apparatus 142, 162 may include a keyboard, a mouse, a trackball, a touchscreen (e.g., capacitive touchscreen, a resistive touchscreen, a multi-touch touchscreen, etc.), etc. Likewise, the display apparatus 130, 170 may include any apparatus capable of displaying information to a user, such as a graphical user interface 132, 172 including electrode status information, graphical maps of electrical activation, indications of whether a patient may benefit from cardiac conduction system pacing therapy and/or another cardiac therapy, locations of where a cardiac conduction system block may be located within the patient's cardiac conduction network, a plurality of signals for the external electrodes over one or more heartbeats, QRS complexes, various cardiac therapy scenario selection regions, various rankings of cardiac therapy scenarios, various pacing parameters, electrical heterogeneity information (EHI), textual instructions, graphical depictions of anatomy of a human heart, images or graphical depictions of the patient's heart, graphical depictions of locations of one or more electrodes, graphical depictions of a human torso, images or graphical depictions of the patient's torso, graphical depictions of a patient's cardiac conduction network and any cardiac conduction system block located therein, graphical depictions or actual images of implanted electrodes and/or leads, etc. Further, the display apparatus 130, 170 may include a liquid crystal display, an organic light-emitting diode screen, a touchscreen, a cathode ray tube display, etc.
The processing programs or routines stored and/or executed by the computing apparatus 140 and the remote computing device 160 may include programs or routines for computational mathematics, matrix mathematics, decomposition algorithms, compression algorithms (e.g., data compression algorithms), calibration algorithms, image construction algorithms, signal processing algorithms (e.g., various filtering algorithms, Fourier transforms, fast Fourier transforms, etc.), standardization algorithms, comparison algorithms, vector mathematics, or any other processing used to implement one or more illustrative methods and/or processes described herein. Data stored and/or used by the computing apparatus 140 and the remote computing device 160 may include, for example, electrical signal/waveform data from the electrode apparatus 110 (e.g., a plurality of QRS complexes), electrical activation times from the electrode apparatus 110, cardiac sound/signal/waveform data from acoustic sensors, graphics (e.g., graphical elements, icons, buttons, windows, dialogs, pull-down menus, graphic areas, graphic regions, 3D graphics, etc.), graphical user interfaces, results from one or more processing programs or routines employed according to the disclosure herein (e.g., electrical signals, electrical heterogeneity information, etc.), or any other data that may be used for carrying out the one and/or more processes or methods described herein.
In one or more embodiments, the illustrative systems, methods, and interfaces may be implemented using one or more computer programs executed on programmable computers, such as computers that include, for example, processing capabilities, data storage (e.g., volatile or non-volatile memory and/or storage elements), input devices, and output devices. Program code and/or logic described herein may be applied to input data to perform functionality described herein and generate desired output information. The output information may be applied as input to one or more other devices and/or methods as described herein or as would be applied in a known fashion.
The one or more programs used to implement the systems, methods, and/or interfaces described herein may be provided using any programmable language, e.g., a high-level procedural and/or object orientated programming language that is suitable for communicating with a computer system. Any such programs may, for example, be stored on any suitable device, e.g., a storage media, that is readable by a general or special purpose program running on a computer system (e.g., including processing apparatus) for configuring and operating the computer system when the suitable device is read for performing the procedures described herein. In other words, at least in one embodiment, the illustrative systems, methods, and interfaces may be implemented using a computer readable storage medium, configured with a computer program, where the storage medium so configured causes the computer to operate in a specific and predefined manner to perform functions described herein. Further, in at least one embodiment, the illustrative systems, methods, and interfaces may be described as being implemented by logic (e.g., object code) encoded in one or more non-transitory media that includes code for execution and, when executed by a processor or processing circuitry, is operable to perform operations such as the methods, processes, and/or functionality described herein.
The computing apparatus 140 and the remote computing device 160 may be, for example, any fixed or mobile computer system (e.g., a controller, a microcontroller, a personal computer, minicomputer, tablet computer, etc.). The exact configurations of the computing apparatus 140 and the remote computing device 160 are not limiting, and essentially any device capable of providing suitable computing capabilities and control capabilities (e.g., signal analysis, mathematical functions such as medians, modes, averages, maximum value determination, minimum value determination, slope determination, minimum slope determination, maximum slope determination, graphics processing, etc.) may be used. As described herein, a digital file may be any medium (e.g., volatile or non-volatile memory, a CD-ROM, a punch card, magnetic recordable tape, etc.) containing digital bits (e.g., encoded in binary, trinary, etc.) that may be readable and/or writeable by the computing apparatus 140 and the remote computing device 160 described herein. Also, as described herein, a file in user-readable format may be any representation of data (e.g., ASCII text, binary numbers, hexadecimal numbers, decimal numbers, graphically, etc.) presentable on any medium (e.g., paper, a display, etc.) readable and/or understandable by a user.
In view of the above, it will be readily apparent that the functionality as described in one or more embodiments according to the present disclosure may be implemented in any manner as would be known to one skilled in the art. As such, the computer language, the computer system, or any other software/hardware which is to be used to implement the processes described herein shall not be limiting on the scope of the systems, processes, or programs (e.g., the functionality provided by such systems, processes, or programs) described herein. Further, additional illustrative systems, methods, and devices that may be used with the present disclosure may be described in U.S. Provisional Patent Application Ser. No. 62/913,002 entitled “Systems, Methods, and Devices for Determining Cardiac Condition” and filed on Oct. 9, 2019.
The illustrative electrode apparatus 110 may be configured to measure body-surface potentials of a patient 14 and, more particularly, torso-surface potentials of a patient 14. As shown in
The illustrative electrode apparatus 110 may be further configured to measure, or monitor, sounds from at least one or both the patient 14. As shown in
Further, the electrodes 112 and the acoustic sensors 120 may be electrically connected to interface/amplifier circuitry 116 via wired connection 118. The interface/amplifier circuitry 116 may be configured to amplify the signals from the electrodes 112 and the acoustic sensors 120 and provide the signals to one or both of the computing apparatus 140 and the remote computing device 160. Other illustrative systems may use a wireless connection to transmit the signals sensed by electrodes 112 and the acoustic sensors 120 to the interface/amplifier circuitry 116 and, in turn, to one or both of the computing apparatus 140 and the remote computing device 160, e.g., as channels of data. In one or more embodiments, the interface/amplifier circuitry 116 may be electrically coupled to the computing apparatus 140 using, e.g., analog electrical connections, digital electrical connections, wireless connections, bus-based connections, network-based connections, internet-based connections, etc.
Although in the example of
The electrodes 112 may be configured to surround the heart of the patient 14 and record, or monitor, the electrical signals associated with the depolarization and repolarization of the heart after the signals have propagated through the torso of a patient 14. Each of the electrodes 112 may be used in a unipolar configuration to sense the torso-surface potentials that reflect the cardiac signals. The interface/amplifier circuitry 116 may also be coupled to a return or indifferent electrode (not shown) that may be used in combination with each electrode 112 for unipolar sensing.
In some examples, there may be about 12 to about 50 electrodes 112 and about 12 to about 50 acoustic sensors 120 spatially distributed around the torso of a patient. Other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120. It is to be understood that the electrodes 112 and acoustic sensors 120 may not be arranged or distributed in an array extending all the way around or completely around the patient 14. Instead, the electrodes 112 and acoustic sensors 120 may be arranged in an array that extends only part of the way or partially around the patient 14. For example, the electrodes 112 and acoustic sensors 120 may be distributed on the anterior, posterior, and left sides of the patient with less or no electrodes and acoustic sensors proximate the right side (including posterior and anterior regions of the right side of the patient).
The computing apparatus 140 may record and analyze the torso-surface potential signals sensed by electrodes 112 and the sound signals sensed by the acoustic sensors 120, which are amplified/conditioned by the interface/amplifier circuitry 116. The computing apparatus 140 may be configured to analyze the electrical signals from the electrodes 112 to provide electrocardiogram (ECG) signals, information, or data from the patient's heart as will be further described herein. The computing apparatus 140 may be configured to analyze the signals from the electrodes 112 to provide surrogate cardiac electrical activation data such as surrogate cardiac electrical activation times, e.g., representative of actual, or local, electrical activation times of one or more regions of the patient's heart as will be further described herein. Measurement of activation times can be performed by picking an appropriate fiducial point (e.g., peak values, minimum values, minimum slopes, maximum slopes, zero crossings, threshold crossings, etc. of a near or far-field EGM) and measuring time between the onset of cardiac depolarization (e.g., onset of QRS complexes) and the appropriate fiducial point (e.g., within the electrical activity). The activation time between the onset of the QRS complex (or the peak Q wave) to the fiducial point may be referred to as q-LV time. In at least one embodiment, the earliest QRS onset from all of the plurality of electrodes may be utilized as the starting point for each activation time for each electrode, and the maximum slope following the onset of the QRS complex may be utilized as the end point of each activation time for each electrode. The computing apparatus 140 may be configured to analyze the electrical signals from the acoustic sensors 120 to provide sound signals, information, or data from the patient's body and/or devices implanted therein (such as a left ventricular assist device).
Additionally, the computing apparatus 140 and the remote computing device 160 may be configured to provide graphical user interfaces 132, 172 depicting various information related to the electrode apparatus 110 and the data gathered, or sensed, using the electrode apparatus 110. For example, the graphical user interfaces 132, 172 may depict ECGs including QRS complexes obtained using the electrode apparatus 110 and sound data including sound waves obtained using the acoustic sensors 120 as well as other information related thereto. Illustrative systems and methods may noninvasively use the electrical information collected using the electrode apparatus 110 and the sound information collected using the acoustic sensors 120 to evaluate a patient's cardiac health and to evaluate and configure cardiac therapy being delivered to the patient.
Further, the electrode apparatus 110 may further include reference electrodes and/or drive electrodes to be, e.g. positioned about the lower torso of the patient 14, that may be further used by the system 100. For example, the electrode apparatus 110 may include three reference electrodes, and the signals from the three reference electrodes may be combined to provide a reference signal. Further, the electrode apparatus 110 may use of three caudal reference electrodes (e.g., instead of standard references used in a Wilson Central Terminal) to get a “true” unipolar signal with less noise from averaging three caudally located reference signals.
The vest 114 may be formed of fabric with the electrodes 112 and the acoustic sensors 120 attached to the fabric. The vest 114 may be configured to maintain the position and spacing of electrodes 112 and the acoustic sensors 120 on the torso of the patient 14. Further, the vest 114 may be marked to assist in determining the location of the electrodes 112 and the acoustic sensors 120 on the surface of the torso of the patient 14. In some examples, there may be about 25 to about 256 electrodes 112 and about 25 to about 256 acoustic sensors 120 distributed around the torso of the patient 14, though other configurations may have more or fewer electrodes 112 and more or fewer acoustic sensors 120.
The illustrative systems and methods may be used to provide noninvasive assistance to a user in the evaluation of a patient's cardiac health and/or evaluation and configuration of cardiac therapy being presently delivered to the patient (e.g., by an implantable medical device delivering pacing therapy, by a LVAD, etc.). Further, it is to be understood that the computing apparatus 140 and the remote computing device 160 may be operatively coupled to each other in a plurality of different ways so as to perform, or execute, the functionality described herein. For example, in the embodiment depicted, the computing device 140 may be wireless operably coupled to the remote computing device 160 as depicted by the wireless signal lines emanating therebetween. Additionally, as opposed to wireless connections, one or more of the computing apparatus 140 and the remoting computing device 160 may be operably coupled through one or wired electrical connections.
The illustrative systems and methods described herein may provide users (e.g., clinicians, doctors, etc.) a useful tool to determine whether a patient would benefit from cardiac conduction system pacing therapy and/or another cardiac therapy. Further the illustrative systems and methods described herein may provide users a useful tool to determine where a cardiac conduction system block is located or relatively positioned within the cardiac conduction network of a patient. For example, the illustrative systems and methods may determine how proximal or distal a cardiac conduction system block is located along the cardiac conduction network of the patient. The location of the cardiac conduction system block may be helpful in determining whether cardiac conduction system pacing therapy and/or another cardiac therapy may be successful in treating the patient.
A patient's cardiac conduction network 200 is depicted in
As described, herein, the proximal region 222 of the cardiac conduction network 200 may include the sinoatrial node 230 and the atrioventricular node 232 and the intermodal pathways therebetween, and the distal region 224 of the cardiac conduction network 200 may include the right bundle branch 238, the left posterior bundle 236, and the Purkinje fibers 239. In particular, the most distal area of the cardiac conduction network 200 may be the ends of the Purkinje fibers 239 and the most proximal area of the cardiac conduction network 200 may be the sinoatrial node 230. Thus, the cardiac conduction network 200 may be described as extending from the sinoatrial node 230 to the Purkinje fibers 239.
In
In
An illustrative method 400 for determining whether cardiac conduction system pacing therapy would be beneficial is depicted in
According to various embodiments, the electrical activity is monitored 410 using a plurality of electrodes. The plurality of electrodes may be external surface electrodes configured in a band or a vest similar to as described herein with respect to
It may be described that, when using a plurality of external electrodes, the monitoring process 410 may provide a plurality electrocardiograms (ECGs), signals representative of the depolarization and repolarization of the patient's heart. The plurality of ECGs may, in turn, be used to generate surrogate cardiac electrical activation times 415 representative of the depolarization of the heart. As described herein, surrogate cardiac electrical activation times may be, for example, representative of actual, or local, electrical activation times of one or more regions of the patient's heart. Measurement of activation times can be performed by picking an appropriate fiducial point (e.g., peak values, minimum values, minimum slopes, maximum slopes, zero crossings, threshold crossings, etc. of a near or far-field EGM) and measuring time between the onset of cardiac depolarization (e.g., onset of QRS complexes) and the appropriate fiducial point (e.g., within the electrical activity). The activation time between the onset of the QRS complex (or the peak Q wave) to the fiducial point may be referred to as q-LV time. In at least one embodiment, the earliest QRS onset from all of the plurality of electrodes may be utilized as the starting point for each activation time for each electrode, and the maximum slope following the onset of the QRS complex may be utilized as the end point of each activation time for each electrode.
The monitored electrical activity 410 and, in turn, the electrical activation times 415 may be used to generate electrical heterogeneity information (EHI) 420. The EHI (e.g., data) may be defined as information indicative of at least one of mechanical synchrony or dyssynchrony of the heart and/or electrical synchrony or dyssynchrony of the heart. In other words, EHI may represent a surrogate of actual mechanical and/or electrical functionality of a patient's heart. In at least one embodiment, relative changes in EHI (e.g., from baseline heterogeneity information to therapy heterogeneity information, from a first set of heterogeneity information to a second set of therapy heterogeneity information, etc.) may be used to determine a surrogate value representative of the changes in hemodynamic response (e.g., acute changes in LV pressure gradients). Left ventricular pressure may be typically monitored invasively with a pressure sensor located in the left ventricular of a patient's heart. As such, the use of EHI to determine a surrogate value representative of the left ventricular pressure may avoid invasive monitoring using a left ventricular pressure sensor.
In at least one embodiment, the EHI may include a standard deviation of ventricular activation times measured using some or all of the external electrodes, e.g., of the electrode apparatus 110 described herein with respect
The EHI may be generated using one or more various systems and/or methods. For example, EHI may be generated using an array, or a plurality, of surface electrodes and/or imaging systems as described in U.S. Pat. No. 9,510,763 B2 issued on Dec. 6, 2016, and entitled “ASSESSING INRA-CARDIAC ACTIVATION PATTERNS AND ELECTRICAL DYSSYNCHRONY,” U.S. Pat. No. 8,972,228 B2 issued Mar. 3, 2015, and entitled “ASSESSING INTRACARDIAC ACTIVATION PATTERNS”, and U.S. Pat. No. 8,180,428 B2 issued May 15, 2012 and entitled “METHODS AND SYSTEMS FOR USE IN SELECTING CARDIAC PACING SITES,” each of which is incorporated herein by reference in its entirety.
EHI may include one or more metrics or indices. For example, one of the metrics, or indices, of electrical heterogeneity may be a standard deviation of activation times (SDAT) measured using some or all of the electrodes on the surface of the torso of a patient. In some examples, the SDAT may be calculated using the surrogate, or estimated, cardiac activation times over the surface of a model heart.
In this example, the EHI comprises one or more left, or left-sided, metrics generated based on left-sided activation times of the surrogate cardiac electrical activation times measured using a plurality of left external electrodes. The left external electrodes may include a plurality of left external electrodes positioned to the left side of the patient's torso.
One left, or left-sided metric, or index, of electrical heterogeneity, or dyssynchrony, may be a left standard deviation of surrogate cardiac electrical activation times (LVED) monitored by external electrodes located proximate the left side of a patient. Further, another left, or left-sided metric, or index, of electrical heterogeneity may include an average of surrogate cardiac electrical activation times (LVAT) monitored by external electrodes located proximate the left side of a patient. The LVED and LVAT may be determined (e.g., calculated, computed, etc.) from electrical activity measured only by electrodes proximate the left side of the patient, which may be referred to as “left” electrodes. Activation time determined, or measured, from the left electrodes may be described as being left-sided activation times. The left electrodes may be defined as any surface electrodes located proximate the left ventricle, which includes the body or torso regions to the left of the patient's sternum and spine (e.g., toward the left arm of the patient, the left side of the patient, etc.). In one embodiment, the left electrodes may include all anterior electrodes on the left of the sternum and all posterior electrodes to the left of the spine. In another embodiment, the left electrodes may include all anterior electrodes on the left of the sternum and all posterior electrodes. In yet another embodiment, the left electrodes may be designated based on the contour of the left and right sides of the heart as determined using imaging apparatus (e.g., x-ray, fluoroscopy, etc.).
Another illustrative left, or left-sided metric, or index, of electrical heterogeneity, or dyssynchrony, may include a left-sided late-activation percentage of left-sided surrogate cardiac electrical activation times. In one or more embodiments, the left-sided late-activation percentage of left-sided surrogate cardiac electrical activation times may be determined utilizing a left-sided late-activation threshold. For instance, the percentage of left electrodes that produce surrogate cardiac electrical activation times greater than or equal to left-sided late-activation threshold may be the left-sided late-activation percentage. In at least one embodiment, the left-sided late-activation threshold is 50 milliseconds (ms). The left-sided late-activation threshold may be between about 35 ms and about 85 ms. In one or more embodiments, the left-sided late-activation threshold is greater than or equal to 35 ms, greater than or equal to 45 ms, greater than or equal to 55 ms, greater than or equal to 65 ms, etc., and/or less than or equal to 85 ms, less than or equal to 75 ms, less than or equal to 60 ms, less than or equal to 50 ms, etc.
Thus, in an example where left-sided late-activation threshold is 40 ms, if 22 left electrodes out of 32 left electrodes had surrogate cardiac electrical activation times greater than or equal to 40 ms, then the left-sided late-activation percentage is 69%. Further, in an example where left-sided late-activation threshold is 45 ms, if 4 left electrodes out of 32 left electrode had surrogate cardiac electrical activation times greater than or equal to 45 ms, then the left-sided late-activation percentage is 13%. A large left-sided late-activation percentage may imply delayed activation of a substantial portion of the left region of the patient's heart, e.g., the left ventricle.
The illustrative method 400 may then determine whether cardiac conduction system pacing therapy would benefit the patient 430 based on the generated EHI, and in particular, the left, or left-sided, EHI. For example, one or both of left-sided late-activation percentage and LVAT may be analyzed to determine whether cardiac conduction system pacing therapy would benefit the patient 430. Additionally, it is to be understood that determining whether cardiac conduction system pacing therapy would benefit the patient 430 may not necessarily be a binary, or yes-or-no, determination, and instead, may be a likelihood of cardiac conduction system pacing therapy success for the patient. For instance, the likelihood of cardiac conduction system pacing therapy success may be expressed, or represented, by a percentage or through descriptors such as, e.g., “cardiac conduction system pacing therapy highly likely to be beneficial,” “cardiac conduction system pacing therapy likely to be beneficial,” “cardiac conduction system pacing therapy unlikely to be beneficial,” and “cardiac conduction system pacing therapy highly unlikely to be beneficial.”
Additionally, for example, an indication of an indication of whether the cardiac conduction system pacing therapy would benefit the patient based on the generated EHI such as the left EHI may be displayed on a graphical user interface. More specifically, for instance, after electrode apparatus including a plurality of external electrodes has been applied the patient, a user (e.g., clinician, doctor, etc.) may use a graphical user interface of the display to initiate a cardiac conduction system benefit determination by, e.g., selecting a button or other area on the graphical user interface. Thus, in in response to the user initiating the cardiac conduction system pacing therapy benefit determination, the illustrative systems and methods may monitor electrical activity 410, measure surrogate cardiac electrical activation times 415, generate EHI 420, determine whether cardiac conduction system pacing therapy would benefit the patient 430 based on the generated EHI, and then display an indication of an indication of whether the cardiac conduction system pacing therapy would benefit the patient on the graphical user interface.
An illustrative method 430 of determining whether cardiac conduction system pacing therapy would benefit the patient of the method 400 is shown in
The left-sided late-activation percentage may be compared to a left-sided late-activation percentage threshold 432, which as shown in this example, is 40%. Thus, if the left-sided late-activation percentage is greater than or equal to 40%, then the cardiac conduction system block is determined to be located, or positioned, closer to the proximal region of the cardiac conduction network 436, and in turn, cardiac conduction system pacing therapy is determined to be beneficial 438. Conversely, if the left-sided late-activation percentage is less than 40%, then the cardiac conduction system block is determined to be located, or positioned, closer to the distal region of the cardiac conduction network 440, and in turn, cardiac conduction system pacing therapy is not determined to likely be beneficial 442.
The left-sided late-activation percentage threshold may be between about 30% and about 80%. In one or more embodiments, the left-sided late-activation percentage threshold is greater than or equal to 30%, greater than or equal to 40%, greater than or equal to 60%, greater than or equal to 70%, etc., and/or less than or equal to 80%, less than or equal to 65%, less than or equal to 50%, etc.
The LVAT may be compared to a LVAT threshold 434, which as shown in this example, is 50 ms. Thus, if the LVAT is greater than or equal to 50 ms, then the cardiac conduction system block is determined to be located, or positioned, closer to the proximal region of the cardiac conduction network 436, and in turn, cardiac conduction system pacing therapy is determined to be beneficial 438. Conversely, if the LVAT is less than 50 ms, then the cardiac conduction system block is determined to be located, or positioned, closer to the distal region of the cardiac conduction network 440, and in turn, cardiac conduction system pacing therapy is not determined to likely be beneficial 442.
The LVAT threshold may be between about 35 ms and about 85 ms. In one or more embodiment, the left-sided late-activation threshold is greater than or equal to 35 ms, greater than or equal to 45 ms, greater than or equal to 55 ms, greater than or equal to 65 ms, etc. and/or less than or equal to 85 ms, less than or equal to 75 ms, less than or equal to 60 ms, less than or equal to 50 ms, etc.
Optionally, each of the left-sided late-activation percentage and LVAT determination processes 432, 434 may be used in conjunction to determine whether cardiac conduction system pacing therapy would benefit the patient 430. For example, in this embodiment, both the left-sided late-activation percentage must be greater than or equal to the left-sided late-activation percentage threshold 432 and the LVAT must be greater than or equal to the LVAT threshold 434 for a determination that the cardiac conduction system block located, or positioned, closer to the proximal region of the cardiac conduction network 436, and in turn, that cardiac conduction system pacing therapy is beneficial 438. Conversely, in this embodiment, if only one of the left-sided late-activation percentage and LVAT are greater than or equal to their respective threshold, then the cardiac conduction system block is determined to be located, or positioned, closer to the distal region of the cardiac conduction network 440, and in turn, cardiac conduction system pacing therapy is not determined to likely be beneficial 442.
Three different sets of intrinsic electrical cardiac data for patients who later received His bundle pacing are depicted in
Anterior and posterior activation maps for intrinsic, or baseline, activation and during His bundle pacing for two patients, Subject A and Subject B, who are subject to left bundle branch blocks are depicted in
The illustrative systems and methods may determine that Subject A would benefit from conduction system pacing therapy because, e.g., Subject A's intrinsic LVAT exceeds the LVAT threshold of 50 ms. Conversely, the illustrative systems and methods may not determine that Subject B would benefit from conduction system pacing therapy because, e.g., Subject B's intrinsic LVAT is less than the LVAT threshold of 50 ms.
The results of the delivery of His bundle pacing therapy to both Subjects A and B indicate that the illustrative systems and methods were correct as His bundle pacing therapy appears to have only benefitted Subject A. More specifically, Subject A's SDAT decreased by nearly 50% and LVAT decreased by 37% during His bundle pacing. In contrast, Subject B's SDAT marginally decreased by about 15% and LVAT actually increased by 18%. In one or more embodiments, the threshold for determining whether a left bundle branch block has been corrected is a greater than 20% reduction in LVAT from intrinsic or baseline.
As described herein, the illustrative systems and methods may assist a user (e.g., clinician, doctor, etc.) to determine whether a patient may benefit from cardiac conduction system pacing therapy and/or determine the location of cardiac conduction system block within or along the cardiac conduction network. In one or more embodiments, illustrative cardiac conduction system pacing therapy may utilize any implantable or non-implantable cardiac pacing system intended to pace or deliver electrical paces to one or more areas or regions of the cardiac conduction system of the patient. The cardiac conduction system pacing therapy may use a single pacing electrode defining a single pacing vector or a plurality of pacing electrodes defining a plurality of pacing vectors.
One example of cardiac conduction system pacing therapy may be ventricle from atrium (VfA) pacing therapy described and shown herein with respect to
Another example of cardiac conduction system pacing therapy may be His bundle pacing therapy as, e.g., described in U.S. patent application Ser. No. 16/163,132 filed Oct. 17, 2018, entitled “His Bundle and Bundle Branch Pacing Adjustment,” which is incorporated herein by reference in its entirety. Still another example of cardiac conduction system pacing therapy may be intraseptal left ventricular endocardial pacing therapy as, e.g., described in U.S. Pat. No. 7,177,704 issued on Feb. 13, 2007, entitled “Pacing Method and Apparatus,” which is incorporated herein by reference in its entirety.
An illustrative ventricle from atrium (VfA) cardiac therapy system is depicted in
The device 10 may be described as a leadless implantable medical device. As used herein, “leadless” refers to a device being free of a lead extending out of the patient's heart 8. Further, although a leadless device may have a lead, the lead would not extend from outside of the patient's heart to inside of the patient's heart or would not extend from inside of the patient's heart to outside of the patient's heart. Some leadless devices may be introduced through a vein, but once implanted, the device is free of, or may not include, any transvenous lead and may be configured to provide cardiac therapy without using any transvenous lead. Further, a leadless VfA device, in particular, does not use a lead to operably connect to an electrode in the ventricle when a housing of the device is positioned in the atrium. Additionally, a leadless electrode may be coupled to the housing of the medical device without using a lead between the electrode and the housing.
The device 10 may include a dart electrode assembly 12 defining, or having, a straight shaft extending from a distal end region of device 10. The dart electrode assembly 12 may be placed, or at least configured to be placed, through the atrial myocardium and the central fibrous body and into the ventricular myocardium 14, or along the ventricular septum, without perforating entirely through the ventricular endocardial or epicardial surfaces. The dart electrode assembly 12 may carry, or include, an electrode at a distal end region of the shaft such that the electrode may be positioned within the ventricular myocardium for sensing ventricular signals and delivering ventricular pacing pulses (e.g., to depolarize the left ventricle and/or right ventricle to initiate a contraction of the left ventricle and/or right ventricle). In some examples, the electrode at the distal end region of the shaft is a cathode electrode provided for use in a bipolar electrode pair for pacing and sensing. While the implant region 4 as illustrated may enable one or more electrodes of the dart electrode assembly 12 to be positioned in the ventricular myocardium, it is recognized that a device having the aspects disclosed herein may be implanted at other locations for multiple chamber pacing (e.g., dual or triple chamber pacing), single chamber pacing with multiple chamber sensing, single chamber pacing and/or sensing, or other clinical therapy and applications as appropriate.
It is to be understood that although device 10 is described herein as including a single dart electrode assembly, the device 10 may include more than one dart electrode assembly placed, or configured to be placed, through the atrial myocardium and the central fibrous body, and into the ventricular myocardium 14, or along the ventricular septum, without perforating entirely through the ventricular endocardial or epicardial surfaces. Additionally, each dart electrode assembly may carry, or include, more than a single electrode at the distal end region, or along other regions (e.g., proximal or central regions), of the shaft.
The cardiac therapy system 2 may also include a separate medical device 50 (depicted diagrammatically in
In the case of shock therapy (e.g., defibrillation shocks provided by the defibrillation electrode of the defibrillation lead), the separate medical device 50 (e.g., extravascular ICD) may include a control circuit that uses a therapy delivery circuit to generate defibrillation shocks having any of a number of waveform properties, including leading-edge voltage, tilt, delivered energy, pulse phases, and the like. The therapy delivery circuit may, for instance, generate monophasic, biphasic, or multiphasic waveforms. Additionally, the therapy delivery circuit may generate defibrillation waveforms having different amounts of energy. For example, the therapy delivery circuit may generate defibrillation waveforms that deliver a total of between approximately 60-80 Joules (J) of energy for subcutaneous defibrillation.
The separate medical device 50 may further include a sensing circuit. The sensing circuit may be configured to obtain electrical signals sensed via one or more combinations of electrodes and to process the obtained signals. The components of the sensing circuit may include analog components, digital components, or a combination thereof. The sensing circuit may, for example, include one or more sense amplifiers, filters, rectifiers, threshold detectors, analog-to-digital converters (ADCs), or the like. The sensing circuit may convert the sensed signals to digital form and provide the digital signals to the control circuit for processing and/or analysis. For example, the sensing circuit may amplify signals from sensing electrodes and convert the amplified signals to multi-bit digital signals by an ADC, and then provide the digital signals to the control circuit. In one or more embodiments, the sensing circuit may also compare processed signals to a threshold to detect the existence of atrial or ventricular depolarizations (e.g., P- or R-waves) and indicate the existence of the atrial depolarization (e.g., P-waves) or ventricular depolarizations (e.g., R-waves) to the control circuit.
The device 10 and the separate medical device 50 may cooperate to provide cardiac therapy to the patient's heart 8. For example, the device 10 and the separate medical device 50 may be used to detect tachycardia, monitor tachycardia, and/or provide tachycardia-related therapy. For example, the device 10 may communicate with the separate medical device 50 wirelessly to trigger shock therapy using the separate medical device 50. As used herein, “wirelessly” refers to an operative coupling or connection without using a metal conductor between the device 10 and the separate medical device 50. In one example, wireless communication may use a distinctive, signaling, or triggering electrical-pulse provided by the device 10 that conducts through the patient's tissue and is detectable by the separate medical device 50. In another example, wireless communication may use a communication interface (e.g., an antenna) of the device 10 to provide electromagnetic radiation that propagates through patient's tissue and is detectable, for example, using a communication interface (e.g., an antenna) of the separate medical device 50.
In at least one embodiment, the housing 30 may be described as extending between a distal end region 32 and a proximal end region 34 and as defining a generally-cylindrical shape, e.g., to facilitate catheter delivery. In other embodiments, the housing 30 may be prismatic or any other shape to perform the functionality and utility described herein. The housing 30 may include a delivery tool interface member 26, e.g., defined, or positioned, at the proximal end region 34, for engaging with a delivery tool during implantation of the device 10.
All or a portion of the housing 30 may function as a sensing and/or pacing electrode during cardiac therapy. In the example shown, the housing 30 includes a proximal housing-based electrode 24 that circumscribes a proximal portion (e.g., closer to the proximal end region 34 than the distal end region 32) of the housing 30. When the housing 30 is (e.g., defines, formed from, etc.) an electrically-conductive material, such as a titanium alloy or other examples listed above, portions of the housing 30 may be electrically insulated by a non-conductive material, such as a coating of parylene, polyurethane, silicone, epoxy, or other biocompatible polymer, leaving one or more discrete areas of conductive material exposed to form, or define, the proximal housing-based electrode 24. When the housing 30 is (e.g., defines, formed from, etc.) a non-conductive material, such as a ceramic, glass or polymer material, an electrically-conductive coating or layer, such as a titanium, platinum, stainless steel, or alloys thereof, may be applied to one or more discrete areas of the housing 30 to form, or define, the proximal housing-based electrode 24. In other examples, the proximal housing-based electrode 24 may be a component, such as a ring electrode, that is mounted or assembled onto the housing 30. The proximal housing-based electrode 24 may be electrically coupled to internal circuitry of the device 10, e.g., via the electrically-conductive housing 30 or an electrical conductor when the housing 30 is a non-conductive material.
In the example shown, the proximal housing-based electrode 24 is located nearer to the housing proximal end region 34 than the housing distal end region 32, and therefore, may be referred to as a proximal housing-based electrode 24. In other examples, however, the proximal housing-based electrode 24 may be located at other positions along the housing 30, e.g., more distal relative to the position shown.
At the distal end region 32, the device 10 may include a distal fixation and electrode assembly 36, which may include one or more fixation members 20 and one or more dart electrode assemblies 12 of equal or unequal length. In one such example as shown, a single dart electrode assembly 12 includes a shaft 40 extending distally away from the housing distal end region 32 and one or more electrode elements, such as a tip electrode 42 at or near the free, distal end region of the shaft 40. The tip electrode 42 may have a conical or hemi-spherical distal tip with a relatively narrow tip-diameter (e.g., less than about 1 millimeter (mm)) for penetrating into and through tissue layers without using a sharpened tip or needle-like tip having sharpened or beveled edges.
The dart electrode assembly 12 may be configured to pierce through one or more tissue layers to position the tip electrode 42 within a desired tissue layer such as, e.g., the ventricular myocardium. As such, the height 47, or length, of the shaft 40 may correspond to the expected pacing site depth, and the shaft 40 may have a relatively-high compressive strength along its longitudinal axis to resist bending in a lateral or radial direction when pressed against and into the implant region 4. If a second dart electrode assembly 12 is employed, its length may be unequal to the expected pacing site depth and may be configured to act as an indifferent electrode for delivering of pacing energy to and/or sensing signals from the tissue. In one embodiment, a longitudinal axial force may be applied against the tip electrode 42, e.g., by applying longitudinal pushing force to the proximal end 34 of the housing 30, to advance the dart electrode assembly 12 into the tissue within the target implant region.
The shaft 40 may be described as longitudinally non-compressive and/or elastically deformable in lateral or radial directions when subjected to lateral or radial forces to allow temporary flexing, e.g., with tissue motion, but may return to its normally straight position when lateral forces diminish. Thus, the dart electrode assembly 12 including the shaft 40 may be described as being resilient. When the shaft 40 is not exposed to any external force, or to only a force along its longitudinal central axis, the shaft 40 may retain a straight, linear position as shown.
In other words, the shaft 40 of the dart electrode assembly 12 may be a normally straight member and may be rigid. In other embodiments, the shaft 40 may be described as being relatively stiff but still possessing limited flexibility in lateral directions. Further, the shaft 40 may be non-rigid to allow some lateral flexing with heart motion. However, in a relaxed state, when not subjected to any external forces, the shaft 40 may maintain a straight position as shown to hold the tip electrode 42 spaced apart from the housing distal end region 32 at least by a height, or length, 47 of the shaft 40.
The one or more fixation members 20 may be described as one or more “tines” having a normally curved position. The tines may be held in a distally extended position within a delivery tool. The distal tips of tines may penetrate the heart tissue to a limited depth before elastically, or resiliently, curving back proximally into the normally curved position (shown) upon release from the delivery tool. Further, the fixation members 20 may include one or more aspects described in, for example, U.S. Pat. No. 9,675,579 (Grubac et al.), issued 13 Jun. 2017, and U.S. Pat. No. 9,119,959 (Rys et al.), issued 1 Sep. 2015, each of which is incorporated herein by reference in its entirety.
In some examples, the distal fixation and electrode assembly 36 includes a distal housing-based electrode 22. In the case of using the device 10 as a pacemaker for multiple chamber pacing (e.g., dual or triple chamber pacing) and sensing, the tip electrode 42 may be used as a cathode electrode paired with the proximal housing-based electrode 24 serving as a return anode electrode. Alternatively, the distal housing-based electrode 22 may serve as a return anode electrode paired with tip electrode 42 for sensing ventricular signals and delivering ventricular pacing pulses. In other examples, the distal housing-based electrode 22 may be a cathode electrode for sensing atrial signals and delivering pacing pulses to the atrial myocardium in the target implant region 4. When the distal housing-based electrode 22 serves as an atrial cathode electrode, the proximal housing-based electrode 24 may serve as the return anode paired with the tip electrode 42 for ventricular pacing and sensing and as the return anode paired with the distal housing-based electrode 22 for atrial pacing and sensing.
As shown in this illustration, the target implant region 4 in some pacing applications is along the atrial endocardium 18, generally inferior to the AV node 15 and the His bundle 5. The dart electrode assembly 12 may at least partially define the height 47, or length, of the shaft 40 for penetrating through the atrial endocardium 18 in the target implant region 4, through the central fibrous body 16, and into the ventricular myocardium 14 without perforating through the ventricular endocardial surface 17. When the height 47, or length, of the dart electrode assembly 12 is fully advanced into the target implant region 4, the tip electrode 42 may rest within the ventricular myocardium 14, and the distal housing-based electrode 22 may be positioned in intimate contact with or close proximity to the atrial endocardium 18. The dart electrode assembly 12 may have a total combined height 47, or length, of tip electrode 42 and shaft 40 from about 3 mm to about 8 mm in various examples. The diameter of the shaft 40 may be less than about 2 mm, and may be about 1 mm or less, or even about 0.6 mm or less.
In some embodiments, any of the tissue-piercing electrodes of the present disclosure may be implanted in the basal and/or septal region of the left ventricular myocardium of the patient's heart. In particular, the tissue-piercing electrode may be implanted from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. Once implanted, the tissue-piercing electrode may be positioned in the target implant region 4 (
In some embodiments, the tissue-piercing electrode may be positioned in the basal septal region of the left ventricular myocardium when implanted. The basal septal region may include one or more of the basal anteroseptal area 2, basal inferoseptal area 3, mid-anteroseptal area 8, and mid-inferoseptal area 9.
In some embodiments, the tissue-piercing electrode may be positioned in the high inferior/posterior basal septal region of the left ventricular myocardium when implanted. The high inferior/posterior basal septal region of the left ventricular myocardium may include a portion of one or more of the basal inferoseptal area 3 and mid-inferoseptal area 9 (e.g., the basal inferoseptal area only, the mid-inferoseptal area only, or both the basal inferoseptal area and the mid-inferoseptal area). For example, the high inferior/posterior basal septal region may include region 324 illustrated generally as a dashed-line boundary. As shown, the dashed line boundary represents an approximation of where the high inferior/posterior basal septal region is located, which may take a somewhat different shape or size depending on the particular application.
A block diagram of circuitry is depicted in
The power source 98 may provide power to the circuitry of the device 10 including each of the components 80, 82, 84, 86, 88, 90 as needed. The power source 98 may include one or more energy storage devices, such as one or more rechargeable or non-rechargeable batteries. The connections (not shown) between the power source 98 and each of the components 80, 82, 84, 86, 88, 90 may be understood from the general block diagram illustrated to one of ordinary skill in the art. For example, the power source 98 may be coupled to one or more charging circuits included in the therapy delivery circuit 84 for providing the power used to charge holding capacitors included in the therapy delivery circuit 84 that are discharged at appropriate times under the control of the control circuit 80 for delivering pacing pulses, e.g., according to a dual chamber pacing mode such as DDI(R). The power source 98 may also be coupled to components of the sensing circuit 86, such as sense amplifiers, analog-to-digital converters, switching circuitry, etc., sensors 90, the telemetry circuit 88, and the memory 82 to provide power to the various circuits.
The functional blocks shown in
The memory 82 may include any volatile, non-volatile, magnetic, or electrical non-transitory computer readable storage media, such as random-access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically-erasable programmable ROM (EEPROM), flash memory, or any other memory device. Furthermore, the memory 82 may include a non-transitory computer readable media storing instructions that, when executed by one or more processing circuits, cause the control circuit 80 and/or other processing circuitry to determine posterior left bundle branch engagement and/or perform a single, dual, or triple chamber calibrated pacing therapy (e.g., single or multiple chamber pacing), or other cardiac therapy functions (e.g., sensing or delivering therapy), attributed to the device 10. The non-transitory computer-readable media storing the instructions may include any of the media listed above.
The control circuit 80 may communicate, e.g., via a data bus, with the therapy delivery circuit 84 and the sensing circuit 86 for sensing cardiac electrical signals and controlling delivery of cardiac electrical stimulation therapies in response to sensed cardiac events, e.g., P-waves and R-waves, or the absence thereof. The tip electrode 42, the distal housing-based electrode 22, and the proximal housing-based electrode 24 may be electrically coupled to the therapy delivery circuit 84 for delivering electrical stimulation pulses to the patient's heart and to the sensing circuit 86 and for sensing cardiac electrical signals.
The sensing circuit 86 may include an atrial (A) sensing channel 87 and a ventricular (V) sensing channel 89. The distal housing-based electrode 22 and the proximal housing-based electrode 24 may be coupled to the atrial sensing channel 87 for sensing atrial signals, e.g., P-waves attendant to the depolarization of the atrial myocardium. In examples that include two or more selectable distal housing-based electrodes, the sensing circuit 86 may include switching circuitry for selectively coupling one or more of the available distal housing-based electrodes to cardiac event detection circuitry included in the atrial sensing channel 87. Switching circuitry may include a switch array, switch matrix, multiplexer, or any other type of switching device suitable to selectively couple components of the sensing circuit 86 to selected electrodes. The tip electrode 42 and the proximal housing-based electrode 24 may be coupled to the ventricular sensing channel 89 for sensing ventricular signals, e.g., R-waves attendant to the depolarization of the ventricular myocardium.
Each of the atrial sensing channel 87 and the ventricular sensing channel 89 may include cardiac event detection circuitry for detecting P-waves and R-waves, respectively, from the cardiac electrical signals received by the respective sensing channels. The cardiac event detection circuitry included in each of the channels 87 and 89 may be configured to amplify, filter, digitize, and rectify the cardiac electrical signal received from the selected electrodes to improve the signal quality for detecting cardiac electrical events. The cardiac event detection circuitry within each channel 87 and 89 may include one or more sense amplifiers, filters, rectifiers, threshold detectors, comparators, analog-to-digital converters (ADCs), timers, or other analog or digital components. A cardiac event sensing threshold, e.g., a P-wave sensing threshold and an R-wave sensing threshold, may be automatically adjusted by each respective sensing channel 87 and 89 under the control of the control circuit 80, e.g., based on timing intervals and sensing threshold values determined by the control circuit 80, stored in the memory 82, and/or controlled by hardware, firmware, and/or software of the control circuit 80 and/or the sensing circuit 86.
Upon detecting a cardiac electrical event based on a sensing threshold crossing, the sensing circuit 86 may produce a sensed event signal that is passed to the control circuit 80. For example, the atrial sensing channel 87 may produce a P-wave sensed event signal in response to a P-wave sensing threshold crossing. The ventricular sensing channel 89 may produce an R-wave sensed event signal in response to an R-wave sensing threshold crossing. The sensed event signals may be used by the control circuit 80 for setting pacing escape interval timers that control the basic time intervals used for scheduling cardiac pacing pulses. A sensed event signal may trigger or inhibit a pacing pulse depending on the particular programmed pacing mode. For example, a P-wave sensed event signal received from the atrial sensing channel 87 may cause the control circuit 80 to inhibit a scheduled atrial pacing pulse and schedule a ventricular pacing pulse at a programmed atrioventricular (A-V) pacing interval. If an R-wave is sensed before the A-V pacing interval expires, the ventricular pacing pulse may be inhibited. If the A-V pacing interval expires before the control circuit 80 receives an R-wave sensed event signal from the ventricular sensing channel 89, the control circuit 80 may use the therapy delivery circuit 84 to deliver the scheduled ventricular pacing pulse synchronized to the sensed P-wave.
In some examples, the device 10 may be configured to deliver a variety of pacing therapies including bradycardia pacing, cardiac resynchronization therapy, post-shock pacing, and/or tachycardia-related therapy, such as ATP, among others. For example, the device 10 may be configured to detect non-sinus tachycardia and deliver ATP. The control circuit 80 may determine cardiac event time intervals, e.g., P-P intervals between consecutive P-wave sensed event signals received from the atrial sensing channel 87, R-R intervals between consecutive R-wave sensed event signals received from the ventricular sensing channel 89, and P-R and/or R-P intervals received between P-wave sensed event signals and R-wave sensed event signals. These intervals may be compared to tachycardia detection intervals for detecting non-sinus tachycardia. Tachycardia may be detected in a given heart chamber based on a threshold number of tachycardia detection intervals being detected.
The therapy delivery circuit 84 may include atrial pacing circuit 83 and ventricular pacing circuit 85. Each pacing circuit 83, 85 may include charging circuitry, one or more charge storage devices such as one or more low voltage holding capacitors, an output capacitor, and/or switching circuitry that controls when the holding capacitor(s) are charged and discharged across the output capacitor to deliver a pacing pulse to the pacing electrode vector coupled to respective pacing circuits 83, 85. The tip electrode 42 and the proximal housing-based electrode 24 may be coupled to the ventricular pacing circuit 85 as a bipolar cathode and anode pair for delivering ventricular pacing pulses, e.g., upon expiration of an A-V or V-V pacing interval set by the control circuit 80 for providing atrial-synchronized ventricular pacing and a basic lower ventricular pacing rate.
The atrial pacing circuit 83 may be coupled to the distal housing-based electrode 22 and the proximal housing-based electrode 24 to deliver atrial pacing pulses. The control circuit 80 may set one or more atrial pacing intervals according to a programmed lower pacing rate or a temporary lower rate set according to a rate-responsive sensor indicated pacing rate. Atrial pacing circuit may be controlled to deliver an atrial pacing pulse if the atrial pacing interval expires before a P-wave sensed event signal is received from the atrial sensing channel 87. The control circuit 80 starts an A-V pacing interval in response to a delivered atrial pacing pulse to provide synchronized multiple chamber pacing (e.g., dual or triple chamber pacing).
Charging of a holding capacitor of the atrial or ventricular pacing circuit 83, 85 to a programmed pacing voltage amplitude and discharging of the capacitor for a programmed pacing pulse width may be performed by the therapy delivery circuit 84 according to control signals received from the control circuit 80. For example, a pace timing circuit included in the control circuit 80 may include programmable digital counters set by a microprocessor of the control circuit 80 for controlling the basic pacing time intervals associated with various single chamber or multiple chamber pacing (e.g., dual or triple chamber pacing) modes or anti-tachycardia pacing sequences. The microprocessor of the control circuit 80 may also set the amplitude, pulse width, polarity, or other characteristics of the cardiac pacing pulses, which may be based on programmed values stored in the memory 82.
Control parameters utilized by the control circuit 80 for sensing cardiac events and controlling pacing therapy delivery may be programmed into the memory 82 via the telemetry circuit 88, which may also be described as a communication interface. The telemetry circuit 88 includes a transceiver and antenna for communicating with an external device, such as a programmer or home monitor, using radio frequency communication or other communication protocols. The control circuit 80 may use the telemetry circuit 88 to receive downlink telemetry from and send uplink telemetry to the external device. In some cases, the telemetry circuit 88 may be used to transmit and receive communication signals to/from another medical device implanted in the patient.
The techniques described in this disclosure, including those attributed to the IMD 10, device 50, the computing apparatus 140, and the computing device 160 and/or various constituent components, may be implemented, at least in part, in hardware, software, firmware, or any combination thereof. For example, various aspects of the techniques may be implemented within one or more processors, including one or more microprocessors, DSPs, ASICs, FPGAs, or any other equivalent integrated or discrete logic circuitry, as well as any combinations of such components, embodied in programmers, such as physician or patient programmers, stimulators, image processing devices, or other devices. The term “module,” “processor,” or “processing circuitry” may generally refer to any of the foregoing logic circuitry, alone or in combination with other logic circuitry, or any other equivalent circuitry.
Such hardware, software, and/or firmware may be implemented within the same device or within separate devices to support the various operations and functions described in this disclosure. In addition, any of the described units, modules, or components may be implemented together or separately as discrete but interoperable logic devices. Depiction of different features as modules or units is intended to highlight different functional aspects and does not necessarily imply that such modules or units must be realized by separate hardware or software components. Rather, functionality associated with one or more modules or units may be performed by separate hardware or software components or integrated within common or separate hardware or software components.
When implemented in software, the functionality ascribed to the systems, devices and techniques described in this disclosure may be embodied as instructions on a computer-readable medium such as RAM, ROM, NVRAM, EEPROM, FLASH memory, magnetic data storage media, optical data storage media, or the like. The instructions may be executed by processing circuitry and/or one or more processors to support one or more aspects of the functionality described in this disclosure.
All references and publications cited herein are expressly incorporated herein by reference in their entirety for all purposes, except to the extent any aspect incorporated directly contradicts this disclosure.
All scientific and technical terms used herein have meanings commonly used in the art unless otherwise specified. The definitions provided herein are to facilitate understanding of certain terms used frequently herein and are not meant to limit the scope of the present disclosure.
Unless otherwise indicated, all numbers expressing feature sizes, amounts, and physical properties used in the specification and claims may be understood as being modified either by the term “exactly” or “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the foregoing specification and attached claims are approximations that can vary depending upon the desired properties sought to be obtained by those skilled in the art utilizing the teachings disclosed herein or, for example, within typical ranges of experimental error.
The recitation of numerical ranges by endpoints includes all numbers subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5) and any range within that range. Herein, the terms “up to” or “no greater than” a number (e.g., up to 50) includes the number (e.g., 50), and the term “no less than” a number (e.g., no less than 5) includes the number (e.g., 5).
The terms “coupled” or “connected” refer to elements being attached to each other either directly (in direct contact with each other) or indirectly (having one or more elements between and attaching the two elements). Either term may be modified by “operatively” and “operably,” which may be used interchangeably, to describe that the coupling or connection is configured to allow the components to interact to carry out at least some functionality (for example, a first medical device may be operatively coupled to another medical device to transmit information in the form of data or to receive data therefrom).
Terms related to orientation, such as “top,” “bottom,” “side,” and “end,” are used to describe relative positions of components and are not meant to limit the orientation of the embodiments contemplated. For example, an embodiment described as having a “top” and “bottom” also encompasses embodiments thereof rotated in various directions unless the content clearly dictates otherwise.
Reference to “one embodiment,” “an embodiment,” “certain embodiments,” or “some embodiments,” etc., means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the disclosure. Thus, the appearances of such phrases in various places throughout are not necessarily referring to the same embodiment of the disclosure. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” encompass embodiments having plural referents, unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
As used herein, “have,” “having,” “include,” “including,” “comprise,” “comprising” or the like are used in their open-ended sense, and generally mean “including, but not limited to.” It will be understood that “consisting essentially of,” “consisting of,” and the like are subsumed in “comprising,” and the like.
The term “and/or” means one or all the listed elements or a combination of at least two of the listed elements. The phrases “at least one of,” “comprises at least one of,” and “one or more of” followed by a list refers to any one of the items in the list and any combination of two or more items in the list.
The present application claims the benefit of U.S. Provisional Application No. 63/005,055, filed Apr. 3, 2020, which is incorporated herein by reference in its entirety. The disclosure herein relates to systems and methods for use in determining cardiac conduction system therapy benefit using a plurality of external electrodes. Implantable medical devices (IMDs), such as implantable pacemakers, cardioverters, defibrillators, or pacemaker-cardioverter-defibrillators, provide therapeutic electrical stimulation to the heart. IMDs may provide pacing to address bradycardia, or pacing or shocks in order to terminate tachyarrhythmia, such as tachycardia or fibrillation. In some cases, the medical device may sense intrinsic depolarizations of the heart, detect arrhythmia based on the intrinsic depolarizations (or absence thereof), and control delivery of electrical stimulation to the heart if arrhythmia is detected based on the intrinsic depolarizations. IMDs may also provide cardiac resynchronization therapy (CRT), which is a form of pacing. CRT involves the delivery of pacing to the left ventricle, or both the left and right ventricles. The timing and location of the delivery of pacing pulses to the ventricle(s) may be selected to improve the coordination and efficiency of ventricular contraction. IMDS may be described as delivering one or both of Conventional pacing therapy and cardiac conduction system pacing therapy. Conventional, or traditional, pacing therapy may be described as delivering pacing pulses into myocardial tissue that is not part of the cardiac conduction system of the patient's heart such that, e.g., electrical activation propagates from one myocardial cell to another myocardial cell (also referred to as “cell-to-cell”). For instance, the conventional pacing therapy may deliver pacing pulses directly into the muscular heart tissue that is to be depolarized to provide the contraction of the heart. For example, conventional left ventricular pacing therapy may utilize a left ventricular (LV) coronary sinus lead that is implanted so as to extend through one or more veins, the vena cava, the right atrium, and into the coronary sinus to a region adjacent to the free wall of the left ventricle of the heart so as to deliver pacing pulses to the myocardial tissue of the free wall of the left ventricle. Cardiac conduction system pacing therapy may be described as delivering pacing pulses into the cardiac conduction system. More specifically, the cardiac conduction system pacing therapy may include one or more parts of the cardiac conduction system such as the left bundle branch, bundle of His, atrioventricular node, right bundle branch, etc. For example, a ventricle-from-atrium (VfA) lead may deliver pacing pulses directly to the left bundle branch of the cardiac conduction system such that the pulses propagate along the left bundle branch and Purkinje fibers to initiate depolarization of cardiac tissues proximate thereto (e.g., the myocardial tissue of the left ventricle). Systems for implanting medical devices may include workstations or other equipment in addition to the implantable medical device itself. In some cases, these other pieces of equipment assist the physician or other technician with placing the intracardiac leads at particular locations on the heart. In some cases, the equipment provides information to the physician about the electrical activity of the heart and the location of the intracardiac lead. The equipment may perform similar functions as the medical device, including delivering electrical stimulation to the heart and sensing the depolarizations of the heart. In some cases, the equipment may include equipment for obtaining an electrocardiogram (ECG) via electrodes on the surface, or skin, of the patient. More specifically, the patient may have a plurality of electrodes on an ECG belt or vest that surrounds the torso of the patient. After the belt or vest has been secured to the torso, a physician can perform a series of tests to evaluate a patient's cardiac response. The evaluation process can include detection of a baseline rhythm in which no electrical stimuli is delivered to cardiac tissue and another rhythm after electrical stimuli is delivered to the cardiac tissue. The ECG electrodes placed on the body surface of the patient may be used for various therapeutic purposes (e.g., cardiac resynchronization therapy) including optimizing lead location, pacing parameters, etc. based on one or more metrics derived from the signals captured by the ECG electrodes.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3835864 | Rasor et al. | Sep 1974 | A |
| 3865118 | Bures | Feb 1975 | A |
| 3943936 | Rasor et al. | Mar 1976 | A |
| 3949757 | Sabel | Apr 1976 | A |
| 4142530 | Wittkampf | Mar 1979 | A |
| 4151513 | Menken et al. | Apr 1979 | A |
| 4157720 | Greatbatch | Jun 1979 | A |
| RE30366 | Rasor et al. | Aug 1980 | E |
| 4243045 | Mass | Jan 1981 | A |
| 4250884 | Hartlaub et al. | Feb 1981 | A |
| 4256115 | Bilitch | Mar 1981 | A |
| 4263919 | Levin | Apr 1981 | A |
| 4280502 | Baker, Jr. et al. | Jul 1981 | A |
| 4289144 | Gilman | Sep 1981 | A |
| 4310000 | Lindemans | Jan 1982 | A |
| 4312354 | Walters | Jan 1982 | A |
| 4323081 | Wiebusch | Apr 1982 | A |
| 4332259 | McCorkle, Jr. | Jun 1982 | A |
| 4357946 | Dutcher et al. | Nov 1982 | A |
| 4365639 | Goldreyer | Dec 1982 | A |
| 4374382 | Markowitz et al. | Feb 1983 | A |
| 4393883 | Smyth et al. | Jul 1983 | A |
| 4440173 | Hudziak et al. | Apr 1984 | A |
| 4476868 | Thompson | Oct 1984 | A |
| 4479500 | Smits | Oct 1984 | A |
| 4522208 | Buffet | Jun 1985 | A |
| 4537200 | Widrow | Aug 1985 | A |
| 4546777 | Groch et al. | Oct 1985 | A |
| 4556063 | Thompson et al. | Dec 1985 | A |
| 4562841 | Brockway et al. | Jan 1986 | A |
| 4574814 | Buffet | Mar 1986 | A |
| 4593702 | Kepski et al. | Jun 1986 | A |
| 4593955 | Leiber | Jun 1986 | A |
| 4630611 | King | Dec 1986 | A |
| 4635639 | Hakala et al. | Jan 1987 | A |
| 4674508 | DeCote | Jun 1987 | A |
| 4712554 | Garson | Dec 1987 | A |
| 4729376 | DeCote | Mar 1988 | A |
| 4754753 | King | Jul 1988 | A |
| 4759366 | Callaghan | Jul 1988 | A |
| 4776338 | Lekholm et al. | Oct 1988 | A |
| 4787389 | Tarjan | Nov 1988 | A |
| 4793353 | Borkan | Dec 1988 | A |
| 4819662 | Heil et al. | Apr 1989 | A |
| 4830006 | Haluska et al. | May 1989 | A |
| 4858610 | Callaghan et al. | Aug 1989 | A |
| 4865037 | Chin et al. | Sep 1989 | A |
| 4886064 | Strandberg | Dec 1989 | A |
| 4887609 | Cole, Jr. | Dec 1989 | A |
| 4928688 | Mower | May 1990 | A |
| 4953564 | Berthelsen | Sep 1990 | A |
| 4967746 | Vandegriff | Nov 1990 | A |
| 4987897 | Funke | Jan 1991 | A |
| 4989602 | Sholder et al. | Feb 1991 | A |
| 5012806 | De Bellis | May 1991 | A |
| 5036849 | Hauck et al. | Aug 1991 | A |
| 5040534 | Mann et al. | Aug 1991 | A |
| 5058581 | Silvian | Oct 1991 | A |
| 5078134 | Heilman et al. | Jan 1992 | A |
| 5109845 | Yuuchi et al. | May 1992 | A |
| 5113859 | Funke | May 1992 | A |
| 5113869 | Nappholz et al. | May 1992 | A |
| 5117824 | Keimel et al. | Jun 1992 | A |
| 5127401 | Grievous et al. | Jul 1992 | A |
| 5133353 | Hauser | Jul 1992 | A |
| 5144950 | Stoop et al. | Sep 1992 | A |
| 5154170 | Bennett et al. | Oct 1992 | A |
| 5170784 | Ramon et al. | Dec 1992 | A |
| 5174289 | Cohen | Dec 1992 | A |
| 5179945 | Van Hofwegen et al. | Jan 1993 | A |
| 5193539 | Schulman et al. | Mar 1993 | A |
| 5193540 | Schulman et al. | Mar 1993 | A |
| 5241961 | Henry | Sep 1993 | A |
| 5243977 | Trabucco et al. | Sep 1993 | A |
| 5255692 | Neubauer et al. | Oct 1993 | A |
| 5259387 | dePinto | Nov 1993 | A |
| 5269326 | Verrier | Dec 1993 | A |
| 5284136 | Hauck et al. | Feb 1994 | A |
| 5300107 | Stokes et al. | Apr 1994 | A |
| 5301677 | Hsung | Apr 1994 | A |
| 5305760 | McKown et al. | Apr 1994 | A |
| 5312439 | Loeb | May 1994 | A |
| 5313953 | Yomtov et al. | May 1994 | A |
| 5314459 | Swanson et al. | May 1994 | A |
| 5318594 | Limousin et al. | Jun 1994 | A |
| 5318597 | Hauck et al. | Jun 1994 | A |
| 5324316 | Schulman et al. | Jun 1994 | A |
| 5331966 | Bennett et al. | Jul 1994 | A |
| 5334222 | Salo et al. | Aug 1994 | A |
| 5342408 | Decoriolis et al. | Aug 1994 | A |
| 5370667 | Alt | Dec 1994 | A |
| 5372606 | Lang et al. | Dec 1994 | A |
| 5376106 | Stahmann et al. | Dec 1994 | A |
| 5383915 | Adams | Jan 1995 | A |
| 5388578 | Yomtov et al. | Feb 1995 | A |
| 5404877 | Nolan et al. | Apr 1995 | A |
| 5405367 | Schulman et al. | Apr 1995 | A |
| 5411031 | Yomtov | May 1995 | A |
| 5411525 | Swanson et al. | May 1995 | A |
| 5411535 | Fujii et al. | May 1995 | A |
| 5456691 | Snell | Oct 1995 | A |
| 5458622 | Alt | Oct 1995 | A |
| 5466246 | Silvian | Nov 1995 | A |
| 5468254 | Hahn et al. | Nov 1995 | A |
| 5472453 | Alt | Dec 1995 | A |
| 5522866 | Fernald | Jun 1996 | A |
| 5540727 | Tockman et al. | Jul 1996 | A |
| 5545186 | Olson et al. | Aug 1996 | A |
| 5545202 | Dahl et al. | Aug 1996 | A |
| 5554177 | Kieval et al. | Sep 1996 | A |
| 5562711 | Yerich et al. | Oct 1996 | A |
| 5571146 | Jones et al. | Nov 1996 | A |
| 5591214 | Lu | Jan 1997 | A |
| 5620466 | Haefner et al. | Apr 1997 | A |
| 5634938 | Swanson et al. | Jun 1997 | A |
| 5649968 | Alt et al. | Jul 1997 | A |
| 5662688 | Haefner et al. | Sep 1997 | A |
| 5674259 | Gray | Oct 1997 | A |
| 5683426 | Greenhut et al. | Nov 1997 | A |
| 5683432 | Goedeke et al. | Nov 1997 | A |
| 5706823 | Wodlinger | Jan 1998 | A |
| 5709215 | Perttu et al. | Jan 1998 | A |
| 5720770 | Nappholz et al. | Feb 1998 | A |
| 5728140 | Salo et al. | Mar 1998 | A |
| 5728154 | Crossett et al. | Mar 1998 | A |
| 5741314 | Daly et al. | Apr 1998 | A |
| 5741315 | Lee et al. | Apr 1998 | A |
| 5749909 | Schroeppel et al. | May 1998 | A |
| 5752976 | Duffin et al. | May 1998 | A |
| 5752977 | Grievous et al. | May 1998 | A |
| 5755736 | Gillberg et al. | May 1998 | A |
| 5759199 | Snell et al. | Jun 1998 | A |
| 5774501 | Halpern et al. | Jun 1998 | A |
| 5792195 | Carlson et al. | Aug 1998 | A |
| 5792202 | Rueter | Aug 1998 | A |
| 5792203 | Schroeppel | Aug 1998 | A |
| 5792205 | Alt et al. | Aug 1998 | A |
| 5792208 | Gray | Aug 1998 | A |
| 5814089 | Stokes et al. | Sep 1998 | A |
| 5817130 | Cox et al. | Oct 1998 | A |
| 5827216 | Igo et al. | Oct 1998 | A |
| 5836985 | Goyal et al. | Nov 1998 | A |
| 5836987 | Baumann et al. | Nov 1998 | A |
| 5842977 | Lesho et al. | Dec 1998 | A |
| 5855593 | Olson et al. | Jan 1999 | A |
| 5873894 | Vandegriff et al. | Feb 1999 | A |
| 5891184 | Lee et al. | Apr 1999 | A |
| 5897586 | Molina | Apr 1999 | A |
| 5899876 | Flower | May 1999 | A |
| 5899928 | Sholder et al. | May 1999 | A |
| 5919214 | Ciciarelli et al. | Jul 1999 | A |
| 5928271 | Hess et al. | Jul 1999 | A |
| 5935078 | Feierbach | Aug 1999 | A |
| 5941906 | Barreras et al. | Aug 1999 | A |
| 5944744 | Paul et al. | Aug 1999 | A |
| 5954757 | Gray | Sep 1999 | A |
| 5978713 | Prutchi et al. | Nov 1999 | A |
| 5991660 | Goyal | Nov 1999 | A |
| 5991661 | Park et al. | Nov 1999 | A |
| 5999848 | Gord et al. | Dec 1999 | A |
| 5999857 | Weijand et al. | Dec 1999 | A |
| 6016445 | Baura | Jan 2000 | A |
| 6026320 | Carlson et al. | Feb 2000 | A |
| 6029085 | Olson et al. | Feb 2000 | A |
| 6041250 | dePinto | Mar 2000 | A |
| 6044298 | Salo et al. | Mar 2000 | A |
| 6044300 | Gray | Mar 2000 | A |
| 6055454 | Heemels | Apr 2000 | A |
| 6070104 | Hine et al. | May 2000 | A |
| 6073050 | Griffith | Jun 2000 | A |
| 6076016 | Feierbach | Jun 2000 | A |
| 6077236 | Cunningham | Jun 2000 | A |
| 6080187 | Alt et al. | Jun 2000 | A |
| 6083248 | Thompson | Jul 2000 | A |
| 6106551 | Crossett et al. | Aug 2000 | A |
| 6115636 | Ryan | Sep 2000 | A |
| 6128526 | Stadler et al. | Oct 2000 | A |
| 6132456 | Sommer et al. | Oct 2000 | A |
| 6141581 | Olson et al. | Oct 2000 | A |
| 6141588 | Cox et al. | Oct 2000 | A |
| 6141592 | Pauly | Oct 2000 | A |
| 6144879 | Gray | Nov 2000 | A |
| 6162195 | Igo et al. | Dec 2000 | A |
| 6164284 | Schulman et al. | Dec 2000 | A |
| 6167310 | Grevious | Dec 2000 | A |
| 6201993 | Kruse et al. | Mar 2001 | B1 |
| 6208894 | Schulman et al. | Mar 2001 | B1 |
| 6211799 | Post et al. | Apr 2001 | B1 |
| 6221011 | Bardy | Apr 2001 | B1 |
| 6240316 | Richmond et al. | May 2001 | B1 |
| 6240317 | Villaseca et al. | May 2001 | B1 |
| 6256534 | Dahl | Jul 2001 | B1 |
| 6259947 | Olson et al. | Jul 2001 | B1 |
| 6266558 | Gozani et al. | Jul 2001 | B1 |
| 6266567 | Ishikawa et al. | Jul 2001 | B1 |
| 6270457 | Bardy | Aug 2001 | B1 |
| 6272377 | Sweeney et al. | Aug 2001 | B1 |
| 6273856 | Sun et al. | Aug 2001 | B1 |
| 6277072 | Bardy | Aug 2001 | B1 |
| 6280380 | Bardy | Aug 2001 | B1 |
| 6285903 | Rosenthal et al. | Sep 2001 | B1 |
| 6285907 | Kramer et al. | Sep 2001 | B1 |
| 6292698 | Duffin et al. | Sep 2001 | B1 |
| 6295473 | Rosar | Sep 2001 | B1 |
| 6297943 | Carson | Oct 2001 | B1 |
| 6298271 | Weijand | Oct 2001 | B1 |
| 6307751 | Bodony et al. | Oct 2001 | B1 |
| 6312378 | Bardy | Nov 2001 | B1 |
| 6315721 | Schulman et al. | Nov 2001 | B2 |
| 6336903 | Bardy | Jan 2002 | B1 |
| 6345202 | Richmond et al. | Feb 2002 | B2 |
| 6351667 | Godie | Feb 2002 | B1 |
| 6351669 | Hartley et al. | Feb 2002 | B1 |
| 6353759 | Hartley et al. | Mar 2002 | B1 |
| 6358203 | Bardy | Mar 2002 | B2 |
| 6361780 | Ley et al. | Mar 2002 | B1 |
| 6368284 | Bardy | Apr 2002 | B1 |
| 6371922 | Baumann et al. | Apr 2002 | B1 |
| 6393316 | Gillberg et al. | May 2002 | B1 |
| 6398728 | Bardy | Jun 2002 | B1 |
| 6400982 | Sweeney et al. | Jun 2002 | B2 |
| 6400990 | Silvian | Jun 2002 | B1 |
| 6408208 | Sun | Jun 2002 | B1 |
| 6409674 | Brockway et al. | Jun 2002 | B1 |
| 6411848 | Kramer et al. | Jun 2002 | B2 |
| 6424865 | Ding | Jul 2002 | B1 |
| 6434429 | Kraus et al. | Aug 2002 | B1 |
| 6438410 | Hsu et al. | Aug 2002 | B2 |
| 6438417 | Rockwell et al. | Aug 2002 | B1 |
| 6438421 | Stahmann et al. | Aug 2002 | B1 |
| 6440066 | Bardy | Aug 2002 | B1 |
| 6441747 | Khair et al. | Aug 2002 | B1 |
| 6442426 | Kroll | Aug 2002 | B1 |
| 6442432 | Lee | Aug 2002 | B2 |
| 6443891 | Grevious | Sep 2002 | B1 |
| 6445953 | Bulkes et al. | Sep 2002 | B1 |
| 6453200 | Koslar | Sep 2002 | B1 |
| 6459929 | Hopper et al. | Oct 2002 | B1 |
| 6470215 | Kraus et al. | Oct 2002 | B1 |
| 6471645 | Warkentin et al. | Oct 2002 | B1 |
| 6480745 | Nelson et al. | Nov 2002 | B2 |
| 6487443 | Olson et al. | Nov 2002 | B2 |
| 6490487 | Kraus et al. | Dec 2002 | B1 |
| 6498951 | Larson et al. | Dec 2002 | B1 |
| 6507755 | Gozani et al. | Jan 2003 | B1 |
| 6507759 | Prutchi et al. | Jan 2003 | B1 |
| 6508771 | Padmanabhan et al. | Jan 2003 | B1 |
| 6512940 | Brabec et al. | Jan 2003 | B1 |
| 6522915 | Ceballos et al. | Feb 2003 | B1 |
| 6526311 | Begemann | Feb 2003 | B2 |
| 6539253 | Thompson et al. | Mar 2003 | B2 |
| 6542775 | Ding et al. | Apr 2003 | B2 |
| 6553258 | Stahmann et al. | Apr 2003 | B2 |
| 6561975 | Pool et al. | May 2003 | B1 |
| 6564807 | Schulman et al. | May 2003 | B1 |
| 6574506 | Kramer et al. | Jun 2003 | B2 |
| 6584351 | Ekwall | Jun 2003 | B1 |
| 6584352 | Combs et al. | Jun 2003 | B2 |
| 6597948 | Rockwell et al. | Jul 2003 | B1 |
| 6597951 | Kramer et al. | Jul 2003 | B2 |
| 6622046 | Fraley et al. | Sep 2003 | B2 |
| 6623518 | Thompson et al. | Sep 2003 | B2 |
| 6628985 | Sweeney et al. | Sep 2003 | B2 |
| 6647292 | Bardy et al. | Nov 2003 | B1 |
| 6666844 | Igo et al. | Dec 2003 | B1 |
| 6689117 | Sweeney et al. | Feb 2004 | B2 |
| 6690959 | Thompson | Feb 2004 | B2 |
| 6694189 | Begemann | Feb 2004 | B2 |
| 6704602 | Berg et al. | Mar 2004 | B2 |
| 6718212 | Parry et al. | Apr 2004 | B2 |
| 6721597 | Bardy et al. | Apr 2004 | B1 |
| 6738670 | Almendinger et al. | May 2004 | B1 |
| 6746797 | Benson et al. | Jun 2004 | B2 |
| 6749566 | Russ | Jun 2004 | B2 |
| 6754528 | Bardy et al. | Jun 2004 | B2 |
| 6758810 | Lebel et al. | Jul 2004 | B2 |
| 6763269 | Cox | Jul 2004 | B2 |
| 6778860 | Ostroff et al. | Aug 2004 | B2 |
| 6788971 | Sloman et al. | Sep 2004 | B1 |
| 6788974 | Bardy et al. | Sep 2004 | B2 |
| 6804558 | Haller et al. | Oct 2004 | B2 |
| 6807442 | Myklebust et al. | Oct 2004 | B1 |
| 6847844 | Sun et al. | Jan 2005 | B2 |
| 6869404 | Schulhauser et al. | Mar 2005 | B2 |
| 6871095 | Stahmann et al. | Mar 2005 | B2 |
| 6871096 | Hill | Mar 2005 | B2 |
| 6878112 | Linberg et al. | Apr 2005 | B2 |
| 6885889 | Chinchoy | Apr 2005 | B2 |
| 6892094 | Ousdigian et al. | May 2005 | B2 |
| 6897788 | Khair et al. | May 2005 | B2 |
| 6904315 | Panken et al. | Jun 2005 | B2 |
| 6922592 | Thompson et al. | Jul 2005 | B2 |
| 6931282 | Esler | Aug 2005 | B2 |
| 6931286 | Sigg et al. | Aug 2005 | B2 |
| 6934585 | Schloss et al. | Aug 2005 | B1 |
| 6941169 | Pappu | Sep 2005 | B2 |
| 6957107 | Rogers et al. | Oct 2005 | B2 |
| 6978176 | Lattouf | Dec 2005 | B2 |
| 6980675 | Evron et al. | Dec 2005 | B2 |
| 6985773 | Von Arx et al. | Jan 2006 | B2 |
| 6990375 | Kloss et al. | Jan 2006 | B2 |
| 6993389 | Ding et al. | Jan 2006 | B2 |
| 7001366 | Ballard | Feb 2006 | B2 |
| 7003350 | Denker et al. | Feb 2006 | B2 |
| 7006864 | Echt et al. | Feb 2006 | B2 |
| 7013176 | Ding et al. | Mar 2006 | B2 |
| 7013178 | Reinke et al. | Mar 2006 | B2 |
| 7027871 | Burnes et al. | Apr 2006 | B2 |
| 7031711 | Brown et al. | Apr 2006 | B2 |
| 7031771 | Brown et al. | Apr 2006 | B2 |
| 7035684 | Lee et al. | Apr 2006 | B2 |
| 7050849 | Echt et al. | May 2006 | B2 |
| 7060031 | Webb et al. | Jun 2006 | B2 |
| 7063693 | Guenst | Jun 2006 | B2 |
| 7082336 | Ransbury et al. | Jul 2006 | B2 |
| 7085606 | Flach et al. | Aug 2006 | B2 |
| 7092758 | Sun et al. | Aug 2006 | B2 |
| 7110824 | Amundson et al. | Sep 2006 | B2 |
| 7120504 | Osypka | Oct 2006 | B2 |
| 7130681 | Gebhardt et al. | Oct 2006 | B2 |
| 7139613 | Reinke et al. | Nov 2006 | B2 |
| 7142912 | Wagner et al. | Nov 2006 | B2 |
| 7146225 | Guenst et al. | Dec 2006 | B2 |
| 7146226 | Lau et al. | Dec 2006 | B2 |
| 7149581 | Goedeke | Dec 2006 | B2 |
| 7149588 | Lau et al. | Dec 2006 | B2 |
| 7158839 | Lau | Jan 2007 | B2 |
| 7162307 | Patrias | Jan 2007 | B2 |
| 7164952 | Lau et al. | Jan 2007 | B2 |
| 7177700 | Cox | Feb 2007 | B1 |
| 7177704 | Laske et al. | Feb 2007 | B2 |
| 7181284 | Burnes et al. | Feb 2007 | B2 |
| 7181505 | Haller et al. | Feb 2007 | B2 |
| 7184830 | Echt et al. | Feb 2007 | B2 |
| 7186214 | Ness | Mar 2007 | B2 |
| 7191015 | Lamson et al. | Mar 2007 | B2 |
| 7200437 | Nabutovsky et al. | Apr 2007 | B1 |
| 7200439 | Zdeblick et al. | Apr 2007 | B2 |
| 7206423 | Feng et al. | Apr 2007 | B1 |
| 7209785 | Kim et al. | Apr 2007 | B2 |
| 7209790 | Thompson et al. | Apr 2007 | B2 |
| 7211884 | Davis et al. | May 2007 | B1 |
| 7212871 | Morgan | May 2007 | B1 |
| 7226440 | Gelfand et al. | Jun 2007 | B2 |
| 7228183 | Sun et al. | Jun 2007 | B2 |
| 7231248 | Kramer et al. | Jun 2007 | B2 |
| 7231253 | Tidemand et al. | Jun 2007 | B2 |
| 7236821 | Cates et al. | Jun 2007 | B2 |
| 7236829 | Farazi et al. | Jun 2007 | B1 |
| 7254448 | Almendinger et al. | Aug 2007 | B2 |
| 7260436 | Kilgore et al. | Aug 2007 | B2 |
| 7270669 | Sra | Sep 2007 | B1 |
| 7272448 | Morgan et al. | Sep 2007 | B1 |
| 7277755 | Falkenberg et al. | Oct 2007 | B1 |
| 7280872 | Mosesov et al. | Oct 2007 | B1 |
| 7286866 | Okerlund et al. | Oct 2007 | B2 |
| 7288096 | Chin | Oct 2007 | B2 |
| 7289847 | Gill et al. | Oct 2007 | B1 |
| 7289852 | Helfinstine et al. | Oct 2007 | B2 |
| 7289853 | Campbell et al. | Oct 2007 | B1 |
| 7289855 | Nghiem et al. | Oct 2007 | B2 |
| 7302294 | Kamath et al. | Nov 2007 | B2 |
| 7305266 | Kroll | Dec 2007 | B1 |
| 7307321 | Avanzino | Dec 2007 | B1 |
| 7308297 | Reddy et al. | Dec 2007 | B2 |
| 7308299 | Burrell et al. | Dec 2007 | B2 |
| 7310556 | Bulkes | Dec 2007 | B2 |
| 7317950 | Lee | Jan 2008 | B2 |
| 7319905 | Morgan et al. | Jan 2008 | B1 |
| 7321677 | Evron et al. | Jan 2008 | B2 |
| 7321798 | Muhlenberg et al. | Jan 2008 | B2 |
| 7333853 | Mazar et al. | Feb 2008 | B2 |
| 7336994 | Hettrick et al. | Feb 2008 | B2 |
| 7346381 | Okerlund et al. | Mar 2008 | B2 |
| 7346393 | Spinelli et al. | Mar 2008 | B2 |
| 7347819 | Lebel et al. | Mar 2008 | B2 |
| 7366572 | Heruth et al. | Apr 2008 | B2 |
| 7373207 | Lattouf | May 2008 | B2 |
| 7384403 | Sherman | Jun 2008 | B2 |
| 7386342 | Falkenberg et al. | Jun 2008 | B1 |
| 7386351 | Hine et al. | Jun 2008 | B2 |
| 7392090 | Sweeney et al. | Jun 2008 | B2 |
| 7406105 | DelMain et al. | Jul 2008 | B2 |
| 7406349 | Seeberger et al. | Jul 2008 | B2 |
| 7410497 | Hastings et al. | Aug 2008 | B2 |
| 7425200 | Brockway et al. | Sep 2008 | B2 |
| 7433739 | Salys et al. | Oct 2008 | B1 |
| 7454248 | Burrell et al. | Nov 2008 | B2 |
| 7496409 | Greenhut et al. | Feb 2009 | B2 |
| 7496410 | Heil | Feb 2009 | B2 |
| 7499743 | Vass et al. | Mar 2009 | B2 |
| 7502652 | Gaunt et al. | Mar 2009 | B2 |
| 7512448 | Malick et al. | Mar 2009 | B2 |
| 7515969 | Tockman et al. | Apr 2009 | B2 |
| 7526342 | Chin et al. | Apr 2009 | B2 |
| 7529589 | Williams et al. | May 2009 | B2 |
| 7532933 | Hastings et al. | May 2009 | B2 |
| 7536222 | Bardy et al. | May 2009 | B2 |
| 7536224 | Ritscher et al. | May 2009 | B2 |
| 7539541 | Quiles et al. | May 2009 | B2 |
| 7544197 | Kelsch et al. | Jun 2009 | B2 |
| 7546166 | Michels et al. | Jun 2009 | B2 |
| 7558626 | Corbucci | Jul 2009 | B2 |
| 7558631 | Cowan et al. | Jul 2009 | B2 |
| 7565190 | Okerlund et al. | Jul 2009 | B2 |
| 7565195 | Kroll et al. | Jul 2009 | B1 |
| 7584002 | Burnes et al. | Sep 2009 | B2 |
| 7587074 | Zarkh et al. | Sep 2009 | B2 |
| 7590455 | Heruth et al. | Sep 2009 | B2 |
| 7599730 | Hunter et al. | Oct 2009 | B2 |
| 7606621 | Brisken et al. | Oct 2009 | B2 |
| 7610088 | Chinchoy | Oct 2009 | B2 |
| 7610092 | Cowan et al. | Oct 2009 | B2 |
| 7610099 | Almendinger et al. | Oct 2009 | B2 |
| 7610104 | Kaplan et al. | Oct 2009 | B2 |
| 7613500 | Vass et al. | Nov 2009 | B2 |
| 7616991 | Mann et al. | Nov 2009 | B2 |
| 7617001 | Penner et al. | Nov 2009 | B2 |
| 7617007 | Williams et al. | Nov 2009 | B2 |
| 7630764 | Ding et al. | Dec 2009 | B2 |
| 7630767 | Poore et al. | Dec 2009 | B1 |
| 7634313 | Kroll et al. | Dec 2009 | B1 |
| 7635541 | Scott et al. | Dec 2009 | B2 |
| 7637867 | Zdeblick | Dec 2009 | B2 |
| 7640057 | Libbus et al. | Dec 2009 | B2 |
| 7640060 | Zdeblick | Dec 2009 | B2 |
| 7647109 | Hastings et al. | Jan 2010 | B2 |
| 7650186 | Hastings et al. | Jan 2010 | B2 |
| 7657311 | Bardy et al. | Feb 2010 | B2 |
| 7657313 | Rom | Feb 2010 | B2 |
| 7668596 | Von Arx et al. | Feb 2010 | B2 |
| 7682316 | Anderson et al. | Mar 2010 | B2 |
| 7691047 | Ferrari | Apr 2010 | B2 |
| 7702392 | Echt et al. | Apr 2010 | B2 |
| 7706879 | Burnes et al. | Apr 2010 | B2 |
| 7713194 | Zdeblick | May 2010 | B2 |
| 7713195 | Zdeblick | May 2010 | B2 |
| 7729783 | Michels et al. | Jun 2010 | B2 |
| 7734333 | Ghanem et al. | Jun 2010 | B2 |
| 7734343 | Ransbury et al. | Jun 2010 | B2 |
| 7738958 | Zdeblick et al. | Jun 2010 | B2 |
| 7738964 | Von Arx et al. | Jun 2010 | B2 |
| 7742629 | Zarkh et al. | Jun 2010 | B2 |
| 7742812 | Ghanem et al. | Jun 2010 | B2 |
| 7742816 | Masoud et al. | Jun 2010 | B2 |
| 7742822 | Masoud et al. | Jun 2010 | B2 |
| 7743151 | Vallapureddy et al. | Jun 2010 | B2 |
| 7747047 | Okerlund et al. | Jun 2010 | B2 |
| 7747335 | Williams | Jun 2010 | B2 |
| 7751881 | Cowan et al. | Jul 2010 | B2 |
| 7758521 | Morris et al. | Jul 2010 | B2 |
| 7761150 | Ghanem et al. | Jul 2010 | B2 |
| 7761164 | Verhoef et al. | Jul 2010 | B2 |
| 7765001 | Echt et al. | Jul 2010 | B2 |
| 7769452 | Ghanem et al. | Aug 2010 | B2 |
| 7778685 | Evron et al. | Aug 2010 | B2 |
| 7778686 | Vass et al. | Aug 2010 | B2 |
| 7783362 | Whitehurst et al. | Aug 2010 | B2 |
| 7792588 | Harding | Sep 2010 | B2 |
| 7797059 | Bornzin et al. | Sep 2010 | B1 |
| 7801596 | Fischell et al. | Sep 2010 | B2 |
| 7809438 | Echt et al. | Oct 2010 | B2 |
| 7813785 | Okerlund et al. | Oct 2010 | B2 |
| 7840281 | Kveen et al. | Nov 2010 | B2 |
| 7844331 | Li et al. | Nov 2010 | B2 |
| 7844348 | Swoyer et al. | Nov 2010 | B2 |
| 7846088 | Ness | Dec 2010 | B2 |
| 7848815 | Brisken et al. | Dec 2010 | B2 |
| 7848823 | Drasler et al. | Dec 2010 | B2 |
| 7860455 | Fukumoto et al. | Dec 2010 | B2 |
| 7871433 | Lattouf | Jan 2011 | B2 |
| 7877136 | Moffitt et al. | Jan 2011 | B1 |
| 7877142 | Moaddeb et al. | Jan 2011 | B2 |
| 7877144 | Coles, Jr. et al. | Jan 2011 | B2 |
| 7881786 | Jackson | Feb 2011 | B2 |
| 7881791 | Sambelashvili et al. | Feb 2011 | B2 |
| 7881798 | Miesel et al. | Feb 2011 | B2 |
| 7881806 | Horrigan et al. | Feb 2011 | B2 |
| 7881810 | Chitre et al. | Feb 2011 | B1 |
| 7890173 | Brisken et al. | Feb 2011 | B2 |
| 7890181 | Denzene et al. | Feb 2011 | B2 |
| 7890192 | Kelsch et al. | Feb 2011 | B1 |
| 7894885 | Bartal et al. | Feb 2011 | B2 |
| 7894894 | Stadler et al. | Feb 2011 | B2 |
| 7894902 | Rom | Feb 2011 | B2 |
| 7894907 | Cowan et al. | Feb 2011 | B2 |
| 7894910 | Cowan et al. | Feb 2011 | B2 |
| 7894915 | Chitre et al. | Feb 2011 | B1 |
| 7899537 | Kroll et al. | Mar 2011 | B1 |
| 7899541 | Cowan et al. | Mar 2011 | B2 |
| 7899542 | Cowan et al. | Mar 2011 | B2 |
| 7899554 | Williams et al. | Mar 2011 | B2 |
| 7901360 | Yang et al. | Mar 2011 | B1 |
| 7904170 | Harding | Mar 2011 | B2 |
| 7907993 | Ghanem et al. | Mar 2011 | B2 |
| 7912544 | Min et al. | Mar 2011 | B1 |
| 7920928 | Yang et al. | Apr 2011 | B1 |
| 7925343 | Min et al. | Apr 2011 | B1 |
| 7930022 | Zhang et al. | Apr 2011 | B2 |
| 7930027 | Prakash et al. | Apr 2011 | B2 |
| 7930040 | Kelsch et al. | Apr 2011 | B1 |
| 7937135 | Ghanem et al. | May 2011 | B2 |
| 7937148 | Jacobson | May 2011 | B2 |
| 7937161 | Hastings et al. | May 2011 | B2 |
| 7941214 | Kleckner et al. | May 2011 | B2 |
| 7941218 | Sambelashvili et al. | May 2011 | B2 |
| 7945333 | Jacobson | May 2011 | B2 |
| 7946997 | Hubinette | May 2011 | B2 |
| 7949404 | Hill | May 2011 | B2 |
| 7949405 | Feher | May 2011 | B2 |
| 7953486 | Daum et al. | May 2011 | B2 |
| 7953493 | Fowler et al. | May 2011 | B2 |
| 7962202 | Bhunia | Jun 2011 | B2 |
| 7974702 | Fain et al. | Jul 2011 | B1 |
| 7979136 | Young et al. | Jul 2011 | B2 |
| 7983753 | Severin | Jul 2011 | B2 |
| 7991467 | Markowitz et al. | Aug 2011 | B2 |
| 7991471 | Ghanem et al. | Aug 2011 | B2 |
| 7996063 | Vass et al. | Aug 2011 | B2 |
| 7996087 | Cowan et al. | Aug 2011 | B2 |
| 8000791 | Sunagawa et al. | Aug 2011 | B2 |
| 8000807 | Morris et al. | Aug 2011 | B2 |
| 8001975 | DiSilvestro et al. | Aug 2011 | B2 |
| 8002700 | Ferek-Petric et al. | Aug 2011 | B2 |
| 8002718 | Buchholtz et al. | Aug 2011 | B2 |
| 8010209 | Jacobson | Aug 2011 | B2 |
| 8019419 | Panescu et al. | Sep 2011 | B1 |
| 8019434 | Quiles et al. | Sep 2011 | B2 |
| 8027727 | Freeberg | Sep 2011 | B2 |
| 8027729 | Sunagawa et al. | Sep 2011 | B2 |
| 8032219 | Neumann et al. | Oct 2011 | B2 |
| 8036743 | Savage et al. | Oct 2011 | B2 |
| 8046065 | Burnes et al. | Oct 2011 | B2 |
| 8046079 | Bange et al. | Oct 2011 | B2 |
| 8046080 | Von Arx et al. | Oct 2011 | B2 |
| 8050297 | Delmain et al. | Nov 2011 | B2 |
| 8050759 | Stegemann et al. | Nov 2011 | B2 |
| 8050774 | Kveen et al. | Nov 2011 | B2 |
| 8055345 | Li et al. | Nov 2011 | B2 |
| 8055350 | Roberts | Nov 2011 | B2 |
| 8060185 | Hunter et al. | Nov 2011 | B2 |
| 8060212 | Rios et al. | Nov 2011 | B1 |
| 8065018 | Haubrich et al. | Nov 2011 | B2 |
| 8068920 | Gaudiani | Nov 2011 | B2 |
| 8073542 | Doerr | Dec 2011 | B2 |
| 8078278 | Penner | Dec 2011 | B2 |
| 8078283 | Cowan et al. | Dec 2011 | B2 |
| 8095123 | Gray | Jan 2012 | B2 |
| 8102789 | Rosar et al. | Jan 2012 | B2 |
| 8103359 | Reddy | Jan 2012 | B2 |
| 8103361 | Moser | Jan 2012 | B2 |
| 8105714 | Schmidt et al. | Jan 2012 | B2 |
| 8112148 | Giftakis et al. | Feb 2012 | B2 |
| 8114021 | Robertson et al. | Feb 2012 | B2 |
| 8121680 | Falkenberg et al. | Feb 2012 | B2 |
| 8123684 | Zdeblick | Feb 2012 | B2 |
| 8126545 | Flach et al. | Feb 2012 | B2 |
| 8131334 | Lu et al. | Mar 2012 | B2 |
| 8140161 | Willerton et al. | Mar 2012 | B2 |
| 8145308 | Sambelashvili et al. | Mar 2012 | B2 |
| 8150521 | Crowley et al. | Apr 2012 | B2 |
| 8160672 | Kim et al. | Apr 2012 | B2 |
| 8160702 | Mann et al. | Apr 2012 | B2 |
| 8160704 | Freeberg | Apr 2012 | B2 |
| 8165694 | Carbanaru et al. | Apr 2012 | B2 |
| 8175715 | Cox | May 2012 | B1 |
| 8180428 | Kaiser et al. | May 2012 | B2 |
| 8180451 | Hickman et al. | May 2012 | B2 |
| 8185213 | Kveen et al. | May 2012 | B2 |
| 8187161 | Li et al. | May 2012 | B2 |
| 8195293 | Limousin et al. | Jun 2012 | B2 |
| 8204590 | Sambelashvili et al. | Jun 2012 | B2 |
| 8204595 | Pianca et al. | Jun 2012 | B2 |
| 8204605 | Hastings et al. | Jun 2012 | B2 |
| 8209014 | Doerr | Jun 2012 | B2 |
| 8214041 | Van Gelder et al. | Jul 2012 | B2 |
| 8214043 | Matos | Jul 2012 | B2 |
| 8224244 | Kim et al. | Jul 2012 | B2 |
| 8229556 | Li | Jul 2012 | B2 |
| 8233985 | Bulkes et al. | Jul 2012 | B2 |
| 8262578 | Bharmi et al. | Sep 2012 | B1 |
| 8265748 | Liu et al. | Sep 2012 | B2 |
| 8265757 | Mass et al. | Sep 2012 | B2 |
| 8280521 | Haubrich et al. | Oct 2012 | B2 |
| 8285387 | Utsi et al. | Oct 2012 | B2 |
| 8290598 | Boon et al. | Oct 2012 | B2 |
| 8290600 | Hastings et al. | Oct 2012 | B2 |
| 8295939 | Jacobson | Oct 2012 | B2 |
| 8301254 | Mosesov et al. | Oct 2012 | B2 |
| 8315701 | Cowan et al. | Nov 2012 | B2 |
| 8315708 | Berthelsdorf et al. | Nov 2012 | B2 |
| 8321014 | Maskara et al. | Nov 2012 | B2 |
| 8321021 | Kisker et al. | Nov 2012 | B2 |
| 8321036 | Brockway et al. | Nov 2012 | B2 |
| 8332036 | Hastings et al. | Dec 2012 | B2 |
| 8335563 | Stessman | Dec 2012 | B2 |
| 8335568 | Heruth et al. | Dec 2012 | B2 |
| 8340750 | Prakash et al. | Dec 2012 | B2 |
| 8340780 | Hastings et al. | Dec 2012 | B2 |
| 8352025 | Jacobson | Jan 2013 | B2 |
| 8352027 | Spinelli et al. | Jan 2013 | B2 |
| 8352028 | Wenger | Jan 2013 | B2 |
| 8352038 | Mao et al. | Jan 2013 | B2 |
| 8359098 | Lund et al. | Jan 2013 | B2 |
| 8364261 | Stubbs et al. | Jan 2013 | B2 |
| 8364276 | Willis | Jan 2013 | B2 |
| 8369959 | Meskens | Feb 2013 | B2 |
| 8369962 | Abrahamson | Feb 2013 | B2 |
| 8380320 | Spital | Feb 2013 | B2 |
| 8383269 | Scott et al. | Feb 2013 | B2 |
| 8386051 | Rys | Feb 2013 | B2 |
| 8391964 | Musley et al. | Mar 2013 | B2 |
| 8391981 | Mosesov | Mar 2013 | B2 |
| 8391990 | Smith et al. | Mar 2013 | B2 |
| 8401616 | Verard et al. | Mar 2013 | B2 |
| 8406874 | Liu et al. | Mar 2013 | B2 |
| 8406879 | Shuros et al. | Mar 2013 | B2 |
| 8406886 | Gaunt et al. | Mar 2013 | B2 |
| 8406899 | Reddy et al. | Mar 2013 | B2 |
| 8412352 | Griswold et al. | Apr 2013 | B2 |
| 8417340 | Goossen | Apr 2013 | B2 |
| 8417341 | Freeberg | Apr 2013 | B2 |
| 8423149 | Hennig | Apr 2013 | B2 |
| 8428716 | Mullen et al. | Apr 2013 | B2 |
| 8428722 | Verhoef et al. | Apr 2013 | B2 |
| 8433402 | Ruben et al. | Apr 2013 | B2 |
| 8433409 | Johnson et al. | Apr 2013 | B2 |
| 8433420 | Bange et al. | Apr 2013 | B2 |
| 8447412 | Dal Molin et al. | May 2013 | B2 |
| 8452413 | Young et al. | May 2013 | B2 |
| 8457740 | Osche | Jun 2013 | B2 |
| 8457742 | Jacobson | Jun 2013 | B2 |
| 8457744 | Janzig et al. | Jun 2013 | B2 |
| 8457761 | Wariar | Jun 2013 | B2 |
| 8467871 | Maskara | Jun 2013 | B2 |
| 8478407 | Demmer et al. | Jul 2013 | B2 |
| 8478408 | Hastings et al. | Jul 2013 | B2 |
| 8478431 | Griswold et al. | Jul 2013 | B2 |
| 8494632 | Sun et al. | Jul 2013 | B2 |
| 8504156 | Bonner et al. | Aug 2013 | B2 |
| 8509910 | Sowder et al. | Aug 2013 | B2 |
| 8509916 | Byrd et al. | Aug 2013 | B2 |
| 8515559 | Roberts et al. | Aug 2013 | B2 |
| 8521268 | Zhang et al. | Aug 2013 | B2 |
| 8525340 | Eckhardt et al. | Sep 2013 | B2 |
| 8527068 | Ostroff | Sep 2013 | B2 |
| 8532790 | Griswold | Sep 2013 | B2 |
| 8538526 | Stahmann et al. | Sep 2013 | B2 |
| 8541131 | Lund | Sep 2013 | B2 |
| 8543205 | Ostroff | Sep 2013 | B2 |
| 8547248 | Zdeblick et al. | Oct 2013 | B2 |
| 8548605 | Ollivier | Oct 2013 | B2 |
| 8554333 | Wu et al. | Oct 2013 | B2 |
| 8565882 | Matoes | Oct 2013 | B2 |
| 8565897 | Regnier et al. | Oct 2013 | B2 |
| 8571678 | Wang | Oct 2013 | B2 |
| 8577327 | Makdissi et al. | Nov 2013 | B2 |
| 8588926 | Moore et al. | Nov 2013 | B2 |
| 8594775 | Ghosh et al. | Nov 2013 | B2 |
| 8612002 | Faltys et al. | Dec 2013 | B2 |
| 8615310 | Khairkhahan et al. | Dec 2013 | B2 |
| 8617082 | Zhang et al. | Dec 2013 | B2 |
| 8626280 | Allavatam et al. | Jan 2014 | B2 |
| 8626294 | Sheldon et al. | Jan 2014 | B2 |
| 8634908 | Cowan | Jan 2014 | B2 |
| 8634912 | Bornzin et al. | Jan 2014 | B2 |
| 8634919 | Hou et al. | Jan 2014 | B1 |
| 8639333 | Stadler et al. | Jan 2014 | B2 |
| 8639335 | Peichel et al. | Jan 2014 | B2 |
| 8644934 | Hastings et al. | Feb 2014 | B2 |
| 8649859 | Smith et al. | Feb 2014 | B2 |
| 8670842 | Bornzin et al. | Mar 2014 | B1 |
| 8676314 | Maskara et al. | Mar 2014 | B2 |
| 8676319 | Knoll | Mar 2014 | B2 |
| 8676335 | Katoozi et al. | Mar 2014 | B2 |
| 8700173 | Edlund | Apr 2014 | B2 |
| 8700181 | Bomzin et al. | Apr 2014 | B2 |
| 8705599 | Dal Molin et al. | Apr 2014 | B2 |
| 8718766 | Wahlberg | May 2014 | B2 |
| 8718773 | Willis et al. | May 2014 | B2 |
| 8725260 | Shuros et al. | May 2014 | B2 |
| 8731642 | Zarkh et al. | May 2014 | B2 |
| 8738133 | Shuros et al. | May 2014 | B2 |
| 8738147 | Hastings et al. | May 2014 | B2 |
| 8744555 | Allavatam et al. | Jun 2014 | B2 |
| 8744572 | Greenbut et al. | Jun 2014 | B1 |
| 8747314 | Stahmann et al. | Jun 2014 | B2 |
| 8750994 | Ghosh et al. | Jun 2014 | B2 |
| 8750998 | Ghosh et al. | Jun 2014 | B1 |
| 8755884 | Demmer et al. | Jun 2014 | B2 |
| 8758365 | Bonner et al. | Jun 2014 | B2 |
| 8768459 | Ghosh et al. | Jul 2014 | B2 |
| 8768483 | Schmitt et al. | Jul 2014 | B2 |
| 8774572 | Hamamoto | Jul 2014 | B2 |
| 8781582 | Ziegler et al. | Jul 2014 | B2 |
| 8781605 | Bornzin et al. | Jul 2014 | B2 |
| 8788035 | Jacobson | Jul 2014 | B2 |
| 8788053 | Jacobson | Jul 2014 | B2 |
| 8798740 | Samade et al. | Aug 2014 | B2 |
| 8798745 | Jacobson | Aug 2014 | B2 |
| 8798762 | Fain et al. | Aug 2014 | B2 |
| 8798770 | Reddy | Aug 2014 | B2 |
| 8805505 | Roberts | Aug 2014 | B1 |
| 8805528 | Corndorf | Aug 2014 | B2 |
| 8812109 | Blomqvist et al. | Aug 2014 | B2 |
| 8818504 | Bodner et al. | Aug 2014 | B2 |
| 8827913 | Havel et al. | Sep 2014 | B2 |
| 8831747 | Min et al. | Sep 2014 | B1 |
| 8855789 | Jacobson | Oct 2014 | B2 |
| 8861830 | Brada et al. | Oct 2014 | B2 |
| 8868186 | Kroll | Oct 2014 | B2 |
| 8886307 | Sambelashvili et al. | Nov 2014 | B2 |
| 8886311 | Anderson et al. | Nov 2014 | B2 |
| 8886339 | Faltys et al. | Nov 2014 | B2 |
| 8903473 | Rogers et al. | Dec 2014 | B2 |
| 8903513 | Ollivier | Dec 2014 | B2 |
| 8909336 | Navarro-Paredes et al. | Dec 2014 | B2 |
| 8914131 | Bornzin et al. | Dec 2014 | B2 |
| 8923795 | Makdissi et al. | Dec 2014 | B2 |
| 8923963 | Bonner et al. | Dec 2014 | B2 |
| 8938300 | Rosero | Jan 2015 | B2 |
| 8942806 | Sheldon et al. | Jan 2015 | B2 |
| 8948883 | Eggen et al. | Feb 2015 | B2 |
| 8958892 | Khairkhahan et al. | Feb 2015 | B2 |
| 8972228 | Ghosh et al. | Mar 2015 | B2 |
| 8977358 | Ewert et al. | Mar 2015 | B2 |
| 8989873 | Locsin | Mar 2015 | B2 |
| 8996109 | Karst et al. | Mar 2015 | B2 |
| 9002467 | Smith et al. | Apr 2015 | B2 |
| 9008776 | Cowan et al. | Apr 2015 | B2 |
| 9008777 | Dianaty et al. | Apr 2015 | B2 |
| 9014818 | Deterre et al. | Apr 2015 | B2 |
| 9017341 | Bornzin et al. | Apr 2015 | B2 |
| 9020611 | Khairkhahan et al. | Apr 2015 | B2 |
| 9033996 | West | May 2015 | B1 |
| 9037262 | Regnier et al. | May 2015 | B2 |
| 9042984 | Demmer et al. | May 2015 | B2 |
| 9072872 | Asleson et al. | Jul 2015 | B2 |
| 9072911 | Hastings et al. | Jul 2015 | B2 |
| 9072913 | Jacobson | Jul 2015 | B2 |
| 9101281 | Reinert et al. | Aug 2015 | B2 |
| 9119959 | Rys et al. | Sep 2015 | B2 |
| 9155882 | Grubac et al. | Oct 2015 | B2 |
| 9168372 | Fain | Oct 2015 | B2 |
| 9168380 | Greenhut et al. | Oct 2015 | B1 |
| 9168383 | Jacobson et al. | Oct 2015 | B2 |
| 9180285 | Moore et al. | Nov 2015 | B2 |
| 9192774 | Jacobson | Nov 2015 | B2 |
| 9205225 | Khairkhahan et al. | Dec 2015 | B2 |
| 9216285 | Boling et al. | Dec 2015 | B1 |
| 9216293 | Berthiaume et al. | Dec 2015 | B2 |
| 9216298 | Jacobson | Dec 2015 | B2 |
| 9227077 | Jacobson | Jan 2016 | B2 |
| 9238145 | Wenzel et al. | Jan 2016 | B2 |
| 9242102 | Khairkhahan et al. | Jan 2016 | B2 |
| 9242113 | Smith et al. | Jan 2016 | B2 |
| 9248300 | Rys et al. | Feb 2016 | B2 |
| 9265436 | Min et al. | Feb 2016 | B2 |
| 9265962 | Dianaty et al. | Feb 2016 | B2 |
| 9272155 | Ostroff | Mar 2016 | B2 |
| 9278218 | Karst et al. | Mar 2016 | B2 |
| 9278229 | Reinke et al. | Mar 2016 | B1 |
| 9283381 | Grubac et al. | Mar 2016 | B2 |
| 9283382 | Berthiaume et al. | Mar 2016 | B2 |
| 9289612 | Sambelashbili et al. | Mar 2016 | B1 |
| 9302115 | Molin et al. | Apr 2016 | B2 |
| 9320446 | Gillberg et al. | Apr 2016 | B2 |
| 9333364 | Echt et al. | May 2016 | B2 |
| 9358387 | Suwito et al. | Jun 2016 | B2 |
| 9358400 | Jacobson | Jun 2016 | B2 |
| 9364675 | Deterre et al. | Jun 2016 | B2 |
| 9370663 | Moulder | Jun 2016 | B2 |
| 9375580 | Bonner et al. | Jun 2016 | B2 |
| 9375581 | Baru et al. | Jun 2016 | B2 |
| 9381365 | Kibler et al. | Jul 2016 | B2 |
| 9393424 | Demmer et al. | Jul 2016 | B2 |
| 9393436 | Doerr | Jul 2016 | B2 |
| 9399139 | Demmer et al. | Jul 2016 | B2 |
| 9399140 | Cho et al. | Jul 2016 | B2 |
| 9409033 | Jacobson | Aug 2016 | B2 |
| 9427594 | Bornzin et al. | Aug 2016 | B1 |
| 9433368 | Stahmann et al. | Sep 2016 | B2 |
| 9433780 | Regnier et al. | Sep 2016 | B2 |
| 9457193 | Klimovitch et al. | Oct 2016 | B2 |
| 9474457 | Ghosh | Oct 2016 | B2 |
| 9486151 | Ghosh et al. | Nov 2016 | B2 |
| 9492668 | Sheldon et al. | Nov 2016 | B2 |
| 9492669 | Demmer et al. | Nov 2016 | B2 |
| 9492674 | Schmidt et al. | Nov 2016 | B2 |
| 9492677 | Greenhut et al. | Nov 2016 | B2 |
| 9510763 | Ghosh et al. | Dec 2016 | B2 |
| 9511233 | Sambelashvili | Dec 2016 | B2 |
| 9511236 | Varady et al. | Dec 2016 | B2 |
| 9511237 | Deterre et al. | Dec 2016 | B2 |
| 9517336 | Eggen et al. | Dec 2016 | B2 |
| 9522276 | Shen et al. | Dec 2016 | B2 |
| 9522280 | Fishler et al. | Dec 2016 | B2 |
| 9526522 | Wood et al. | Dec 2016 | B2 |
| 9526891 | Eggen et al. | Dec 2016 | B2 |
| 9526909 | Stahmann et al. | Dec 2016 | B2 |
| 9533163 | Klimovitch et al. | Jan 2017 | B2 |
| 9561382 | Persson et al. | Feb 2017 | B2 |
| 9566012 | Greenhut et al. | Feb 2017 | B2 |
| 9579500 | Rys et al. | Feb 2017 | B2 |
| 9623234 | Anderson | Apr 2017 | B2 |
| 9636511 | Carney et al. | May 2017 | B2 |
| 9643014 | Zhang et al. | May 2017 | B2 |
| 9675579 | Rock et al. | Jun 2017 | B2 |
| 9707399 | Zielinski et al. | Jul 2017 | B2 |
| 9724519 | Demmer et al. | Aug 2017 | B2 |
| 9789319 | Sambelashvili | Oct 2017 | B2 |
| 9808628 | Sheldon et al. | Nov 2017 | B2 |
| 9808633 | Bonner et al. | Nov 2017 | B2 |
| 9877789 | Ghosh | Jan 2018 | B2 |
| 9901732 | Sommer et al. | Feb 2018 | B2 |
| 9924884 | Ghosh et al. | Mar 2018 | B2 |
| 10004467 | Lahm et al. | Jun 2018 | B2 |
| 10064567 | Ghosh et al. | Sep 2018 | B2 |
| 10092744 | Sommer et al. | Oct 2018 | B2 |
| 10099050 | Chen et al. | Oct 2018 | B2 |
| 10166396 | Schrock et al. | Jan 2019 | B2 |
| 10251555 | Ghosh et al. | Apr 2019 | B2 |
| 10315028 | Sommer et al. | Jun 2019 | B2 |
| 10406370 | Makharinsky | Sep 2019 | B1 |
| 10456581 | Liu et al. | Oct 2019 | B2 |
| 10463853 | Drake et al. | Nov 2019 | B2 |
| 10478627 | Muessig | Nov 2019 | B2 |
| 20020032470 | Linberg | Mar 2002 | A1 |
| 20020035376 | Bardy et al. | Mar 2002 | A1 |
| 20020035377 | Bardy et al. | Mar 2002 | A1 |
| 20020035378 | Bardy et al. | Mar 2002 | A1 |
| 20020035380 | Rissmann et al. | Mar 2002 | A1 |
| 20020035381 | Bardy et al. | Mar 2002 | A1 |
| 20020042629 | Bardy et al. | Apr 2002 | A1 |
| 20020042630 | Bardy et al. | Apr 2002 | A1 |
| 20020042634 | Bardy et al. | Apr 2002 | A1 |
| 20020049475 | Bardy et al. | Apr 2002 | A1 |
| 20020049476 | Bardy et al. | Apr 2002 | A1 |
| 20020052636 | Bardy et al. | May 2002 | A1 |
| 20020068958 | Bardy et al. | Jun 2002 | A1 |
| 20020072773 | Bardy et al. | Jun 2002 | A1 |
| 20020082665 | Haller et al. | Jun 2002 | A1 |
| 20020091414 | Bardy et al. | Jul 2002 | A1 |
| 20020095196 | Linberg | Jul 2002 | A1 |
| 20020099423 | Berg et al. | Jul 2002 | A1 |
| 20020103510 | Bardy et al. | Aug 2002 | A1 |
| 20020107545 | Rissmann et al. | Aug 2002 | A1 |
| 20020107546 | Ostroff et al. | Aug 2002 | A1 |
| 20020107547 | Erlinger et al. | Aug 2002 | A1 |
| 20020107548 | Bardy et al. | Aug 2002 | A1 |
| 20020107549 | Bardy et al. | Aug 2002 | A1 |
| 20020107559 | Sanders et al. | Aug 2002 | A1 |
| 20020120299 | Ostroff et al. | Aug 2002 | A1 |
| 20020173830 | Starkweather et al. | Nov 2002 | A1 |
| 20020193846 | Pool et al. | Dec 2002 | A1 |
| 20030004549 | Hill et al. | Jan 2003 | A1 |
| 20030009203 | Lebel et al. | Jan 2003 | A1 |
| 20030028082 | Thompson | Feb 2003 | A1 |
| 20030040779 | Engmark et al. | Feb 2003 | A1 |
| 20030041866 | Linberg et al. | Mar 2003 | A1 |
| 20030045805 | Sheldon et al. | Mar 2003 | A1 |
| 20030083104 | Bonner et al. | May 2003 | A1 |
| 20030088278 | Bardy et al. | May 2003 | A1 |
| 20030093995 | Tadayon et al. | May 2003 | A1 |
| 20030097153 | Bardy et al. | May 2003 | A1 |
| 20030105497 | Zhu et al. | Jun 2003 | A1 |
| 20030114908 | Flach | Jun 2003 | A1 |
| 20030144701 | Mehra et al. | Jul 2003 | A1 |
| 20030187460 | Chin et al. | Oct 2003 | A1 |
| 20030187461 | Chin | Oct 2003 | A1 |
| 20030204233 | Laske et al. | Oct 2003 | A1 |
| 20040024435 | Leckrone et al. | Feb 2004 | A1 |
| 20040064158 | Klein | Apr 2004 | A1 |
| 20040068302 | Rodgers et al. | Apr 2004 | A1 |
| 20040087938 | Leckrone et al. | May 2004 | A1 |
| 20040088035 | Guenst et al. | May 2004 | A1 |
| 20040102830 | Williams | May 2004 | A1 |
| 20040127959 | Amundson et al. | Jul 2004 | A1 |
| 20040133242 | Chapman et al. | Jul 2004 | A1 |
| 20040147969 | Mann et al. | Jul 2004 | A1 |
| 20040147973 | Hauser | Jul 2004 | A1 |
| 20040167558 | Igo et al. | Aug 2004 | A1 |
| 20040167587 | Thompson | Aug 2004 | A1 |
| 20040172071 | Bardy et al. | Sep 2004 | A1 |
| 20040172077 | Chinchoy | Sep 2004 | A1 |
| 20040172104 | Berg et al. | Sep 2004 | A1 |
| 20040176817 | Wahlstrand et al. | Sep 2004 | A1 |
| 20040176818 | Wahlstrand et al. | Sep 2004 | A1 |
| 20040176830 | Fang | Sep 2004 | A1 |
| 20040186529 | Bardy et al. | Sep 2004 | A1 |
| 20040204673 | Flaherty | Oct 2004 | A1 |
| 20040210292 | Bardy et al. | Oct 2004 | A1 |
| 20040210293 | Bardy et al. | Oct 2004 | A1 |
| 20040210294 | Bardy et al. | Oct 2004 | A1 |
| 20040215308 | Bardy et al. | Oct 2004 | A1 |
| 20040220624 | Ritscher et al. | Nov 2004 | A1 |
| 20040220626 | Wagner | Nov 2004 | A1 |
| 20040220639 | Mulligan et al. | Nov 2004 | A1 |
| 20040230283 | Prinzen et al. | Dec 2004 | A1 |
| 20040249431 | Ransbury et al. | Dec 2004 | A1 |
| 20040260348 | Bakken et al. | Dec 2004 | A1 |
| 20040267303 | Guenst | Dec 2004 | A1 |
| 20050008210 | Evron et al. | Jan 2005 | A1 |
| 20050038477 | Kramer et al. | Feb 2005 | A1 |
| 20050061320 | Lee et al. | Mar 2005 | A1 |
| 20050070962 | Echt et al. | Mar 2005 | A1 |
| 20050102003 | Grabek et al. | May 2005 | A1 |
| 20050137629 | Dyjach et al. | Jun 2005 | A1 |
| 20050137638 | Yonce et al. | Jun 2005 | A1 |
| 20050137671 | Liu | Jun 2005 | A1 |
| 20050149138 | Min et al. | Jul 2005 | A1 |
| 20050165466 | Morris et al. | Jul 2005 | A1 |
| 20050182465 | Ness | Aug 2005 | A1 |
| 20050203410 | Jenkins | Sep 2005 | A1 |
| 20050277990 | Ostroff et al. | Dec 2005 | A1 |
| 20050283208 | Von Arx et al. | Dec 2005 | A1 |
| 20050288743 | Ahn et al. | Dec 2005 | A1 |
| 20060042830 | Maghribi et al. | Mar 2006 | A1 |
| 20060052829 | Sun et al. | Mar 2006 | A1 |
| 20060052830 | Spinelli et al. | Mar 2006 | A1 |
| 20060064135 | Brockway | Mar 2006 | A1 |
| 20060064149 | Belacazar et al. | Mar 2006 | A1 |
| 20060074285 | Zarkh et al. | Apr 2006 | A1 |
| 20060085039 | Hastings et al. | Apr 2006 | A1 |
| 20060085041 | Hastings et al. | Apr 2006 | A1 |
| 20060085042 | Hastings et al. | Apr 2006 | A1 |
| 20060095078 | Tronnes | May 2006 | A1 |
| 20060106442 | Richardson et al. | May 2006 | A1 |
| 20060116746 | Chin | Jun 2006 | A1 |
| 20060135999 | Bodner et al. | Jun 2006 | A1 |
| 20060136004 | Cowan et al. | Jun 2006 | A1 |
| 20060161061 | Echt et al. | Jul 2006 | A1 |
| 20060161205 | Mitrani et al. | Jul 2006 | A1 |
| 20060200002 | Guenst | Sep 2006 | A1 |
| 20060206151 | Lu | Sep 2006 | A1 |
| 20060212079 | Routh et al. | Sep 2006 | A1 |
| 20060235478 | Van Gelder et al. | Oct 2006 | A1 |
| 20060241701 | Markowitz et al. | Oct 2006 | A1 |
| 20060241705 | Neumann et al. | Oct 2006 | A1 |
| 20060247672 | Vidlund et al. | Nov 2006 | A1 |
| 20060259088 | Pastore et al. | Nov 2006 | A1 |
| 20060265018 | Smith et al. | Nov 2006 | A1 |
| 20070004979 | Wojciechowicz et al. | Jan 2007 | A1 |
| 20070016098 | Kim et al. | Jan 2007 | A1 |
| 20070027508 | Cowan | Feb 2007 | A1 |
| 20070049975 | Cates et al. | Mar 2007 | A1 |
| 20070078490 | Cowan et al. | Apr 2007 | A1 |
| 20070088394 | Jacobson | Apr 2007 | A1 |
| 20070088396 | Jacobson | Apr 2007 | A1 |
| 20070088397 | Jacobson | Apr 2007 | A1 |
| 20070088398 | Jacobson | Apr 2007 | A1 |
| 20070088405 | Jaconson | Apr 2007 | A1 |
| 20070135882 | Drasler et al. | Jun 2007 | A1 |
| 20070135883 | Drasler et al. | Jun 2007 | A1 |
| 20070150037 | Hastings et al. | Jun 2007 | A1 |
| 20070150038 | Hastings et al. | Jun 2007 | A1 |
| 20070156190 | Cinbis | Jul 2007 | A1 |
| 20070219525 | Gelfand et al. | Sep 2007 | A1 |
| 20070219590 | Hastings et al. | Sep 2007 | A1 |
| 20070225545 | Ferrari | Sep 2007 | A1 |
| 20070233206 | Frikart et al. | Oct 2007 | A1 |
| 20070233216 | Liu | Oct 2007 | A1 |
| 20070239244 | Morgan et al. | Oct 2007 | A1 |
| 20070255376 | Michels et al. | Nov 2007 | A1 |
| 20070276444 | Gelbart et al. | Nov 2007 | A1 |
| 20070293900 | Sheldon et al. | Dec 2007 | A1 |
| 20070293904 | Gelbart et al. | Dec 2007 | A1 |
| 20070299475 | Levin et al. | Dec 2007 | A1 |
| 20080004663 | Jorgenson | Jan 2008 | A1 |
| 20080021505 | Hastings et al. | Jan 2008 | A1 |
| 20080021519 | De Geest et al. | Jan 2008 | A1 |
| 20080021532 | Kveen et al. | Jan 2008 | A1 |
| 20080065183 | Whitehurst et al. | Mar 2008 | A1 |
| 20080065185 | Worley | Mar 2008 | A1 |
| 20080071318 | Brooke et al. | Mar 2008 | A1 |
| 20080077187 | Levin | Mar 2008 | A1 |
| 20080103539 | Stegemann et al. | May 2008 | A1 |
| 20080109054 | Hastings et al. | May 2008 | A1 |
| 20080119911 | Rosero | May 2008 | A1 |
| 20080130670 | Kim et al. | Jun 2008 | A1 |
| 20080154139 | Shuros et al. | Jun 2008 | A1 |
| 20080154322 | Jackson et al. | Jun 2008 | A1 |
| 20080228234 | Stancer | Sep 2008 | A1 |
| 20080234771 | Chinchoy et al. | Sep 2008 | A1 |
| 20080243217 | Wildon | Oct 2008 | A1 |
| 20080269814 | Rosero | Oct 2008 | A1 |
| 20080269816 | Prakash et al. | Oct 2008 | A1 |
| 20080269823 | Burnes et al. | Oct 2008 | A1 |
| 20080269825 | Chinchoy et al. | Oct 2008 | A1 |
| 20080275518 | Ghanem et al. | Nov 2008 | A1 |
| 20080275519 | Ghanem et al. | Nov 2008 | A1 |
| 20080288008 | Lee | Nov 2008 | A1 |
| 20080288039 | Reddy | Nov 2008 | A1 |
| 20080294208 | Willis et al. | Nov 2008 | A1 |
| 20080294210 | Rosero | Nov 2008 | A1 |
| 20080294229 | Friedman et al. | Nov 2008 | A1 |
| 20080306359 | Zdeblick et al. | Dec 2008 | A1 |
| 20090018599 | Hastings et al. | Jan 2009 | A1 |
| 20090024180 | Kisker et al. | Jan 2009 | A1 |
| 20090036941 | Corbucci | Feb 2009 | A1 |
| 20090048646 | Katoozi et al. | Feb 2009 | A1 |
| 20090062895 | Stahmann et al. | Mar 2009 | A1 |
| 20090082827 | Kveen et al. | Mar 2009 | A1 |
| 20090082828 | Ostroff | Mar 2009 | A1 |
| 20090088813 | Brockway et al. | Apr 2009 | A1 |
| 20090099619 | Lessmeier et al. | Apr 2009 | A1 |
| 20090131907 | Chin et al. | May 2009 | A1 |
| 20090135886 | Robertson et al. | May 2009 | A1 |
| 20090143835 | Pastore et al. | Jun 2009 | A1 |
| 20090171408 | Solem | Jul 2009 | A1 |
| 20090171414 | Kelly et al. | Jul 2009 | A1 |
| 20090204163 | Shuros et al. | Aug 2009 | A1 |
| 20090204170 | Hastings et al. | Aug 2009 | A1 |
| 20090210024 | Jason | Aug 2009 | A1 |
| 20090216292 | Pless et al. | Aug 2009 | A1 |
| 20090234407 | Hastings et al. | Sep 2009 | A1 |
| 20090234411 | Sambelashvili et al. | Sep 2009 | A1 |
| 20090234412 | Sambelashvili | Sep 2009 | A1 |
| 20090234413 | Sambelashvili et al. | Sep 2009 | A1 |
| 20090234414 | Sambelashvili et al. | Sep 2009 | A1 |
| 20090234415 | Sambelashvili et al. | Sep 2009 | A1 |
| 20090248103 | Sambelashvili et al. | Oct 2009 | A1 |
| 20090259272 | Reddy et al. | Oct 2009 | A1 |
| 20090266573 | Engmark et al. | Oct 2009 | A1 |
| 20090275998 | Burnes et al. | Nov 2009 | A1 |
| 20090275999 | Burnes et al. | Nov 2009 | A1 |
| 20090299447 | Jensen et al. | Dec 2009 | A1 |
| 20100013668 | Kantervik | Jan 2010 | A1 |
| 20100016911 | Willis et al. | Jan 2010 | A1 |
| 20100016914 | Mullen et al. | Jan 2010 | A1 |
| 20100023078 | Dong et al. | Jan 2010 | A1 |
| 20100023085 | Wu et al. | Jan 2010 | A1 |
| 20100030061 | Canfield et al. | Feb 2010 | A1 |
| 20100030327 | Chatel | Feb 2010 | A1 |
| 20100042108 | Hibino | Feb 2010 | A1 |
| 20100063375 | Kassab et al. | Mar 2010 | A1 |
| 20100063562 | Cowan et al. | Mar 2010 | A1 |
| 20100065871 | Govari et al. | Mar 2010 | A1 |
| 20100094367 | Sen | Apr 2010 | A1 |
| 20100114209 | Krause et al. | May 2010 | A1 |
| 20100114214 | Morelli et al. | May 2010 | A1 |
| 20100125281 | Jacobson et al. | May 2010 | A1 |
| 20100152798 | Sanghera et al. | Jun 2010 | A1 |
| 20100168761 | Kassab et al. | Jul 2010 | A1 |
| 20100168819 | Freeberg | Jul 2010 | A1 |
| 20100185250 | Rom | Jul 2010 | A1 |
| 20100198288 | Ostroff | Aug 2010 | A1 |
| 20100198291 | Sambelashvili et al. | Aug 2010 | A1 |
| 20100198304 | Wang | Aug 2010 | A1 |
| 20100217367 | Belson | Aug 2010 | A1 |
| 20100228308 | Cowan et al. | Sep 2010 | A1 |
| 20100234906 | Kob | Sep 2010 | A1 |
| 20100234924 | Willis | Sep 2010 | A1 |
| 20100241185 | Mahapatra et al. | Sep 2010 | A1 |
| 20100249729 | Morris et al. | Sep 2010 | A1 |
| 20100286541 | Musley et al. | Nov 2010 | A1 |
| 20100286626 | Petersen | Nov 2010 | A1 |
| 20100286744 | Echt et al. | Nov 2010 | A1 |
| 20100298841 | Prinzen et al. | Nov 2010 | A1 |
| 20100312309 | Harding | Dec 2010 | A1 |
| 20100318147 | Forslund | Dec 2010 | A1 |
| 20110022113 | Ideblick et al. | Jan 2011 | A1 |
| 20110071586 | Jacobson | Mar 2011 | A1 |
| 20110077708 | Ostroff | Mar 2011 | A1 |
| 20110106202 | Ding et al. | May 2011 | A1 |
| 20110112398 | Zarkh et al. | May 2011 | A1 |
| 20110112600 | Cowan et al. | May 2011 | A1 |
| 20110118588 | Komblau et al. | May 2011 | A1 |
| 20110118810 | Cowan et al. | May 2011 | A1 |
| 20110137187 | Yang et al. | Jun 2011 | A1 |
| 20110144720 | Cowan et al. | Jun 2011 | A1 |
| 20110152970 | Jollota et al. | Jun 2011 | A1 |
| 20110160558 | Rassatt et al. | Jun 2011 | A1 |
| 20110160565 | Stubbs | Jun 2011 | A1 |
| 20110160801 | Markowitz et al. | Jun 2011 | A1 |
| 20110160806 | Lyden et al. | Jun 2011 | A1 |
| 20110166620 | Cowan et al. | Jul 2011 | A1 |
| 20110166621 | Cowan et al. | Jul 2011 | A1 |
| 20110184491 | Kivi | Jul 2011 | A1 |
| 20110190835 | Brockway et al. | Aug 2011 | A1 |
| 20110190841 | Sambelashvili et al. | Aug 2011 | A1 |
| 20110196444 | Prakash et al. | Aug 2011 | A1 |
| 20110208260 | Jacobson | Aug 2011 | A1 |
| 20110218587 | Jacobson | Sep 2011 | A1 |
| 20110230734 | Fain et al. | Sep 2011 | A1 |
| 20110230922 | Fishel | Sep 2011 | A1 |
| 20110237967 | Moore et al. | Sep 2011 | A1 |
| 20110245890 | Brisben et al. | Oct 2011 | A1 |
| 20110251660 | Griswold | Oct 2011 | A1 |
| 20110251662 | Griswold et al. | Oct 2011 | A1 |
| 20110270099 | Ruben et al. | Nov 2011 | A1 |
| 20110270339 | Murray, III et al. | Nov 2011 | A1 |
| 20110270340 | Pellegrini et al. | Nov 2011 | A1 |
| 20110276102 | Cohen | Nov 2011 | A1 |
| 20110282423 | Jacobson | Nov 2011 | A1 |
| 20120004527 | Thompson et al. | Jan 2012 | A1 |
| 20120029323 | Zhao | Feb 2012 | A1 |
| 20120035685 | Saha et al. | Feb 2012 | A1 |
| 20120041508 | Rousso et al. | Feb 2012 | A1 |
| 20120059433 | Cowan et al. | Mar 2012 | A1 |
| 20120059436 | Fontaine et al. | Mar 2012 | A1 |
| 20120065500 | Rogers et al. | Mar 2012 | A1 |
| 20120078129 | Bailin | Mar 2012 | A1 |
| 20120078322 | Dal Molin et al. | Mar 2012 | A1 |
| 20120089198 | Ostroff | Apr 2012 | A1 |
| 20120089214 | Kroll et al. | Apr 2012 | A1 |
| 20120093245 | Makdissi et al. | Apr 2012 | A1 |
| 20120095521 | Hintz | Apr 2012 | A1 |
| 20120095539 | Khairkhahan et al. | Apr 2012 | A1 |
| 20120101540 | O'Brien et al. | Apr 2012 | A1 |
| 20120101553 | Reddy | Apr 2012 | A1 |
| 20120109148 | Bonner et al. | May 2012 | A1 |
| 20120109149 | Bonner et al. | May 2012 | A1 |
| 20120109235 | Sheldon et al. | May 2012 | A1 |
| 20120109236 | Jacobson et al. | May 2012 | A1 |
| 20120109259 | Bond et al. | May 2012 | A1 |
| 20120116489 | Khairkhahan et al. | May 2012 | A1 |
| 20120150251 | Giftakis et al. | Jun 2012 | A1 |
| 20120158111 | Khairkhahan et al. | Jun 2012 | A1 |
| 20120165827 | Khairkhahan et al. | Jun 2012 | A1 |
| 20120172690 | Anderson et al. | Jul 2012 | A1 |
| 20120172891 | Lee | Jul 2012 | A1 |
| 20120172892 | Grubac et al. | Jul 2012 | A1 |
| 20120172942 | Berg | Jul 2012 | A1 |
| 20120179221 | Reddy et al. | Jul 2012 | A1 |
| 20120197350 | Roberts et al. | Aug 2012 | A1 |
| 20120197373 | Khairkhahan et al. | Aug 2012 | A1 |
| 20120215285 | Tahmasian et al. | Aug 2012 | A1 |
| 20120232478 | Haslinger | Sep 2012 | A1 |
| 20120232563 | Williams | Sep 2012 | A1 |
| 20120232565 | Kveen et al. | Sep 2012 | A1 |
| 20120245665 | Friedman et al. | Sep 2012 | A1 |
| 20120263218 | Dal Molin et al. | Oct 2012 | A1 |
| 20120277600 | Greenhut | Nov 2012 | A1 |
| 20120277606 | Ellingson et al. | Nov 2012 | A1 |
| 20120283587 | Gosh et al. | Nov 2012 | A1 |
| 20120283795 | Stancer et al. | Nov 2012 | A1 |
| 20120283807 | Deterre et al. | Nov 2012 | A1 |
| 20120284003 | Gosh et al. | Nov 2012 | A1 |
| 20120290025 | Keimel | Nov 2012 | A1 |
| 20120296228 | Zhang et al. | Nov 2012 | A1 |
| 20120296381 | Matos | Nov 2012 | A1 |
| 20120303082 | Dong et al. | Nov 2012 | A1 |
| 20120316613 | Keefe et al. | Dec 2012 | A1 |
| 20130012151 | Hankins | Jan 2013 | A1 |
| 20130013017 | Mullen et al. | Jan 2013 | A1 |
| 20130023975 | Locsin | Jan 2013 | A1 |
| 20130035748 | Bonner et al. | Feb 2013 | A1 |
| 20130041422 | Jacobson | Feb 2013 | A1 |
| 20130053906 | Ghosh et al. | Feb 2013 | A1 |
| 20130053908 | Smith et al. | Feb 2013 | A1 |
| 20130053915 | Holmstrom et al. | Feb 2013 | A1 |
| 20130053921 | Bonner et al. | Feb 2013 | A1 |
| 20130060298 | Splett et al. | Mar 2013 | A1 |
| 20130066169 | Rys et al. | Mar 2013 | A1 |
| 20130072770 | Rao et al. | Mar 2013 | A1 |
| 20130079798 | Tran et al. | Mar 2013 | A1 |
| 20130079861 | Reinert et al. | Mar 2013 | A1 |
| 20130085350 | Schugt et al. | Apr 2013 | A1 |
| 20130085403 | Gunderson et al. | Apr 2013 | A1 |
| 20130085550 | Polefko et al. | Apr 2013 | A1 |
| 20130096649 | Martin et al. | Apr 2013 | A1 |
| 20130103047 | Steingisser et al. | Apr 2013 | A1 |
| 20130103109 | Jacobson | Apr 2013 | A1 |
| 20130110008 | Bourg et al. | May 2013 | A1 |
| 20130110127 | Bornzin et al. | May 2013 | A1 |
| 20130110192 | Tran et al. | May 2013 | A1 |
| 20130110219 | Bornzin et al. | May 2013 | A1 |
| 20130116529 | Min et al. | May 2013 | A1 |
| 20130116738 | Samade et al. | May 2013 | A1 |
| 20130116739 | Brada et al. | May 2013 | A1 |
| 20130116740 | Bornzin et al. | May 2013 | A1 |
| 20130116741 | Bornzin et al. | May 2013 | A1 |
| 20130123872 | Bornzin et al. | May 2013 | A1 |
| 20130123875 | Varady et al. | May 2013 | A1 |
| 20130131591 | Berthiaume et al. | May 2013 | A1 |
| 20130131693 | Berthiaume et al. | May 2013 | A1 |
| 20130131750 | Stadler et al. | May 2013 | A1 |
| 20130131751 | Stadler et al. | May 2013 | A1 |
| 20130150695 | Biela et al. | Jun 2013 | A1 |
| 20130150911 | Perschbacher et al. | Jun 2013 | A1 |
| 20130150912 | Perschbacher et al. | Jun 2013 | A1 |
| 20130184776 | Shuros et al. | Jul 2013 | A1 |
| 20130196703 | Masoud et al. | Aug 2013 | A1 |
| 20130197599 | Sambelashvili et al. | Aug 2013 | A1 |
| 20130197609 | Moore et al. | Aug 2013 | A1 |
| 20130231710 | Jacobson | Sep 2013 | A1 |
| 20130238072 | Deterre et al. | Sep 2013 | A1 |
| 20130238073 | Makdissi et al. | Sep 2013 | A1 |
| 20130253342 | Griswold et al. | Sep 2013 | A1 |
| 20130253343 | Walfhauser et al. | Sep 2013 | A1 |
| 20130253344 | Griswold et al. | Sep 2013 | A1 |
| 20130253345 | Griswold et al. | Sep 2013 | A1 |
| 20130253346 | Griswold et al. | Sep 2013 | A1 |
| 20130253347 | Griswold et al. | Sep 2013 | A1 |
| 20130261497 | Pertijs et al. | Oct 2013 | A1 |
| 20130265144 | Banna et al. | Oct 2013 | A1 |
| 20130268017 | Zhang et al. | Oct 2013 | A1 |
| 20130268042 | Hastings et al. | Oct 2013 | A1 |
| 20130274828 | Willis | Oct 2013 | A1 |
| 20130274847 | Ostroff | Oct 2013 | A1 |
| 20130282070 | Cowan et al. | Oct 2013 | A1 |
| 20130282073 | Cowan et al. | Oct 2013 | A1 |
| 20130138006 | Bornzin et al. | Nov 2013 | A1 |
| 20130296727 | Sullivan et al. | Nov 2013 | A1 |
| 20130303872 | Taff et al. | Nov 2013 | A1 |
| 20130324825 | Ostroff et al. | Dec 2013 | A1 |
| 20130325081 | Karst et al. | Dec 2013 | A1 |
| 20130345770 | Dianaty et al. | Dec 2013 | A1 |
| 20140012344 | Hastings et al. | Jan 2014 | A1 |
| 20140018876 | Ostroff | Jan 2014 | A1 |
| 20140018877 | Demmer et al. | Jan 2014 | A1 |
| 20140031836 | Ollivier | Jan 2014 | A1 |
| 20140039591 | Drasler et al. | Feb 2014 | A1 |
| 20140043146 | Makdissi et al. | Feb 2014 | A1 |
| 20140046395 | Regnier et al. | Feb 2014 | A1 |
| 20140046420 | Moore et al. | Feb 2014 | A1 |
| 20140058240 | Mothilal et al. | Feb 2014 | A1 |
| 20140058494 | Ostroff et al. | Feb 2014 | A1 |
| 20140339570 | Carroll et al. | Feb 2014 | A1 |
| 20140074114 | Khairkhahan et al. | Mar 2014 | A1 |
| 20140074186 | Faltys et al. | Mar 2014 | A1 |
| 20140094891 | Pare et al. | Apr 2014 | A1 |
| 20140100627 | Min | Apr 2014 | A1 |
| 20140107723 | Hou et al. | Apr 2014 | A1 |
| 20140114173 | Bar-Tal et al. | Apr 2014 | A1 |
| 20140114372 | Ghosh et al. | Apr 2014 | A1 |
| 20140121719 | Bonner et al. | May 2014 | A1 |
| 20140121720 | Bonner et al. | May 2014 | A1 |
| 20140121722 | Sheldon et al. | May 2014 | A1 |
| 20140128935 | Kumar et al. | May 2014 | A1 |
| 20140135865 | Hastings et al. | May 2014 | A1 |
| 20140142648 | Smith et al. | May 2014 | A1 |
| 20140148675 | Nordstrom et al. | May 2014 | A1 |
| 20140148815 | Wenzel et al. | May 2014 | A1 |
| 20140155950 | Hastings et al. | Jun 2014 | A1 |
| 20140169162 | Romano et al. | Jun 2014 | A1 |
| 20140172060 | Bornzin et al. | Jun 2014 | A1 |
| 20140180306 | Grubac et al. | Jun 2014 | A1 |
| 20140180366 | Edlund | Jun 2014 | A1 |
| 20140207149 | Hastings et al. | Jul 2014 | A1 |
| 20140207210 | Willis et al. | Jul 2014 | A1 |
| 20140214104 | Greenhut et al. | Jul 2014 | A1 |
| 20140222098 | Baru et al. | Aug 2014 | A1 |
| 20140222109 | Moulder | Aug 2014 | A1 |
| 20140228913 | Molin et al. | Aug 2014 | A1 |
| 20140236172 | Hastings et al. | Aug 2014 | A1 |
| 20140243848 | Auricchio et al. | Aug 2014 | A1 |
| 20140255298 | Cole et al. | Sep 2014 | A1 |
| 20140257324 | Fain | Sep 2014 | A1 |
| 20140257422 | Herken | Sep 2014 | A1 |
| 20140257444 | Cole et al. | Sep 2014 | A1 |
| 20140276929 | Foster et al. | Sep 2014 | A1 |
| 20140303704 | Suwito et al. | Oct 2014 | A1 |
| 20140309706 | Jacobson | Oct 2014 | A1 |
| 20140323882 | Ghosh et al. | Oct 2014 | A1 |
| 20140323892 | Ghosh et al. | Oct 2014 | A1 |
| 20140330208 | Christie et al. | Nov 2014 | A1 |
| 20140330287 | Thompson-Nauman et al. | Nov 2014 | A1 |
| 20140330326 | Thompson-Nauman et al. | Nov 2014 | A1 |
| 20140358135 | Sambelashvili et al. | Dec 2014 | A1 |
| 20140371832 | Ghosh | Dec 2014 | A1 |
| 20140371833 | Ghosh et al. | Dec 2014 | A1 |
| 20140379041 | Foster | Dec 2014 | A1 |
| 20150025612 | Haasl et al. | Jan 2015 | A1 |
| 20150039041 | Smith et al. | Feb 2015 | A1 |
| 20150051609 | Schmidt et al. | Feb 2015 | A1 |
| 20150051610 | Schmidt et al. | Feb 2015 | A1 |
| 20150051611 | Schmidt et al. | Feb 2015 | A1 |
| 20150051612 | Schmidt et al. | Feb 2015 | A1 |
| 20150051613 | Schmidt et al. | Feb 2015 | A1 |
| 20150051614 | Schmidt et al. | Feb 2015 | A1 |
| 20150051615 | Schmidt et al. | Feb 2015 | A1 |
| 20150051616 | Haasl et al. | Feb 2015 | A1 |
| 20150051682 | Schmidt et al. | Feb 2015 | A1 |
| 20150057520 | Foster et al. | Feb 2015 | A1 |
| 20150057558 | Stahmann et al. | Feb 2015 | A1 |
| 20150057721 | Stahmann et al. | Feb 2015 | A1 |
| 20150088155 | Foster et al. | Mar 2015 | A1 |
| 20150105836 | Bonner et al. | Apr 2015 | A1 |
| 20150142070 | Sambelashvili | May 2015 | A1 |
| 20150148697 | Burnes et al. | May 2015 | A1 |
| 20150149096 | Soykan | May 2015 | A1 |
| 20150157861 | Aghassian | Jun 2015 | A1 |
| 20150173655 | Demmer et al. | Jun 2015 | A1 |
| 20150190638 | Smith et al. | Jul 2015 | A1 |
| 20150196756 | Stahmann et al. | Jul 2015 | A1 |
| 20150196757 | Stahmann et al. | Jul 2015 | A1 |
| 20150196758 | Stahmann et al. | Jul 2015 | A1 |
| 20150196769 | Stahmann et al. | Jul 2015 | A1 |
| 20150217119 | Nikolski et al. | Aug 2015 | A1 |
| 20150221898 | Chi et al. | Aug 2015 | A1 |
| 20150224315 | Stahmann | Aug 2015 | A1 |
| 20150224320 | Stahmann | Aug 2015 | A1 |
| 20150258345 | Smith et al. | Sep 2015 | A1 |
| 20150290468 | Zhang | Oct 2015 | A1 |
| 20150297905 | Greenhut et al. | Oct 2015 | A1 |
| 20150297907 | Zhang | Oct 2015 | A1 |
| 20150305637 | Greenhut et al. | Oct 2015 | A1 |
| 20150305638 | Zhang | Oct 2015 | A1 |
| 20150305639 | Greenhut et al. | Oct 2015 | A1 |
| 20150305640 | Reinke et al. | Oct 2015 | A1 |
| 20150305641 | Stadler et al. | Oct 2015 | A1 |
| 20150305642 | Reinke et al. | Oct 2015 | A1 |
| 20150305695 | Lahm et al. | Oct 2015 | A1 |
| 20150306374 | Seifert et al. | Oct 2015 | A1 |
| 20150306375 | Marshall et al. | Oct 2015 | A1 |
| 20150306406 | Crutchfield et al. | Oct 2015 | A1 |
| 20150306407 | Crutchfield et al. | Oct 2015 | A1 |
| 20150306408 | Greenhut et al. | Oct 2015 | A1 |
| 20150321016 | O'Brien et al. | Nov 2015 | A1 |
| 20150328459 | Chin et al. | Nov 2015 | A1 |
| 20150335894 | Bornzin et al. | Nov 2015 | A1 |
| 20160015287 | Anderson et al. | Jan 2016 | A1 |
| 20160015322 | Anderson et al. | Jan 2016 | A1 |
| 20160023000 | Cho et al. | Jan 2016 | A1 |
| 20160030757 | Jacobson | Feb 2016 | A1 |
| 20160033177 | Barot et al. | Feb 2016 | A1 |
| 20160045738 | Ghosh et al. | Feb 2016 | A1 |
| 20160045744 | Gillberg et al. | Feb 2016 | A1 |
| 20160051821 | Sambelashvili et al. | Feb 2016 | A1 |
| 20160059002 | Grubac et al. | Mar 2016 | A1 |
| 20160067486 | Brown et al. | Mar 2016 | A1 |
| 20160067487 | Demmer et al. | Mar 2016 | A1 |
| 20160067490 | Carney et al. | Mar 2016 | A1 |
| 20160110856 | Hoof et al. | Apr 2016 | A1 |
| 20160114161 | Amblard et al. | Apr 2016 | A1 |
| 20160121127 | Klimovitch et al. | May 2016 | A1 |
| 20160121128 | Fishler et al. | May 2016 | A1 |
| 20160121129 | Persson et al. | May 2016 | A1 |
| 20160129239 | Anderson | May 2016 | A1 |
| 20160213919 | Suwito et al. | Jul 2016 | A1 |
| 20160213937 | Reinke et al. | Jul 2016 | A1 |
| 20160213939 | Carney et al. | Jul 2016 | A1 |
| 20160228026 | Jackson | Aug 2016 | A1 |
| 20160317825 | Jacobson | Nov 2016 | A1 |
| 20160367823 | Cowan et al. | Dec 2016 | A1 |
| 20170014629 | Ghosh et al. | Jan 2017 | A1 |
| 20170035315 | Jackson | Feb 2017 | A1 |
| 20170043173 | Sharma et al. | Feb 2017 | A1 |
| 20170043174 | Greenhut et al. | Feb 2017 | A1 |
| 20170056670 | Sheldon et al. | Mar 2017 | A1 |
| 20170182327 | Liu | Jun 2017 | A1 |
| 20170189681 | Anderson | Jul 2017 | A1 |
| 20170209689 | Chen | Jul 2017 | A1 |
| 20170216575 | Asleson et al. | Aug 2017 | A1 |
| 20170246461 | Ghosh | Aug 2017 | A1 |
| 20170303840 | Stadler et al. | Oct 2017 | A1 |
| 20170304624 | Friedman et al. | Oct 2017 | A1 |
| 20170326369 | Koop et al. | Nov 2017 | A1 |
| 20170326372 | Koop et al. | Nov 2017 | A1 |
| 20170340885 | Sambelashvili | Nov 2017 | A1 |
| 20180008829 | An et al. | Jan 2018 | A1 |
| 20180021567 | An et al. | Jan 2018 | A1 |
| 20180021581 | An et al. | Jan 2018 | A1 |
| 20180021582 | An et al. | Jan 2018 | A1 |
| 20180050208 | Shuros et al. | Feb 2018 | A1 |
| 20180078773 | Thakur et al. | Mar 2018 | A1 |
| 20180078779 | An et al. | Mar 2018 | A1 |
| 20180117324 | Schilling et al. | May 2018 | A1 |
| 20180140848 | Stahmann | May 2018 | A1 |
| 20180178007 | Shuros et al. | Jun 2018 | A1 |
| 20180212451 | Schmidt et al. | Jul 2018 | A1 |
| 20180263522 | Ghosh | Sep 2018 | A1 |
| 20180264262 | Haasl et al. | Sep 2018 | A1 |
| 20180264272 | Haasl et al. | Sep 2018 | A1 |
| 20180264273 | Haasl et al. | Sep 2018 | A1 |
| 20180264274 | Haasl et al. | Sep 2018 | A1 |
| 20180280686 | Shuros et al. | Oct 2018 | A1 |
| 20180326215 | Ghosh | Nov 2018 | A1 |
| 20190030346 | Li | Jan 2019 | A1 |
| 20190038906 | Koop et al. | Feb 2019 | A1 |
| 20190083779 | Yang et al. | Mar 2019 | A1 |
| 20190083800 | Yang et al. | Mar 2019 | A1 |
| 20190083801 | Yang et al. | Mar 2019 | A1 |
| 20190111270 | Zhou | Apr 2019 | A1 |
| 20190192860 | Ghosh et al. | Jun 2019 | A1 |
| 20190192863 | Koop et al. | Jun 2019 | A1 |
| 20190201698 | Herrmann | Jul 2019 | A1 |
| 20190269926 | Ghosh | Sep 2019 | A1 |
| 20190290905 | Yang et al. | Sep 2019 | A1 |
| 20190290909 | Ghosh | Sep 2019 | A1 |
| 20190290910 | Yang et al. | Sep 2019 | A1 |
| 20190298990 | De Kock | Oct 2019 | A1 |
| 20190314636 | Shuros et al. | Oct 2019 | A1 |
| 20190351236 | Koop | Nov 2019 | A1 |
| 20200069949 | Ghosh | Mar 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 2008279789 | Oct 2011 | AU |
| 2008329620 | May 2014 | AU |
| 2014203793 | Jul 2014 | AU |
| 202933393 | May 2013 | CN |
| 0362611 | Apr 1990 | EP |
| 0459 239 | Dec 1991 | EP |
| 0 728 497 | Aug 1996 | EP |
| 1 541 191 | Jun 2005 | EP |
| 1 702 648 | Sep 2006 | EP |
| 1 904 166 | Jun 2011 | EP |
| 2 452 721 | May 2012 | EP |
| 2 471 452 | Jul 2012 | EP |
| 2 662 113 | Nov 2013 | EP |
| 1 703 944 | Jul 2015 | EP |
| 2005245215 | Sep 2005 | JP |
| WO 9500202 | Jan 1995 | WO |
| WO 9636134 | Nov 1996 | WO |
| WO 9724981 | Jul 1997 | WO |
| WO 0222206 | Mar 2002 | WO |
| WO 03092800 | Nov 2003 | WO |
| WO 2005000206 | Jan 2005 | WO |
| WO 2005042089 | May 2005 | WO |
| WO 2006086435 | Aug 2006 | WO |
| WO 2006113659 | Oct 2006 | WO |
| WO 2007073435 | Jun 2007 | WO |
| WO 2007075974 | Jul 2007 | WO |
| WO 2009006531 | Jan 2009 | WO |
| WO 2013080038 | Jun 2013 | WO |
| WO 2013098644 | Jul 2013 | WO |
| WO 2015081221 | Jun 2015 | WO |
| WO 2016011042 | Jan 2016 | WO |
| WO 2016077099 | May 2016 | WO |
| WO 2016110856 | Jul 2016 | WO |
| WO 2016171891 | Oct 2016 | WO |
| WO 2017075193 | May 2017 | WO |
| WO 2018009569 | Jan 2018 | WO |
| WO 2018017226 | Jan 2018 | WO |
| WO 2018017361 | Jan 2018 | WO |
| WO 2018035343 | Feb 2018 | WO |
| WO 201081519 | May 2018 | WO |
| Entry |
|---|
| US 8,886,318 B2, 11/2014, Jacobson et al. (withdrawn) |
| International Search Report and Written Opinion from PCT Application No. PCT/US2021/025151, dated Jun. 30, 2021, 13 pages. |
| U.S. Appl. No. 10/039,305, filed Aug. 27, 2019, Asleson et al. |
| U.S. Appl. No. 16/944,230, filed Jul. 31, 2020, Gelfman et al. |
| U.S. Appl. No. 17/031,182, filed Sep. 24, 2020, Ghosh et al. |
| U.S. Appl. No. 17/070,361, filed Oct. 14, 2020, Hine et al. |
| U.S. Appl. No. 63/059,878, filed Jul. 31, 2020, Whitman et al. |
| http://www.isrctn.com/ISRCTN47824547, public posting published Aug. 2019. |
| Abed et al., “Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillation,” Heart Rhythm Society, Jan. 2013; 10(1):90-100. |
| Adragão et al., “Ablation of pulmonary vein foci for the treatment of atrial fibrillation; percutaneous electroanatomical guided approach,” Europace, Oct. 2002; 4(4):391-9. |
| Aliot et al., “Arrhythmia detection by dual-chamber implantable cardioverter defibrillators: A review of current algorithms,” Europace, Jul. 2004; 6(4):273-86. |
| Amirahmadi et al., “Ventricular Tachycardia Caused by Mesothelial Cyst,” Indian Pacing and Electrophysiology Journal, 2013; 13(1):43-44. |
| Ammirabile et al., “Pitx2 confers left morphological, molecular, and functional identity to the sinus venosus myocardium,” Cardiovasc Res., Feb. 2012; 93(2):291-301. |
| Anderson et al., “Left bundle branch block and the evolving role of QRS morphology in selection of patients for cardiac resynchronization”, Journal of Interventional Cardio Electrophysiology, vol. 52, No. 3. Aug. 20, 2018, pp. 353-374. |
| Anfinsen, “Non-pharmacological Treatment of Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jan. 2002; 2(1):4-14. |
| Anné et al., “Ablation of post-surgical intra-atrial reentrant Tachycardia,” European Heart Journal, 2002; 23:169-1616. |
| Arenal et al., “Dominant frequency differences in atrial fibrillation patients with and without left ventricular systolic dysfunction,” Europace, Apr. 2009; 11(4):450-457. |
| Arriagada et al., “Predictors of arrhythmia recurrence in patients with lone atrial fibrillation,” Europace, Jan. 2008; 10(1):9-14. |
| Asirvatham et al., “Cardiac Anatomic Considerations in Pediatric Electrophysiology,” Indian Pacing and Electrophysiology Journal, Apr. 2008; 8(Suppl 1):S75-S91 1000. |
| Asirvatham et al., “Intramyocardial Pacing and Sensing for the Enhancement of Cardiac Stimulation and Sensing Specificity,” Pacing Clin. Electrophysiol., Jun. 2007, 30(6):748-754. |
| Asirvatham et al., “Letter to the Editor,” J Cardiovasc Electrophysiol., Mar. 2010; 21(3): E77. |
| Balmer et al., “Long-term follow up of children with congenital complete atrioventricular block and the impact of pacemaker therapy,” Europace, Oct. 2002; 4(4):345-349. |
| Barold et al., “Conventional and biventricular pacing in patients with first-degree atrioventricular block,” Europace, Oct. 2012; 14(10):1414-9. |
| Barold et al., “The effect of hyperkalaemia on cardiac rhythm devices,” Europace, Apr. 2014; 16(4):467-76. |
| Bayrak et al., “Added value of transoesophageal echocardiography during transseptal puncture performed by inexperienced operators,” Europace, May 2012; 14(5):661-5. |
| Bergau et al., “Measurement of Left Atrial Pressure is a Good Predictor of Freedom From Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jul. 2014; 14(4):181-93. |
| Bernstein et al., “The revised NASPE/BPEG generic code for antibradycardia, adaptive-rate, and multisite pacing. North American Society of Pacing and Electrophysiology/British Pacing and Electrophysiology Group,” Pacing Clin Electrophysiol., Feb. 2002; 25(2):260-4. |
| Bito et al., “Early exercise training after myocardial infarction prevents contractile but not electrical remodeling or hypertrophy,” Cardiovascular Research, Apr. 2010; 86(1):72-81. |
| Bollmann et al., “Analysis of surface electrocardiograms in atrial fibrillation: techniques, research, and clinical applications,” Europace, Nov. 2006; 8(11):911-926. |
| Bortone et al., “Evidence for an incomplete mitral isthmus block after failed ablation of a left postero-inferior concealed accessory pathway,” Europace, Jun. 2006; 8(6):434-7. |
| Boulos et al., “Electroanatomical mapping and radiofrequency ablation of an accessory pathway associated with a large aneurysm of the coronary sinus,” Europace, Nov. 2004; 6(6):608-12. |
| Brembilla-Perrot et al., “Incidence and prognostic significance of spontaneous and inducible antidromic tachycardia,” Europace, Jun. 2013; 15(6):871-876. |
| Buber et al., “Morphological features of the P-waves at surface electrocardiogram as surrogate to mechanical function of the left atrium following a successful modified maze procedure,” Europace, Apr. 2014; 16(4):578-86. |
| Burashnikov et al., “Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation,” Pacing Clin Electrophysiol., Mar. 2006; 29(3):290-5. |
| Burashnikov et al., “Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation,” Heart Rhythm, Jan. 2012; 9(1):125-31. |
| Calvo et al., “Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes,” Europace, Jan. 2010; 12(1):30-6. |
| Can et al., ““Atrial torsades de pointes” Induced by Low-Energy Shock From Implantable-Cardioverter Defibrillator,” Indian Pacing and Electrophysiology Journal, Sep. 2013; 13(5):194-199. |
| Carroz et al., “Pseudo-pacemaker syndrome in a young woman with first-degree atrio-ventricular block,” Europace, Apr. 2010; 12(4):594-596. |
| Catanchin et al., “Wolff-Parkinson-White syndrome with an unroofed coronary sinus without persistent left superior vena cava treated with catheter cryoablation,” Indian Pacing and Electrophysiology Journal, Aug. 2008; 8(3):227-233. |
| Cazeau et al., “Cardiac resynchronization therapy,” Europace, Sep. 2004; 5 Suppl 1:S42-8. |
| Cerqueira et al., “Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association,” Circulation, Jan. 29, 2002; 105(4):539-42. |
| Chandra et al., “Evaluation of KCB-328, a new IKr blocking antiarrhythmic agent in pacing induced canine atrial fibrillation,” Europace, Sep. 2004; 6(5):384-91. |
| Chang et al., “Electrophysiological characteristics and catheter ablation in patients with paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation,” J Cardiovasc Electrophysiol., Apr. 2008; 19(4):367-73. |
| Charron et al., “A familial form of conduction defect related to a mutation in the PRKAG2 gene,” Europace, Aug. 2007; 9(8):597-600. |
| Chou et al., “Effects of SEA0400 on Arrhythmogenicity in a Langendorff-Perfused 1-Month Myocardial Infarction Rabbit Model,” Pacing Clin Electrophysiol., May 2013; 36(5):596-606. |
| Ciploetta et al., “Posterior Coronary Vein as the Substrate for an Epicardial Accessory Pathway,” Indian Pacing and Electrophysiology Journal, Aug. 2013; 13(4):142-7. |
| Climent et al., “Effects of endocardial microwave energy ablation,” Indian Pacing and Electrophysiology Journal, Jul. 2005; 5(3):233-43. |
| Comtois et al., “Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry,” Europace, Sep. 2005; 7 Suppl 2:10-20. |
| Crick et al., “Anatomy of the pig heart: comparisons with normal human cardiac structure,” J. Anat., 1998, 193:105-119. |
| Daoulah et al., “Unintended Harm and Benefit of the Implantable Defibrillator in an Unfortunate 19-Year-Old Male: Featuring a Sequence of Rare Life-threatening Complications of Cardiac Procedures,” Indian Pacing and Electrophysiology Journal, Aug. 2013; 13(4):151-6. |
| De Mattia et al., “Paroxysmal atrial fibrillation triggered by a monomorphic ventricular couplet in a patient with acute coronary syndrome,” Indian Pacing and Electrophysiology Journal, Jan. 2012; 12(1):19-23. |
| DeSimone et al., “New approach to cardiac resynchronization therapy: CRT without left ventricular lead,” Apr. 25, 2014, 2 pages. |
| De Sisti et al., “Electrophysiological determinants of atrial fibrillation in sinus node dysfunction despite atrial pacing,” Europace, Oct. 2000; 2(4):304-11. |
| De Voogt et al., “Electrical characteristics of low atrial septum pacing compared with right atrial appendage pacing,” Europace, Jan. 2005; 7(1):60-6. |
| De Voogt et al., “A technique of lead insertion for low atrial septal pacing,” Pacing Clin Electrophysiol., Jul. 2005; 28(7):639-46. |
| Dizon et al. “Real-time stroke volume measurements for the optimization of cardiac resynchronization therapy parameters,” Europace, Sep. 2010; 12(9):1270-1274. |
| Duckett et al., “Relationship between endocardial activation sequences defined by high-density mapping to early septal contraction (septal flash) in patients with left bundle branch block undergoing cardiac resynchronization therapy,” Europace, Jan. 2012; 14(1):99-106. |
| Eksik et al., “Influence of atrioventricular nodal reentrant tachycardia ablation on right to left inter-atrial conduction,” Indian Pacing and Electrophysiology Journal, Oct. 2005; 5(4):279-88. |
| Fiala et al., “Left Atrial Voltage during Atrial Fibrillation in Paroxysmal and Persistent Atrial Fibrillation Patients,” PACE, May 2010; 33(5):541-548. |
| Fragakis et al., “Acute beta-adrenoceptor blockade improves efficacy of ibutilide in conversion of atrial fibrillation with a rapid ventricular rate,” Europace, Jan. 2009; 11(1):70-4. |
| Frogoudaki et al., “Pacing for adult patients with left atrial isomerism: efficacy and technical considerations,” Europace, Apr. 2003; 5(2):189-193. |
| Ganapathy et al., “Implantable Device to Monitor Cardiac Activity with Sternal Wires,” Pacing Clin. Electrophysiol., Dec. 2014; Epub Aug. 24, 2014; 37(12):1630-40. |
| Geddes, “Accuracy limitations of chronaxie values,” IEEE Trans Biomed Eng., Jan. 2004; 51(1):176-81. |
| Gertz et al., “The impact of mitral regurgitation on patients undergoing catheter ablation of atrial fibrillation,” Europace, Aug. 2011; 13(8):1127-32. |
| Girmatsion et al., “Changes in microRNA-1 expression and IKI up-regulation in human atrial fibrillation,” Heart Rhythm, Dec. 2009; 6(12):1802-9. |
| Goette et al., “Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles,” European Heart Journal, Jun. 2009; 30(11):1411-20. |
| Goette et al., “Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms,” Europace, Feb. 2008; 10(2):238-41. |
| Gómez et al., “Nitric oxide inhibits Kv4.3 and human cardiac transient outward potassium current (Ito1),” Cardiovasc Res., Dec. 2008; 80(3):375-84. |
| Gros et al., “Connexin 30 is expressed in the mouse sino-atrial node and modulates heart rate,” Cardiovascular Research, Jan. 2010; 85(1):45-55. |
| Guenther et al., “Substernal Lead Implantation: A Novel Option to Manage OFT Failure in S-ICD patients,” Clinical Research Cardiology, Feb. 2015; Epub Oct. 2, 2014; 104(2):189-91. |
| Guillem et al., “Noninvasive mapping of human atrial fibrillation,” J Cardiovasc Electrophysiol., May 2009; 20(5):507-513. |
| Hachisuka et al., “Development and Performance Analysis of an Intra-Body Communication Device,” The 12th International Conference on Solid State Sensors, Actuators and Microsystems, vol. 4A1.3, pp. 1722-1725, 2003. |
| Hakacova et al., “Septal atrial pacing for the prevention of atrial fibrillation,” Europace, 2007; 9:1124-1128. |
| Hasan et al., “Safety, efficacy, and performance of implanted recycled cardiac rhythm management (CRM) devices in underprivileged patients,” Pacing Clin Electrophysiol., Jun. 2011; 34(6):653-8. |
| Hawkins, “Epicardial Wireless Pacemaker for Improved Left Ventricular Reynchronization (Conceptual Design)”, Dec. 2010, A Thesis presented to the Faculty of California Polytechnic State University, San Luis Obispo, 57 pp. |
| He et al., “Three-dimensional cardiac electrical imaging from intracavity recordings,” IEEE Trans Biomed Eng., Aug. 2007; 54(8):1454-60. |
| Heist et al., “Direct visualization of epicardial structures and ablation utilizing a visually guided laser balloon catheter: preliminary findings,” J Cardiovasc Electrophysiol., Jul. 2011; 22(7):808-12. |
| Henz et al., “Synchronous Ventricular Pacing without Crossing the Tricuspid Valve or Entering the Coronary Sinus—Preliminary Results,” J Cardiovasc Electrophysiol., Dec. 2009; 20(12):1391-1397. |
| Hiippala et al., “Automatic Atrial Threshold Measurement and Adjustment in Pediatric Patients,” Pacing Clin Electrophysiol., Mar. 2010; 33(3):309-13. |
| Ho, “Letter to the Editor” J Cardiovasc Electrophysiol., Mar. 2010; 21(3): E76. |
| Höijer et al., “Improved cardiac function and quality of life following upgrade to dual chamber pacing after long-term ventricular stimulation,” European Heart Journal, Mar. 2002; 23(6):490-497. |
| Huang et al., “A Novel Pacing Strategy With Low and Stable Output: Pacing the Left Bundle Branch Immediately Beyond the Conduction Block,” Can J Cardiol., Dec. 2007; Epub Sep. 22, 2017; 33(12):1736.e1-1736.e. |
| Inter-Office Memo, Model 6426-85 Canine Feasibility AV Septal 8 mm Screw-In Right Single Pass DDD Lead Final Report (AR # 0120A0207). |
| Ishigaki et al., “Prevention of immediate recurrence of atrial fibrillation with low-dose landiolol after radiofrequency catheter ablation,” Journal of Arrhythmia, Oct. 2015; 31(5):279-285. |
| Israel, “The role of pacing mode in the development of atrial fibrillation,” Europace, Feb. 2006; 8(2):89-95. |
| Janion et al., “Dispersion of P wave duration and P wave vector in patients with atrial septal aneurysm,” Europace, Jul. 2007; 9(7):471-4. |
| Kabra et al., “Recent Trends in Imaging for Atrial Fibrillation Ablation,” Indian Pacing and Electrophysiology Journal, 2010; 10(5):215-227. |
| Kalbfleisch et al., “Catheter Ablation with Radiofrequency Energy: Biophysical Aspects and Clinical Applications,” Journal of Cardiovascular Electrophysiology, Oct. 2008; 3(2):173-186. |
| Katritsis et al., “Classification and differential diagnosis of atrioventricular nodal re-entrant tachycardia,” Europace, Jan. 2006; 8(1):29-36. |
| Katritsis et al., “Anatomically left-sided septal slow pathway ablation in dextrocardia and situs inversus totalis,” Europace, Aug. 2008; 10(8):1004-5. |
| Khairy et al., “Cardiac Arrhythmias In Congenital Heart Diseases,” Indian Pacing and Electrophysiology Journal, Nov.-Dec. 2009; 9(6):299-317. |
| Kimmel et al., “Single-site ventricular and biventricular pacing: investigation of latest depolarization strategy,” Europace, Dec. 2007; 9(12):1163-1170. |
| Knackstedt et al., “Electro-anatomic mapping systems in arrhythmias,” Europace, Nov. 2008; 10 Suppl 3:iii28-iii34. |
| Kobayashi et al., “Successful Ablation of Antero-septal Accessory Pathway in the Non-Coronary Cusp in a Child,” Indian Pacing and Electrophysiology Journal, 2012; 12(3):124-130. |
| Kojodjojo et al., “4:2:1 conduction of an AF initiating trigger,” Indian Pacing and Electrophysiology Journal, Nov. 2015; 15(5):255-8. |
| Kołodzińska et al., “Differences in encapsulating lead tissue in patients who underwent transvenous lead removal,” Europace, Jul. 2012; 14(7):994-1001. |
| Konecny et al., “Synchronous intra-myocardial ventricular pacing without crossing the tricuspid valve or entering the coronary sinus,” Cardiovascular Revascularization Medicine, 2013; 14:137-138. |
| Kriatselis et al., “Ectopic atrial tachycardias with early activation at His site: radiofrequency ablation through a retrograde approach,” Europace, Jun. 2008; 10(6):698-704. |
| Lalu et al., “Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart,” Eur Heart J., Jan. 2005; 26(1):27-35. |
| Laske et al., “Excitation of the Intrinsic Conduction System Through His and Interventricular Septal Pacing,” Pacing Clin. Electrophysiol., Apr. 2006; 29(4):397-405. |
| Leclercq, “Problems and troubleshooting in regular follow-up of patients with cardiac resynchronization therapy,” Europace, Nov. 2009; 11 Suppl 5:v66-71. |
| Lee et al., “An unusual atrial tachycardia in a patient with Friedreich ataxia,” Europace, Nov. 2011; 13(11):1660-1. |
| Lee et al., “Blunted Proarrhythmic Effect of Nicorandil in a Langendorff-Perfused Phase-2 Myocardial Infarction Rabbit Model,” Pacing Clin Electrophysiol., Feb. 2013; 36(2):142-51. |
| Lemay et al., “Spatial dynamics of atrial activity assessed by the vectorcardiogram: from sinus rhythm to atrial fibrillation,” Europace, Nov. 2007; 9 Suppl 6:vi109-18. |
| Levy et al., “Does the mechanism of action of biatrial pacing for atrial fibrillation involve changes in cardiac haemodynamics? Assessment by Doppler echocardiography and natriuretic peptide measurements,” Europace, Apr. 2000; 2(2):127-35. |
| Lewalter et al., “Comparison of spontaneous atrial fibrillation electrogram potentials to the P wave electrogram amplitude in dual chamber pacing with unipolar atrial sensing,” Europace, Apr. 2000; 2(2):136-40. |
| Liakopoulos et al., “Sequential deformation and physiological considerations in unipolar right and left ventricular pacing,” European Journal of Cardio-thoracic Surgery, Apr. 1, 2006; 29S1:S188-197. |
| Lian et al., “Computer modeling of ventricular rhythm during atrial fibrillation and ventricular pacing,” IEEE Transactions on Biomedical Engineering, Aug. 2006; 53(8):1512-1520. |
| Lim et al., “Right ventricular lead implantation facilitated by a guiding sheath in a patient with severe chamber dilatation with tricuspid regurgitation,” Indian Pacing and Electrophysiology Journal, Sep. 2011; 11(5):156-8. |
| Lim et al., “Coupled pacing improves left ventricular function during simulated atrial fibrillation without mechanical dyssynchrony,” Europace, Mar. 2010; 12(3):430-6. |
| Lou et al., “Tachy-brady arrhythmias: The critical role of adenosine-induced sinoatrial conduction block in post-tachycardia pauses,” Heart Rhythm., Jan. 2013; 10(1):110-8. |
| Lutomsky et al., “Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging,” Europace, May 2008; 10(5):593-9. |
| Macedo et al., “Septal accessory pathway: anatomy, causes for difficulty, and an approach to ablation,” Indian Pacing and Electrophysiology Journal, Jul. 2010; 10(7):292-309. |
| Mafi-Rad et al., “Feasibility and Acute Hemodynamic Effect of Left Ventricular Septal Pacing by Transvenous Approach Through the Interventricular Septum,” Circ Arrhythm Electrophysoil., Mar. 2016; 9(3):e003344. |
| Mani et al., “Dual Atrioventricular Nodal Pathways Physiology: A Review of Relevant Anatomy, Electrophysiology, and Electrocardiographic Manifestations,” Indian Pacing and Electrophysiology Journal, Jan. 2014; 14(1):12-25. |
| Manios et al., “Effects of successful cardioversion of persistent atrial fibrillation on right ventricular refractoriness and repolarization,” Europace, Jan. 2005; 7(1):34-9. |
| Manolis et al., “Prevention of atrial fibrillation by inter-atrial septum pacing guided by electrophysiological testing, in patients with delayed interatrial conduction,” Europace, Apr. 2002; 4(2):165-174. |
| Marino et al., “Inappropriate mode switching clarified by using a chest radiograph,” Journal of Arrhythmia, Aug. 2015; 31(4):246-248. |
| Markowitz et al., “Time course and predictors of autonomic dysfunction after ablation of the slow atrioventricular nodal pathway,” Pacing Clin Electrophysiol., Dec. 2004; 27(12):1638-43. |
| Marshall et al., “The effects of temperature on cardiac pacing thresholds,” Pacing Clin Electrophysiol., Jul. 2010, 33(7):826-833. |
| McSharry et al., “A Dynamical Model for Generating Synthetic Electrocardiogram Signals,” IEEE Transactions on Biomedical Engineering, Mar. 2003; 50(3):289-294. |
| Meijler et al., “Scaling of Atrioventricular Transmission in Mammalian Species: An Evolutionary Riddle!,” Journal of Cfardiovascular Electrophysiology, Aug. 2002; 13(8):826-830. |
| Meiltz et al., “Permanent form of junctional reciprocating tachycardia in adults: peculiar features and results of radiofrequency catheter ablation,” Europace, Jan. 2006; 8(1):21-8. |
| Mellin et al., “Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure,” Eur Heart J., Aug. 2005; 26(15):1544-50. |
| Mestan et al., “The influence of fluid and diuretic administration on the index of atrial contribution in sequentially paced patients,” Europace, Apr. 2006; 8(4):273-8. |
| Metin et al., “Assessment of the P Wave Dispersion and Duration in Elite Women Basketball Players,” Indian Pacing and Electrophysiology Journal, 2010; 10(1):11-20. |
| Mills et al., “Left Ventricular Septal and Left Ventricular Apical Pacing Chronically Maintain Cardiac Contractile Coordination, Pump Function and Efficiency,” Circ Arrhythm Electrophysoil., Oct. 2009; 2(5):571-579. |
| Mitchell et al., “How do atrial pacing algorithms prevent atrial arrhythmias?” Europace, Jul. 2004; 6(4):351-62. |
| Mirzoyev et al., “Embryology of the Conduction System for the Electrophysiologist,” Indian Pacing and Electrophysiology Journal, 2010; 10(8):329-338. |
| Modre et al., “Noninvasive Myocardial Activation Time Imaging: A Novel Inverse Algorithm Applied to Clinical ECG Mapping Data,” IEE Transactions on Biomedical Engineering, Oct. 2002; 49(10):1153-1161. |
| Montgomery et al., “Measurement of diffuse ventricular fibrosis with myocardial T1 in patients with atrial fibrillation,” J Arrhythm., Feb. 2016; 32(1):51-6. |
| Mulpuru et al., “Synchronous ventricular pacing with direct capture of the atrioventricular conduction system: Functional anatomy, terminology, and challenges,” Heart Rhythm, Nov. 2016; Epub Aug. 3, 2016; 13(11):2237-2246. |
| Musa et al., “Inhibition of Platelet-Derived Growth Factor-AB Signaling Prevents Electromechanical Remodeling of Adult Atrial Myocytes that Contact Myofibroblasts,” Heart Rhythm, Jul. 2013; 10(7):1044-1051. |
| Nagy et al., “Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and β-catenin expression,” Cardiovascular Research, Jan. 2010; 85(1):100-9. |
| Namboodiri et al., “Electrophysiological features of atrial flutter in cardiac sarcoidosis: a report of two cases,” Indian Pacing and Electrophysiology Journal, Nov. 2012; 12(6):284-9. |
| Nanthakumar et al., “Assessment of accessory pathway and atrial refractoriness by transesophageal and intracardiac atrial stimulation: An analysis of methodological agreement,” Europace, Jan. 1999; 1(1):55-62. |
| Neto et al., “Temporary atrial pacing in the prevention of postoperative atrial fibrillation,” Pacing Clin Electrophysiol., Jan. 2007; 30(Suppl 1):S79-83. |
| Nishijima et al., “Tetrahydrobiopterin depletion and NOS2 uncoupling contribute to heart failure-induced alterations in atrial electrophysiology,” Cardiovasc Res., Jul. 2011; 91(1):71-9. |
| Niwano et al., “Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring,” Europace, Dec. 2007; 9(12):1209-1215. |
| Okumura et al., “Effects of a high-fat diet on the electrical properties of porcine atria,” Journal of Arrhythmia, Dec. 2015; 31(6):352-358. |
| Olesen et al., “Mutations in sodium channel β-subunit SCN3B are associated with early-onset lone atrial fibrillation,” Cardiovascular Research, Mar. 2011; 89(4):786-93. |
| Ozmen et al., “P wave dispersion is increased in pulmonary stenosis,” Indian Pacing and Electrophysiology Journal, Jan. 2006; 6(1):25-30. |
| Packer et al., “New generation of electro-anatomic mapping: Full intracardiac image integration,” Europace, Nov. 2008; 10 Suppl 3:iii35-41. |
| Page et al., “Ischemic ventricular tachycardia presenting as a narrow complex tachycardia,” Indian Pacing and Electrophysiology Journal, Jul. 2014; 14(4):203-210. |
| Pakarinen et al., “Pre-implant determinants of adequate long-term function of single lead VDD pacemakers,” Europace, Apr. 2002; 4:137-141. |
| Patel et al., “Atrial Fibrillation after Cardiac Surgery: Where are we now?” Indian Pacing and Electrophysiology Journal, Oct.-Dec. 2008; 8(4):281-291. |
| Patel et al., “Successful ablation of a left-sided accessory pathway in a patient with coronary sinus atresia and arteriovenous fistula: clinical and developmental insights,” Indian Pacing and Electrophysiology Journal, Mar. 2011; 11(2):43-49. |
| Peschar et al., “Left Ventricular Septal and Apex Pacing for Optimal Pump Function in Canine Hearts,” J Am Coll Cardiol., Apr. 2, 2003; 41(7):1218-1226. |
| Physiological Research Laboratories, Final Report for an Acute Study for Model 6426-85 AV Septal Leads, Feb. 1996. |
| Porciani et al., “Interatrial septum pacing avoids the adverse effect of interatrial delay in biventricular pacing: an echo-Doppler evaluation,” Europace, Jul. 2002; 4(3):317-324. |
| Potse et al., “A Comparison of Monodomain and Bidomain Reaction-Diffusion Models for Action Potential Propagation in the Human Heart,” IEEE Transactions on Biomedical Engineering, Dec. 2006; 53(12 Pt 1):2425-35. |
| Prystowsky et al., “Case studies with the experts: management decisions in atrial fibrillation,” J Cardiovasc Electrophysiol., Feb. 2008; 19(Suppl. 1):S1-12. |
| Prystowsky, “The history of atrial fibrillation: the last 100 years,” J Cardiovasc Electrophysiol, Jun. 2008; 19(6):575-582. |
| Pytkowski et al., “Paroxysmal atrial fibrillation is associated with increased intra-atrial conduction delay,” Europace, Dec. 2008; 10(12):1415-20. |
| Qu et al., “Dynamics and cardiac arrhythmias,” J Cardiovasc Electrophysiol., Sep. 2006; 17(9):1042-9. |
| Ravens et al., “Role of potassium currents in cardiac arrhythmias,” Europace, Oct. 2008; 10(10):1133-7. |
| Ricci et al., Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias, European Heart Journal, Sep. 2002; 23(18):1471-9. |
| Roberts-Thomson et al., “Focal atrial tachycardia II: management,” Pacing Clin Electrophysiol., Jul. 2006; 29(7):769-78. |
| Rossi et al., “Endocardial vagal atrioventricular node stimulation in humans: reproducibility on 18-month follow-up,” Europace, Dec. 2010; 12(12):1719-24. |
| Rouzet et al., “Contraction delay of the RV outflow tract in patients with Brugada syndrome is dependent on the spontaneous ST-segment elevation pattern,” Heart Rhythm, Dec. 2011; 8(12):1905-12. |
| Russo et al., “Atrial Fibrillation and Beta Thalassemia Major: The Predictive Role of the 12-lead Electrocardiogram Analysis,” Indian Pacing and Electrophysiology Journal, May 2014; 14(3):121-32. |
| Ryu et al., “Simultaneous Electrical and Mechanical Mapping Using 3D Cardiac Mapping System: Novel Approach for Optimal Cardiac Resynchronization Therapy,” Journal of Cardiovascular Electrophysiology, Feb. 2010, 21(2): 219-22. |
| Sairaku et al., “Prediction of sinus node dysfunction in patients with persistent atrial flutter using the flutter cycle length,” Europace, Mar. 2012; 14(3):380-7. |
| Santini et al., “Immediate and long-term atrial sensing stability in single-lead VDD pacing depends on right atrial dimensions,” Europace, Oct. 2001; 3(4):324-31. |
| Saremi et al., “Cardiac Conduction System: Delineation of Anatomic Landmarks With Multidetector CT,” Indian Pacing and Electrophysiology Journal, Nov. 2009; 9(6):318-33. |
| Savelieva et al., “Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches,” Europace, Jun. 2008; 10(6):647-665. |
| Schmidt et al., “Navigated Dense strain imaging for post-radiofrequency ablation lesion assessment in the swine left atria,” Europace, Jan. 2014; 16(1):133-41. |
| Schoonderwoerd et al., “Rapid Pacing Results in Changes in Atrial but not in Ventricular Refractoriness,” Pacing Clin Electrophysiol., Mar. 2002; 25(3):287-90. |
| Schoonderwoerd et al., “Atrial natriuretic peptides during experimental atrial tachycardia: role of developing tachycardiomyopathy,” J Cardiovasc Electrophysiol., Aug. 2004; 15(8):927-32. |
| Schoonderwoerd et al., “Atrial ultrastructural changes during experimental atrial tachycardia depend on high ventricular rate,” J Cardiovasc Electrophysiol., Oct. 2004; 15(10):1167-74. |
| Sedmera, “Function and form in the developing cardiovascular system,” Cardiovasc Res., Jul. 2011; 91(2):252-9. |
| Severi et al., “Alterations of atrial electrophysiology induced by electrolyte variations: combined computational and P-wave analysis,” Europace, Jun. 2010; 12(6):842-9. |
| Seyedi et al., “A Survey on Intrabody Communications for Body Area Network Application,” IEEE Transactions on Biomedical Engineering, vol. 60(8): 2067-2079, 2013. |
| Shah et al., “Stable atrial sensing on long-term follow up of VDD pacemakers,” Indian Pacing and Electrophysiology Journal, Oct. 2006; 6(4):189-93. |
| Shenthar et al., “Permanent pacemaker implantation in a patient with situs solitus, dextrocardia, and corrected transposition of the great arteries using a novel angiographic technique,” Journal of Arrhythmia, Apr. 2014; 30(2):134-138. |
| Shenthar et al., “Transvenous permanent pacemaker implantation in dextrocardia: technique, challenges, outcome, and a brief review of literature,” Europace, Sep. 2014; 16(9):1327-33. |
| Shirayama, “Role of atrial fibrillation threshold evaluation on guiding treatment,” Indian Pacing and Electrophysiology Journal, Oct. 2003; 3(4):224-230. |
| Sperzel et al., “Intraoperative Characterization of Interventricular Mechanical Dyssynchrony Using Electroanatomic Mapping System—A Feasibility Study,” Journal of Interventional Cardiac Electrophysiology, Nov. 2012, 35(2): 189-96. |
| Spickler et al., “Totally Self-Contained lntracardiac Pacemaker,” Journal of Electrocardiology, vol. 3(3&4): 324-331, 1970. |
| Sreeram et al., “Indications for Electrophysiology Study in children,” Indian Pacing and Electrophysiology Journal, Apr.-Jun. 2008; 8(Suppl. 1):S36-S54. |
| Stockburger et al., “Optimization of cardiac resynchronization guided by Doppler echocardiography: haemodynamic improvement and intraindividual variability with different pacing configurations and atrioventricular delays,” Europace, Oct. 2006; 8(10):881-6. |
| Stroobandt et al., “Prediction of Wenckebach Behavior and Block Response in DDD Pacemakers,” Pacing Clin Electrophysiol., Jun. 2006; 9(6):1040-6. |
| Suenari et al., “Idiopathic left ventricular tachycardia with dual electrocardiogram morphologies in a single patient,” Europace, Apr. 2010; 12(4):592-4. |
| Sweeney et al., “Analysis of Ventricular Activation Using Surface Electrocardiogramadict Left Ventricular Reverse Volumetric Remodeling During Cardiac Resynchronization Therapy,” Circulation, Feb. 9, 2010, 121(5): 626-34. |
| Tan et al., “Electrocardiographic evidence of ventricular repolarization remodelling during atrial fibrillation,” Europace, Jan. 2008; 10(1):99-104. |
| Taramasco et al., “Internal low-energy cardioversion: a therapeutic option for restoring sinus rhythm in chronic atrial fibrillation after failure of external cardioversion,” Europace, Jul. 1999; 1(3):179-82. |
| Testa et al., “Rate-control or rhythm-control: where do we stand?” Indian Pacing and Electrophysiology Journal, Oct. 2005; 5(4):296-304. |
| Thejus et al., “N-terminal Pro-Brain Natriuretic Peptide and Atrial Fibrillation,” Indian Pacing and Electrophysiology Journal, Jan. 2009; 9(1):1-4. |
| Thornton et al., “Magnetic Assisted Navigation in Electrophysiology and Cardiac Resynchronisation: A Review,” Indian Pacing and Electrophysiology Journal, Oct. 2006; 6(4):202-13. |
| Tilz et al., “In vivo left-ventricular contact force analysis: comparison of antegrade transseptal with retrograde transaortic mapping strategies and correlation of impedance and electrical amplitude with contact force,” Europace, Sep. 2014; 16(9):1387-95. |
| Tomaske et al., “Do daily threshold trend fluctuations of epicardial leads correlate with pacing and sensing characteristics in paediatric patients?” Europace, Aug. 2007; 9(8):662-668. |
| Tomioka et al., “The effect of ventricular sequential contraction on helical heart during pacing: high septal pacing versus biventricular pacing,” European Journal of Cardio-thoracic Surgery, Apr. 1, 2006; 29S1:S198-206. |
| Tournoux et al., “A ‘Regularly Irregular’ tachycardia: What is the diagnosis?” Europace, Dec. 2008; 10(12):1445-6. |
| Traykov et al., “Electrogram analysis at the His bundle region and the proximal coronary sinus as a tool to predict left atrial origin of focal atrial tachycardias,” Europace, Jul. 2011; 13(7):1022-7. |
| Trudel et al., “Simulation of QRST integral maps with a membrane-based computer heart model employing parallel processing,” IEEE Trans Biomed Eng., Aug. 2004; 51(8):1319-29. |
| Tse et al., “Cardiac dynamics: Alternans and arrhythmogenesis,” Journal of Arrhythmia, Oct. 2016; 32(5):411-417. |
| Tse, “Mechanisms of cardiac arrhythmias,” Journal of Arrhythmia, Apr. 2016; 32(2):75-81. |
| Ueda et al., “Outcomes of single- or dual-chamber implantable cardioverter defibrillator systems in Japanese patients,” Journal of Arrhythmia, Apr. 2016; 32(2):89-94. |
| Van Dam et al., “Volume conductor effects involved in the genesis of the P wave,” Europace, Sep. 2005; 7 Suppl 2:30-8. |
| Van den Berg et al., “Depletion of atrial natriuretic peptide during longstanding atrial fibrillation,” Europace, Sep. 2004; 6(5):433-7. |
| Van Deursen, et al., “Vectorcardiography as a Tool for Easy Optimization of Cardiac Resynchronization Therapy in Canine LBBB Hearts,” Circulation Arrhythmia and Electrophysiology, Jun. 1, 2012, 5(3): 544-52. |
| Van Opstal et al., “Paradoxical increase of stimulus to atrium interval despite His-bundle capture during para-Hisian pacing,” Europace, Dec. 2009; 11(12):1702-4. |
| Veenhuyzen et al., “Diagnostic pacing maneuvers for supraventricular tachycardia: part 1,” Pacing Clin Electrophysiol., Jun. 2011; 34(6):767-82. |
| Veenhuyzen et al., “Diagnostic pacing maneuvers for supraventricular tachycardias: part 2,” Pacing Clin Electrophysiol., Jun. 2012; 35(6):757-69. |
| Veenhuyzen et al., “Principles of Entrainment: Diagnostic Utility for Supraventricular Tachycardia,” Indian Pacing and Electrophysiology Journal, 2008; 8(1):51-65. |
| Verbrugge et al., “Revisiting diastolic filling time as mechanistic insight for response to cardiac resynchronization therapy,” Europace, Dec. 2013; 15(12):1747-56. |
| Verrier et al., “Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation,” Europace, Mar. 2013; 15(3):317-324. |
| Verrijcken et al., “Pacemaker-mediated tachycardia with varying cycle length: what is the mechanism?” Europace, Oct. 2009; 11(10):1400-2. |
| Villani et al., “Reproducibility of internal atrial defibrillation threshold in paroxysmal and persistent atrial fibrillation,” Europace, Jul. 2004; 6(4):267-72. |
| Violi et al., “Antioxidants for prevention of atrial fibrillation: a potentially useful future therapeutic approach? A review of the literature and meta-analysis,” Europace, Aug. 2014; 16(8):1107-1116. |
| Weber et al., “Adenosine sensitive focal atrial tachycardia originating from the non-coronary aortic cusp,” Europace, Jun. 2009; 11(6):823-6. |
| Weber et al., “Open-irrigated laser catheter ablation: relationship between the level of energy, myocardial thickness, and collateral damages in a dog model,” Europace, Jan. 2014; 16(1):142-8. |
| Wegmoller, “Intra-Body Communication for Biomedical Sensor Networks,” Diss. ETH, No. 17323, 1-173, 2007. |
| Wei et al., “Comparative simulation of excitation and body surface electrocardiogram with isotropic and anisotropic computer heart models,” IEEE Trans Biomed Eng., Apr. 1995; 42(4):343-57. |
| Weijs et al., “Clinical and echocardiographic correlates of intra-atrial conduction delay,” Europace, Dec. 2011; 13(12):1681-7. |
| Weiss et al., “The influence of fibre orientation, extracted from different segments of the human left ventricle, on the activation and repolarization sequence: a simulation study,” Europace, Nov. 2007; 9(Suppl. 6):vi96-vi104. |
| Wetzel et al., “A stepwise mapping approach for localization and ablation of ectopic right, left, and septal atrial foci using electroanatomic mapping,” European Heart Journal, Sep. 2002; 23(17):1387-1393. |
| Wlodarska et al., “Thromboembolic complications in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy,” Europace, Aug. 2006; 8(8):596-600. |
| Wong et al., “A review of mitral isthmus ablation,” Indian Pacing and Electrophysiology Journal, 2012; 12(4):152-170. |
| Wu et al., “Acute and long-term outcome after catheter ablation of supraventricular tachycardia in patients after the Mustard or Senning operation for D-transposition of the great arteries,” Europace, Jun. 2013; 15(6):886-91. |
| Xia et al., “Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion,” Pacing Clin Electrophysiol., Aug. 2008; 31(8):1036-40. |
| Yamazaki et al., “Acute Regional Left Atrial Ischemia Causes Acceleration of Atrial Drivers during Atrial Fibrillation,” Heart Rhythm, Jun. 2013; 10(6):901-9. |
| Yang et al., “Focal atrial tachycardia originating from the distal portion of the left atrial appendage: Characteristics and long-term outcomes of radiofrequency ablation,” Europace, Feb. 2012; 14(2):254-60. |
| Yiginer et al., “Advanced Age, Female Gender and Delay in Pacemaker Implantation May Cause TdP in Patients With Complete Atrioventricular Block,” Indian Pacing and Electrophysiology Journal, Oct. 2010; 10(10):454-63. |
| Yoon et al., “Measurement of thoracic current flow in pigs for the study of defibrillation and cardioversion,” IEEE Transactions on Biomedical Engineering, Oct. 2003; 50(10):1167-1773. |
| Yuan et al., “Recording monophasic action potentials using a platinum-electrode ablation catheter,” Europace, Oct. 2000, 2(4):312-9. |
| Yusuf et al., “5-Hydroxytryptamine and Atrial Fibrillation: How Significant is This Piece in the Puzzle?” J Cardiovasc Electrophysiol., Feb. 2003; 14(2):209-14. |
| Zaugg et al., “Current concepts on ventricular fibrillation: a vicious circle of cardiomyocyte calcium overload in the initiation, maintenance, and termination of ventricular fibrillation,” Indian Pacing and Electrophysiology Journal, Apr. 2004; 4(2):85-92. |
| Zhang et al., “Acute atrial arrhythmogenicity and altered Ca(2+) homeostasis in murine RyR2-P2328S hearts,” Cardiovascular Research, Mar. 2011; 89(4):794-804. |
| Zoghi et al., “Electrical stunning and hibernation: suggestion of new terms for short- and long-term cardiac memory,” Europace, Sep. 2004; 6(5):418-24. |
| Zografos et al., “Inhibition of the renin-angiotensin system for prevention of atrial fibrillation,” Pacing Clin Electrophysiol., Oct. 2010; 33(10):1270-85. |
| PCT/US2014/066792) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority. |
| PCT/US2014/013601) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority. |
| PCT/US2014/036782) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Aug. 22, 2014, 11 pages. |
| International Search Report and Written Opinion for Application No. PCT/US2017/047378, 8 pages, dated Dec. 6, 2017. |
| PCT/US2018/050988) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Nov. 14, 2018, 11 pages. |
| PCT/US2018/050993) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Nov. 16, 2018, 7 pages. |
| PCT/US2019/023642) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Jun. 28, 2019, 14 pages. |
| PCT/US2019/023645) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Sep. 4, 2019, 14 pages. |
| PCT/US2019/023646) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Aug. 19, 2019, 15 pages. |
| PCT/IB2019/057352) PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, dated Nov. 27, 2019, 123 pages. |
| International Search Report and Written Opinion for Application No. PCT/US2020/023525, 10 pages, dated Jul. 9, 2020. |
| International Search Report and Written Opinion for Application No. PCT/US2020/047802, 9 pages, dated Nov. 19, 2020. |
| International Search Report and Written Opinion from PCT Application No. PCT/US2020/062466, dated Jan. 27, 2021, 15 pages. |
| Number | Date | Country | |
|---|---|---|---|
| 20210307670 A1 | Oct 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| 63005055 | Apr 2020 | US |
